<SEC-DOCUMENT>0001213900-26-043543.txt : 20260414
<SEC-HEADER>0001213900-26-043543.hdr.sgml : 20260414
<ACCEPTANCE-DATETIME>20260414162246
ACCESSION NUMBER:		0001213900-26-043543
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		7
FILED AS OF DATE:		20260414
DATE AS OF CHANGE:		20260414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HeartBeam, Inc.
		CENTRAL INDEX KEY:			0001779372
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				474881450
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-293307
		FILM NUMBER:		26861070

	BUSINESS ADDRESS:	
		STREET 1:		2118 WALSH AVE., SUITE 210
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050
		BUSINESS PHONE:		408-899-4443

	MAIL ADDRESS:	
		STREET 1:		2118 WALSH AVE., SUITE 210
		CITY:			SANTA CLARA
		STATE:			CA
		ZIP:			95050
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea0285354-424b5_heartbeam.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
Pursuant to Rule 424(b)(5)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-293307</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Red"><B>The
information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell the securities and it
is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Red"><B>Subject
to Completion, dated April 14, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(to
Prospectus dated March 17, 2026)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>HEARTBEAM,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Shares
                                            of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are offering [&#9679;] shares of our common stock, par value $0.0001 per share, (the &ldquo;Common Stock&rdquo;) at an offering price
of $[&#9679;] pursuant to this prospectus supplement and the accompanying base prospectus. This offering is being underwritten on a firm
commitment basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are also offering to each purchaser of shares that would otherwise result in the purchaser&rsquo;s beneficial ownership exceeding 4.99%
of our outstanding Common Stock immediately following the consummation of this offering, the opportunity to purchase pre-funded warrants
(the &ldquo;Pre-Funded Warrants&rdquo;) in lieu of shares of Common Stock. Subject to limited exceptions, a holder of Pre-Funded Warrants
will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together with its affiliates, would beneficially
own in excess of 4.99% (or, at the election of the holder, such limit may be increased to up to 9.99%) of the number of shares of Common
Stock outstanding immediately after giving effect to such exercise. Each Pre-Funded Warrant is exercisable for one share of our Common
Stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of Common Stock is sold in this offering,
minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants will be immediately exercisable
and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants and the shares of
Common Stock issuable upon the exercise thereof are being registered on the registration statement of which this prospectus supplement
is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Common Stock and warrants are listed on The Nasdaq Capital Market under the symbol &ldquo;BEAT&rdquo; and &ldquo;BEATW&rdquo;, respectively.
On [*] 2026, the last reported sale price of our Common Stock on The Nasdaq Capital Market was [*] per share. There is
no established trading market for the Pre-Funded Warrants, and we do not expect a trading market to develop. We do not intend to list
the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. Without a trading market, the liquidity of
the Pre-Funded Warrants will be extremely limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Pre-Funded Warrant</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Public offering price</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#9679;]</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriting discounts and commissions<SUP>(1)</SUP></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proceeds to us, before expenses</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have agreed to reimburse the underwriters for certain expenses. See &ldquo;Underwriting&rdquo;
                                            on page S-26 of this prospectus supplement for additional disclosures regarding underwriting
                                            compensation and estimated offering expenses.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have granted the underwriter an over-allotment option. This option, which is exercisable from time to time, for up to 30 days after
the date of this prospectus supplement, permits the underwriter to purchase up to an aggregate of [&#9679;] additional shares of
common stock. The purchase price to be paid per additional share of common stock shall be equal to the public offering price of one
share of common stock equal to $[&#9679;], less the underwriting discount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investing
in our securities involves a high degree of risk, including that the trading price of our Common Stock has been subject to volatility.
See &ldquo;Risk Factors&rdquo; beginning on page S-19 of this prospectus supplement, page 7 of the accompanying base prospectus and under
similar headings in the documents incorporated by reference into this prospectus supplement and the accompanying base prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriter expects to deliver the securities against payment on or about [&#9679;], 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
date of this prospectus supplement is April [&#9679;], 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Sole
Bookrunner</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt; font-variant: normal"><B>Titan
Partners</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>a
division of American Capital Partners</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9.25pt; text-indent: -9pt; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
    Supplement</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_001"><FONT STYLE="font-size: 10pt">ABOUT
    THIS PROSPECTUS SUPPLEMENT</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-ii</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_002"><FONT STYLE="font-size: 10pt">PROSPECTUS
    SUPPLEMENT SUMMARY</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-1</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_003"><FONT STYLE="font-size: 10pt">OFFERING
    SUMMARY</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-17</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_004"><FONT STYLE="font-size: 10pt">RISK
    FACTORS</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-19</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_005"><FONT STYLE="font-size: 10pt">SPECIAL
    NOTE REGARDING FORWARD LOOKING STATEMENTS</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-21</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_006"><FONT STYLE="font-size: 10pt">USE
    OF PROCEEDS</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-22</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_007"><FONT STYLE="font-size: 10pt">MARKET
    PRICE OF OUR COMMON STOCK</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-22</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_008"><FONT STYLE="font-size: 10pt">DIVIDEND
    POLICY</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-22</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_009"><FONT STYLE="font-size: 10pt">CAPITALIZATION</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-22</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_010"><FONT STYLE="font-size: 10pt">DILUTION</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-23</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_011"><FONT STYLE="font-size: 10pt">DESCRIPTION
    OF SECURITIES WE ARE OFFERING</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-24</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_012"><FONT STYLE="font-size: 10pt">UNDERWRITING</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-26</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_013"><FONT STYLE="font-size: 10pt">LEGAL
    MATTERS</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-32</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_014"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-32</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9.25pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#S_015"><FONT STYLE="font-size: 10pt">INCORPORATION
    BY REFERENCE</FONT></A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">S-33</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Prospectus</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_001">ABOUT
    THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_002">THE COMPANY</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_003">RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_004">SPECIAL
    NOTE REGARDING FORWARD LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_005">USE OF
    PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_006">DESCRIPTION
    OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_007">DESCRIPTION
    OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_008">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_009">DESCRIPTION
    OF RIGHTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_010">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_011">PLAN OF
    DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_012">LEGAL
    MATTERS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_013">EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_014">WHERE
    YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_015">INCORPORATION
    BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_001"></A>ABOUT
THIS PROSPECTUS SUPPLEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus supplement and the accompanying base prospectus are part of a registration statement that we filed with the U.S. Securities
and Exchange Commission, or SEC, utilizing a &ldquo;shelf&rdquo; registration process. This document is in two parts. The first part
is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information contained
in the accompanying base prospectus and the documents incorporated by reference herein. The second part, the accompanying base prospectus,
provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined.
To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the
accompanying base prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement,
you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent
with a statement in another document having a later date-for example, a document incorporated by reference in the accompanying base prospectus-the
statement in the document having the later date modifies or supersedes the earlier statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or
covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should rely only on the information contained in this prospectus supplement or the accompanying base prospectus or incorporated by reference
herein. We have not authorized anyone to provide you with information that is different. The information contained in this prospectus
supplement or the accompanying base prospectus, or incorporated by reference herein or therein is accurate only as of the respective
dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying base prospectus or of any sale of
our Common Stock. It is important for you to read and consider all information contained in this prospectus supplement and the accompanying
base prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should
also read and consider the information in the documents to which we have referred you in the sections entitled &ldquo;Where You Can Find
More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo; in this prospectus supplement and in the
accompanying base prospectus, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are offering to sell, and seeking offers to buy, the securities offered by this prospectus supplement only in jurisdictions where offers
and sales are permitted. The distribution of this prospectus supplement and the accompanying base prospectus and the offering of the
securities offered by this prospectus supplement in certain jurisdictions may be restricted by law. Persons outside the United States
who come into possession of this prospectus supplement and the accompanying base prospectus must inform themselves about, and observe
any restrictions relating to, the offering of the Common Stock and the distribution of this prospectus supplement and the accompanying
base prospectus outside the United States. This prospectus supplement and the accompanying base prospectus do not constitute, and may
not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement
and the accompanying base prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer
or solicitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">When
we refer to &ldquo;BEAT,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and the &ldquo;Company&rdquo; in this prospectus,
we mean HeartBeam, Inc., unless otherwise specified. When we refer to &ldquo;you,&rdquo; we mean the holders of the applicable series
of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_002"></A>PROSPECTUS
SUPPLEMENT SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>The
following information below is only a summary of more detailed information included elsewhere in, or incorporated by reference into,
this prospectus supplement and the accompanying base prospectus, and should be read together with the information contained or incorporated
by reference in other parts of this prospectus supplement and the accompanying base prospectus. This summary highlights selected information
about us and this offering. This summary may not contain all of the information that may be important to you. Before making a decision
to invest in our securities, you should read carefully all of the information contained in or incorporated by reference into this prospectus
supplement and the accompanying base prospectus, including the information set forth under the caption &ldquo;Risk Factors&rdquo; in
this prospectus supplement and the accompanying base prospectus as well as the documents incorporated herein by reference, which are
described under &ldquo;Where You Can Find More Information; Incorporation by Reference&rdquo; in this prospectus supplement. Unless otherwise
indicated or unless the context requires otherwise, this prospectus includes the accounts of HeartBeam, Inc., a Delaware corporation
referred to as &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, &ldquo;HeartBeam&rdquo; or the &ldquo;Company&rdquo;.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Company
Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam
is a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver
innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and
monitoring of cardiac disease outside of a healthcare facility. Our ability to develop higher resolution Electrocardiogram (&ldquo;ECG&rdquo;)
solutions is achieved through the development of our proprietary and patented technology platform that allows us to collect the heart&rsquo;s
electrical activity from three dimensions and synthesize a 12-Lead (&ldquo;12L&rdquo;) ECG from these signals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe our products (&ldquo;Products&rdquo; or &ldquo;Product&rdquo;) and services will benefit many stakeholders, including patients,
healthcare providers, and healthcare payers, and will also address the rapidly growing field of ambulatory cardiac monitoring. As part
of our long-term vision, we believe that we are uniquely positioned to play a central role in high-risk Coronary Artery Disease (&ldquo;CAD&rdquo;)
monitoring, given positive, proof-of-concept data from the initial feasibility studies that demonstrated comparable performance of the
HeartBeam System and the standard 12L ECG in ischemia detection. CAD patients are at increased risk for a heart attack or Myocardial
Infarction (&ldquo;MI&rdquo;). Additionally, our unique portable form-factor will make high-fidelity insights easily accessible, wherever
patients are, compared to a standard 12L ECG, which is typically limited to a healthcare setting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
initial product and service offering is the HeartBeam System. The HeartBeam System is the first U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
cleared cable-free, ambulatory 12L ECG that captures the heart&rsquo;s electrical signals from three dimensions for high-fidelity data
collection and advanced diagnostics for arrhythmia assessment. The HeartBeam System is comprised of a credit card sized 3D ECG recording
device, a patient application, a physician portal, and powerful cloud-based algorithms. Unlike any single-lead or 6-lead consumer device,
HeartBeam&rsquo;s patented cable-free technology captures the heart&rsquo;s electrical signals in three non-coplanar dimensions and synthesizes
them into a familiar 12L ECG display, using a personalized transformation matrix. This allows patients to obtain a 12L ECG reading for
their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind.
The synthesized 12-lead ECG is promptly reviewed by an on-demand, board-certified cardiologist.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam&rsquo;s
credit card sized 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software
received FDA clearance for arrhythmia assessment in December 2025. The HeartBeam System did not generate any revenue in 2025.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are focused on advancing several key initiatives as part of our growth strategy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Limited
                                            Launch</B>: On the back of our recent FDA Clearance for the HeartBeam System, we are initiating
                                            a market introduction in early 2026, focusing on select concierge and preventive cardiology
                                            groups that have proactively signaled strong interest in adopting HeartBeam&rsquo;s technology.
                                            This limited market release will enable the Company to validate real-world performance and
                                            establish reference sites for broader commercialization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2026, the Company announced ClearCardio as its first commercial customer. ClearCardio is a leading preventive cardiology practice
that has served thousands of patients through advanced heart health screening and personalized prevention programs. The partnership includes
an initial staged rollout to ensure a seamless patient and physician experience and plans for broader expansion to thousands of highly
engaged members across multiple U.S. geographies. The initial agreement with ClearCardio is structured as a Letter of Intent (LOI), outlining
the commercial terms and a collaborative rollout plan, including a subscription fee per patient. During the initial deployment phase,
HeartBeam and ClearCardio intend to negotiate and execute a definitive agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Heart
                                            Attack Detection</B>: We are pursuing an expansion of our cleared indications through a heart
                                            attack detection indication, supported by compelling proof-of-concept data and representing
                                            a major expansion opportunity to tens of millions of patients in the U.S.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2026, the Company announced it enrolled the first patients in the ALIGN-ACS study. HeartBeam&rsquo;s technology is uniquely capable
of assessing possible heart attacks outside of traditional clinical settings and this milestone signifies a key step toward a future
FDA indication expansion for heart attack assessment. The ALIGN-ACS pilot study is designed to enroll 100 patients presenting with chest
pain in the emergency room (ER). Patients will be evaluated with both a standard 12-lead ECG and the HeartBeam device and both results
will be compared with each patient&rsquo;s final diagnosis at discharge. As the study is designed to enroll chest pain patients in the
ER, enrollment is expected to progress quickly.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Extended
                                            Wear Patch</B>: We are making significant advancements with an on-demand 12L ECG extended
                                            wear monitor. The Company has developed a working prototype of its novel 12L patch, which
                                            has the potential to be a best-in-class offering in an existing multi-billion-dollar market
                                            with reimbursement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2026, the Company unveiled the working prototype of the 12L patch. In addition to working just like existing patches and continually
recording a patient&rsquo;s heart rhythms with a single lead, HeartBeam&rsquo;s patch has the ability to record an on-demand 12-Lead
ECG by simply placing two fingers on the front of the device. We believe that this 12L patch can disrupt the Ambulatory Cardiac Monitoring
market, a $2B revenue market with established reimbursement, that consists of the long-term continuous monitor and mobile cardiac telemetry
or MCT segments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Longitudinal
                                            Data and AI</B>: The Company believes it has the ability to unlock the power of the unique
                                            data-rich repository generated from our 3D ECG platform and deep learning algorithms. As
                                            adoption grows, the ability for patients to record synthesized 12L ECGs over time will create
                                            the opportunity to build AI-based screening and prediction algorithms that go beyond what
                                            is possible with single-timepoint ECGs or traditional wearables.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2026, the Company and the Icahn School of Medicine at Mount Sinai in New York (&ldquo;Mount Sinai&rdquo;) entered into strategic
AI collaboration to bring clinical-grade heart monitoring into the home. This collaboration will aim to accelerate development of personalized
cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk. It combines Mount
Sinai&rsquo;s world-class AI and clinical expertise with HeartBeam&rsquo;s groundbreaking 3D ECG signal collection technology. The partnership
marks a significant milestone in the Company&rsquo;s long-term strategy to build an ecosystem around its platform and strengthen its
leadership in AI-enabled cardiac monitoring.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2025, we had 16 employees. In January 2026, the Company hired a Chief Commercial Officer, Bryan Humbarger, bringing total
headcount to 17 employees. Mr. Humbarger brings more than 25 years of experience in building and scaling groundbreaking medical technologies.
While initially focused on launching the Company&rsquo;s FDA-cleared 12L system for arrhythmia assessment, he will lead the Company&rsquo;s
broader commercialization strategy across key growth initiatives, including heart attack detection and the 12L ECG extended wear patch.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to strike a balance of managing our headcount in line with cash resources, while also, at the appropriate time, hiring or engaging
additional full-time professionals, employees, and/or consultants in alignment with our growth strategy. To that end, the Company does
not anticipate the need to hire a large sales force during the initial launch of its HeartBeam System. We believe that a few well-placed
resources will help provide the data points required to effectively invest into a broader launch using a scalable model that will lead
to profitable growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
the market is highly competitive for attracting and retaining highly qualified professionals in our industry, we continue our endeavor
to find such candidates for our Company. Our management team and additional personnel that we may hire in the future will be primarily
responsible for executing and implementing growth opportunities, making tactical decisions related to our strategy and pursuing opportunities
to invest in new technologies through strategic partnerships and acquisitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Market
Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chronic
diseases are the number one burden on the healthcare system, driving up costs each year, and cardiovascular illnesses are one of the
top contributors. Regulators, payers, and providers are focused on earlier diagnosis and improved management of these conditions to drive
better outcomes at lower cost. One way to accomplish this is through the use of Connected Medical Devices - solutions that use technology
to provide healthcare services remotely and aim to reduce healthcare expenditures while allowing patients to engage with clinicians and
better self-manage their care. The Connected Medical Device Market size is estimated at $66 billion in 2024, and is expected to reach
$133 billion by 2029, growing at a compounded annual growth (&ldquo;CAGR&rdquo;) of 15% during the forecast period (2024-2029).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cardiovascular
disease is the most expensive disease to manage and is estimated to be responsible for one in every eight healthcare dollars spent in
the US, projected to cost the US healthcare system $1 trillion by 2035. As cardiovascular disease is the leading cause of death worldwide,
early detection, diagnosis, and management of chronic cardiac conditions are necessary to relieve the increasing burden on the healthcare
system. Diagnostic tests such as ECGs are used to detect, diagnose, and track numerous cardiovascular conditions. The market for cardiac
monitoring technologies, such as Holter monitors, patch-based cardiac monitoring technologies, and any other ECG-based technology used
for clinical diagnosis is projected to reach approximately $18 billion by 2030, a CAGR of approximately 8%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">With
advances in mobile communications, diagnostic monitoring of cardiac conditions is increasingly occurring outside the hospital. Global
sales of patient monitoring devices in 2021 were $42 billion. With a CAGR of approximately 11% from 2022 to 2032, the market is projected
to reach a valuation of $125 billion by 2032. The adoption of such technology was greatly accelerated by the COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the US, someone has a heart attack every 40 seconds. We believe there are no products on the market that are portable, easy to use, and
always with the patient to provide physicians with timely and highly accurate information about heart conditions that could be detected
with a standard 12L ECG. A tool that is always with the patient and decreases time to intervention would have a significant effect on
saving lives and healthcare dollars. We believe our technology will address this problem by providing convenient, cost-effective cardiac
monitoring solutions through our two form factors and our evolving software. Our platform is creating an ecosystem for physicians and
patient engagement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Products
and Technology</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam&rsquo;s
IP and novel technology have resulted in our initial Product, the HeartBeam System. Our HeartBeam System device records cardiac signals
with integrated electrodes rather than cables. The electrocardiogram (ECG) signal collection device is similar in size to a credit card,
is about 1/8 inch (4 mm), and weighs about 1 ounce (28 grams). The core technology consists of a series of patented inventions and associated
algorithms that allow us to capture the heart&rsquo;s electrical activity from three distinct directions and get a complete view of the
heart&rsquo;s electrical activity. As a high-fidelity ECG system, it captures heart signals from three distinct directions for actionable
heart health information and allows physicians to diagnose a wide range of non-urgent complex arrhythmias.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ea028535401_img1.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&rsquo;<IMG SRC="ea028535401_img2.jpg" ALT=""></FONT></TD>
  <TD STYLE="width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam
device in ready position (left) and the front view(right)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
patented technology, along with a proprietary algorithm, allows us to generate signals similar to a 12L ECG without the need for cables,
unlike a standard 12L ECG machine. In addition, we use the concept of a baseline, through which we will be able to measure the change
in cardiac parameters between an asymptomatic (baseline) recording and the symptomatic recording. The baseline is personalized for every
patient, offering an increase in diagnostic performance as published previously in JACC: Advances https://www.jacc.org/doi/10.1016/j.jacadv.2023.100454).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ea028535401_img3.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Longer-term,
there will be obvious ease-of-use advantages when comparing our credit card-sized device to the current 12L ECG machine. The small form
factor of our device makes it portable and able to be used by a patient at home or elsewhere. The device can be self-applied versus requiring
a trained professional to apply. Additionally, the ease of use will allow for prompt data collection, immediately upon symptom onset,
which can be sent a physician to assess the patient&rsquo;s ECG in the context of the patient&rsquo;s baseline ECG, symptoms, and cardiac
health history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
we commence our commercialization efforts, The HeartBeam System will consist of a number of capabilities:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
                                            FDA-cleared, cable-free 12L ECG collection device for the assessment of arrhythmias. The
                                            device captures cardiac signals in 3D through three non-coplanar dimensions and transmits
                                            them via Bluetooth connection to a smartphone. The device&rsquo;s small form factor allows
                                            it to always be with the patient. It is easy to use, as all that is required of the patient
                                            is that the device be pressed against the chest.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                            cloud-based software system that serves four basic functions: (1) performing ECG signal quality
                                            checks, (2) synthesizing a 12L ECG from the 3D ECG, and (3) preparing a summary report for
                                            the physician. To facilitate a more accurate physician interpretation of the data, the software
                                            will also overlay the patient&rsquo;s synthesized baseline 12L ECG waveform on the synthesized
                                            12L ECG waveform from the current reading. To ensure high signal quality, the system checks
                                            for noise levels in the recorded signals. Those signals that can be effectively filtered
                                            are accepted and those that have a noise level above an empirically established threshold
                                            are rejected. If a recorded signal is rejected, the user is asked to repeat the recording.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                            web-based physician portal capable of displaying the following relevant information for the
                                            physician to analyze: patient history, symptoms, synthesized 12L ECG, and recorded 3 leads.
                                            Our physician portal assists physicians with their diagnostic interpretation by providing
                                            both the baseline 12L synthesized ECG and the 12L synthesized ECG that is under evaluation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                            dedicated team of cardiologists, offering 24/7/365 services in order to provide a recommended
                                            course of action to patients based on the ECG signals, symptoms, and patient history. The
                                            patient will have the option of having a consult with a medical professional.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe this is the first patient-friendly, portable device of its kind to be cleared by the FDA, and our two FDA clearances are major
milestones for the Company. In addition, our FDA clearances provide the regulatory foundation for subsequent products and expanded indications
for use in our product portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Future
versions of our Products may include an expansion of our cleared indications through a heart attack detection indication, an on-demand
12L ECG extended wear patch monitor, and AI-based classification, screening and prediction algorithms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company believes it has the ability to unlock the power of the unique data-rich repository generated from our 3D ECG platform and deep
learning algorithms. As adoption grows, the ability for patients to record synthesized 12L ECGs over time will create the opportunity
to build AI-based screening and prediction algorithms that go beyond what is possible with single-timepoint ECGs or traditional wearables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
custom software and hardware of our Products are classified as Class II medical devices by the FDA. Premarket review and clearance by
the FDA for Class II devices is generally accomplished through the 510(k) premarket notification process or De Novo process. Given the
proposed intended use of our device, the 510(k) submission or De Novo process is expected to require clinical data to support future
FDA clearances.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Market
Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ECGs
are key diagnostic tests utilized in the diagnosis and monitoring of cardiovascular disease, the number one cause of death worldwide.
According to the American Heart Association, there were approximately 130 million adults living with cardiovascular disease and approximately
20 million adults with diagnosed CAD in the US. The prevalence of these cardiac conditions and thus the market size is increasing, due
to an aging population and lifestyle choices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Every
40 seconds someone in the US has a heart attack, or MI. Unfortunately, there is no way for patients at home to distinguish if the symptoms
they are experiencing are due to an MI, or some other more benign condition such as indigestion. As a result, patients often ignore symptoms
and delay seeking care, which leads to worse outcomes and increased mortality. Shortening that time from symptoms to the door of a medical
facility would reduce complications and save lives. On the other hand, many patients who go to the Emergency Department (ED) with chest
pain are not experiencing an MI. Chest pain is the second most common reason for an ED visit in patients over 45, yet fewer than 20%
of chest pain ED visits result in a diagnosis of a life-threatening condition. These unnecessary ED visits lead to well over $10 billion
in unnecessary healthcare expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ea028535401_img4.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
ECGs are conducted in a healthcare facility setting using a 12L ECG machine, the gold standard. ECGs taken outside of healthcare facilities
are expected to grow more quickly than in-hospital ECGs. Monitoring cardiac patients outside of a hospital is a fast-growing trend, as
it is less expensive and provides a better patient experience. However, while ambulatory cardiac monitoring devices are often much easier
for patients to use, they have fewer leads than the gold standard and therefore cannot offer as comprehensive a picture of cardiac health.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
a standard 12L ECG readout is of great medical value, it is simply impractical to have a standard 12L machine next to patients when they
experience symptoms outside the clinical setting, since recording the event requires attaching multiple electrodes to the patient&rsquo;s
body with professional assistance. While existing technologies use predominantly single lead ECG devices to monitor arrhythmias, these
technologies do not provide information to the physician on the presence of life-threatening conditions such as acute coronary syndrome
(ACS) including MIs, also known as heart attacks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe our technology will address these market needs and has several key attributes that make it a good fit for these patients. Our
Product can be used anywhere when symptoms occur and offers the potential for lifelong patient usage. The device can be always near the
patient and ready to be used for recording a cardiac event. It enables real-time transmission of the ECG signals and a synthesized 12L
ECG. We believe physicians will typically prescribe our solution to chronic cardiovascular patients for long term monitoring, thereby
enabling prolonged data collection and delivering a more complete picture for diagnosis. This will also enable the use of artificial
intelligence (AI) on our future database that will have a unique set of longitudinal ECG signals and synthesized 12L ECGs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
we believe our ECG platform will demonstrate 12L equivalence and clinical and cost-effectiveness advantages, coupled with a patent protected
technology, we believe this might open multiple licensing and/or partnering opportunities with players in the ECG, cardiac monitoring
patch and smart watch verticals.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Clinical
Data</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
technology is backed by robust clinical data, including the VALID-ECG pivotal study, which validated the clinical performance of the
HeartBeam synthesized 12-lead ECG for arrhythmia detection. The results of this pivotal study were presented at the Heart Rhythm Society
conference in April 2025. The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam&rsquo;s synthesized
12L ECG and a simultaneously collected standard 12L ECG. Intervals and amplitudes are important in assessing non-life-threatening arrhythmias.
Data showed a 93.4% overall diagnostic agreement, indicating that HeartBeam&rsquo;s synthesized 12L ECG can support manual detection
of arrhythmias in a manner consistent with standard 12L ECGs. The VALID-ECG pivotal study was a multicenter trial that enrolled 198 patients
across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists, Mount Sinai Hospital, Northwell
Health and Piedmont Heart Institute. Efforts were made to enroll patients with a diverse demographic profile reflective of the intended
use population in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the area of heart attack detection, a landmark clinical study on the Company&rsquo;s technology was published in the August 2023 issue
of the journal JACC: Advances. The publication, &ldquo;Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit
Card-Size Personal Device Integration&rdquo; demonstrated that HeartBeam technology detects the presence of a coronary occlusion, the
cause of heart attacks, with the same accuracy as a standard 12L ECG. The study showed that the automated analysis of the 3D ECG and
12L ECG signals had similar performance in determining whether a coronary artery was occluded. Also in the study, the human interpretation
of the 12L ECGs had significant intra- and inter-observer variability, which does not occur with automated readings. The study also showed
that the presence of the &ldquo;normal baseline&rdquo; recording, a novel feature that is integral to HeartBeam&rsquo;s 3D ECG technology,
dramatically improved the accuracy of interpretation, increasing the Area Under the Curve, a standard measure of diagnostic performance,
from 0.72 to 0.95. This is particularly important since physicians who are analyzing 12L ECGs often do not have access to a normal baseline,
implying that the HeartBeam System could outperform this approach. The study was a collaboration of Harvard Medical School Faculty at
Beth Israel Deaconess Medical Center in Boston, MA, and Clinical Center of Serbia in Belgrade.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical
data supporting the performance of the HeartBeam deep learning algorithm continue to expand. Most recently, results demonstrating its
performance in the classification of atrial fibrillation, atrial flutter and sinus rhythm were presented at HRX in September 2025 in
Atlanta, GA. Earlier data presentations were made at the European Heart Rhythm Society, held in Berlin, Germany in April 2024 and the
Heart Rhythm Society, held in Boston, MA in May 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Competition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
cardiac monitoring and detection market is characterized by rapid technological change and strong competition. There are numerous companies
developing technologies that are competitive, in a broad sense, to our products, and many of these companies have significantly greater
resources than HeartBeam.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the category of ambulatory cardiac monitors - devices that are intended to be used outside of a health facility setting - there are two
major segments: consumer devices and devices prescribed for ACS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Consumer
Devices</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
consumer device segment consists of devices that are FDA cleared but are sold directly to patients, without a prescription. Generally,
these devices are single lead ECG devices intended to recognize heart rhythm abnormalities, such as atrial fibrillation, but are not
intended for ischemia detection or for life threatening conditions such as heart attack.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apple
                                            Inc, a public company located in Cupertino, CA, produces the Apple Watch, which includes
                                            an ECG functionality. The Apple Watch is a single lead ECG with two electrodes that contact
                                            the wrist and the finger and is intended to detect some common cardiac arrhythmias, such
                                            as Atrial Fibrillation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AliveCor
                                            Inc, a private company located in Mountain View, CA, produces the KardiaMobile, KardiaMobile
                                            Card and KardiaMobile 6L devices. These devices are intended to detect some common cardiac
                                            arrhythmias, such as Atrial Fibrillation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Google
                                            Inc, a public company located in Mountain View, CA, produces the Pixel 2 smartwatch and ECG
                                            app. The Pixel 2 watch is a single lead ECG with two electrodes that contact the fingers
                                            and is intended to detect some common cardiac arrhythmias, such as Atrial Fibrillation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Samsung
                                            Electronics Co., Ltd, based in Seoul, South Korea, is publicly traded in Korea. It produces
                                            the Galaxy Watch3 and Galaxy Watch Active2 smartwatches with an ECG functionality, intended
                                            to detect some common cardiac arrhythmias, such as Atrial Fibrillation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Devices
prescribed for ischemia detection</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are a small number of devices that have been cleared by FDA to be used outside of healthcare facilities that provide information for
patients with potential ischemic events such as MIs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Avertix
                                            Medical Inc. (formerly Angel Medical Systems, Inc.) is a private company based in Eatontown,
                                            NJ. The AngelMed Guardian is an implantable cardiac monitor for patients who are deemed to
                                            be extremely high risk for an MI. Physicians implant the AngelMed Guardian in patients. We
                                            believe that the HeartBeam System device will be a viable alternative to the AngelMed Guardian,
                                            as it does not require an implant and does not have a high up-front cost.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SHL
                                            Telemedicine Ltd., is based in Tel Aviv, Israel and is publicly traded. It produces Smartheart,
                                            a 12L ECG indicated for patient use at home. Smartheart Pro is larger and more complex than
                                            our solution, requiring the placement of an electrode belt, two underarm electrodes and a
                                            waist electrode, and moistening the areas before use. Most patients would find this technology
                                            impractical to be carried with them at all times because of the large size and complex lead
                                            attachment procedure.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Patch
monitoring companies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
patch monitor cardiac monitoring segment consists of devices that are FDA cleared and are prescribed by cardiologists and electrophysiologists
for the primary purpose of diagnosing patients with cardiac arrhythmias. Generally, these devices are single lead or 3-lead ECG devices
intended to recognize heart rhythm abnormalities, such as atrial fibrillation, heart blocks, etc. but are not intended for ischemia detection
or for life threatening conditions such as heart attack. While these platforms are widely adopted for rhythm management, they are technically
constrained from detecting complex ischemic conditions, a diagnostic gap HeartBeam intends to fill by offering a 12-lead equivalent ECG
signal within a patch form factor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">iRhythm
                                            Technologies is a public company based in San Francisco, CA, which is a manufacturer of cardiac
                                            monitoring patches such as Zio XT and Zio AT. While iRhythm has established a significant
                                            footprint with its Zio single-lead wearable patch platform, it is primarily limited to arrhythmia
                                            detection and lacks the diagnostic depth of a 12-lead ECG required to identify complex conditions
                                            like myocardial ischemia.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Boston
                                            Scientific is a public company based in Marlborough, Massachusetts, which is a manufacturer
                                            of The BodyGuardian cardiac monitoring platform. The BodyGuardian cardiac monitoring platform
                                            allows for transitions between Holter, Event, and Mobile Cardiac Telemetry (MCT) modes using
                                            a single patch sensor. While the system provides flexible configurations in single or 3-lead
                                            formats, its clinical utility is primarily restricted to arrhythmia detection and does not
                                            provide the comprehensive diagnostic depth of a 12-lead ECG.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">BioTelemetry,
                                            a subsidiary of Philips, is a public company based in Malvern, PA, which is a manufacturer
                                            of a portfolio of Mobile Cardiac Telemetry (MCOT) and Extended Monitoring - ePatch monitoring
                                            systems. These devices primarily utilize single or 3-lead configurations optimized for the
                                            detection of common arrhythmias and atrial fibrillation during a patient&rsquo;s daily activities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Intellectual
Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe our intellectual property (&ldquo;IP&rdquo;) protects our innovations, and our goal is to become a leader in the ambulatory ECG
sector. For some aspects of our proprietary technology, we rely on trade secret protection, while for others we pursue patent protection.
It is our view that the combination of these two methods of IP protection maximizes our chances for success.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s patent portfolio includes twenty-five (25) issued patents worldwide, consisting of seventeen (17) issued patents in the
United States and eight (8) issued patents outside of the United States, including one (1) European patent granted with unitary effect
under the Unitary Patent system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the United States, the Company also has twelve (12) additional pending patent applications. Outside the United States, the Company has
twenty-two (22) pending patent applications in jurisdictions including Canada, China, the European Union, Japan, South Korea, and Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
issued patents are expected to expire between April 11, 2036, and April 21, 2042. The pending applications, regardless of publication
status, are projected to expire between April 11, 2036, and February 20, 2045.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Over
the course of 2025 and into early 2026, we were granted a total of eight (8) new patents relating to its compact, mobile three-lead cardiac
monitoring technologies and automated diagnostics, methods for atrial fibrillation detection, photoplethysmogram data analysis and presentation,
and electrocardiogram patch devices and methods. These patents significantly strengthen HeartBeam&rsquo;s intellectual property position
surrounding its credit card-sized ECG device, reinforcing both the defensive and offensive moats around the company&rsquo;s core technology.
They also expand the application of risk-based diagnostic algorithms across HeartBeam&rsquo;s wearable device portfolio and cover methods
for automatically assessing a patient&rsquo;s risk of an acute cardiac event by evaluating clinical risk factors and generating a diagnostic
report.In addition, HeartBeam continues to expand its intellectual property portfolio and filed two (2) non-provisional, three (3) provisional
and three (3) continuing patent applications throughout 2025, further strengthening the protection of its proprietary technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s issued and pending U.S. patent claims are directed to compact electrocardiogram (ECG) systems for remote detection and/or
diagnosis of acute myocardial infarction (&ldquo;AMI&rdquo;). Outside of the U.S., the pending applications in the European Union, Canada
(&ldquo;CA&rdquo;), Australia (&ldquo;AU&rdquo;), Japan (&ldquo;JP&rdquo;), South Korea (&ldquo;KR&rdquo;), and China (&ldquo;CN&rdquo;)
generally correspond to the Company&rsquo;s U.S filings. The following table sets forth a brief description of issued and pending patents,
including their respective titles:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Patent
    Type</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Application
    No.<BR>
    Pat. No.</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Predicted<BR>
    Expiration</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    Summary</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (US)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif">15/096,159 US 10,433,744</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sep 15, 2036</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING
    DEVICE AND METHOD FOR AUTOMATED DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial
    infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">15/632,155 US 10,117,592</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/092,152 US 11,877,853</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jun 2, 2037</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/202,299 US 11,071,490</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS Methods and apparatuses
    for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (DE)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">16777474.4 DE 602016073016.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (FR)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">16777474.4 FR 3280326</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (GB)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">16777474.4 GB 3280326</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (NL)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">16777474.4 NL 3280326</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (UP) </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">22174820.5 Unitary Patent 4066732</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (EU)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">25183340.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">MOBILE THREE-LEAD CARDIAC MONITORING DEVICE AND METHOD FOR AUTOMATED
    DIAGNOSTICS Methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (EU)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">19894815.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nov 18, 2039</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">HAND HELD DEVICE FOR AUTOMATIC CARDIAC RISK AND DIAGNOSTIC ASSESSMENT
    Method and apparatus for performing automatic cardiac diagnosis.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/296,669 US 11,701,049</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nov 18, 2039</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">HAND HELD DEVICE FOR AUTOMATIC CARDIAC RISK AND DIAGNOSTIC ASSESSMENT
    Method and apparatus for performing automatic cardiac diagnosis.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">18/324,111 US 12,402,823</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nov 18, 2039</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">HAND HELD DEVICE FOR AUTOMATIC CARDIAC RISK AND DIAGNOSTIC ASSESSMENT
    Method and apparatus for performing automatic cardiac diagnosis.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">17/443,456 US 11,793,444</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS Adhesive patch methods and
    apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 9%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    Type</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 14%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    No. Pat. No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 14%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 12%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Predicted
    Expiration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 47%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    Summary</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/570,368 US 11,419,538</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS Adhesive
    patch methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/363,685<BR>
    12,539,067</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 11, 2036</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ELECTROCARDIOGRAM PATCH DEVICES AND METHODS Adhesive
    patch methods and apparatuses for remote and detection and/or diagnosis of acute myocardial infarction (AMI).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/609,014 US 12,207,908</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2041</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (AU)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020275409</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2040</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (CA)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3137669</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2040</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (EU)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20806312.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 13, 2040</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (JP)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021568329 JP 7682105</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2040</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (JP)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025080149</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 20, 2040</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (EU)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21892942.0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 12, 2041</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    WITH HYBRID ELECTRODE Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/252,803</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 12, 2041</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT MOBILE THREE-LEAD CARDIAC MONITORING DEVICE
    WITH HYBRID ELECTRODE Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (CA)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3204059</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan 4, 2042</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS
    Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events
    (e.g., acute myocardial infarction).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (CN)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202280014121.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan 4, 2042</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS
    Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events
    (e.g., acute myocardial infarction).</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (EP)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22734829.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan 4, 2042</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS
    Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events
    (e.g., acute myocardial infarction).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    Type</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    No.<BR>
    Pat. No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Predicted<BR>
    Expiration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    Summary</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (JP)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023-540687</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jan
    4,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMBULATORY
    ELECTROCARDIOGRAM PATCH DEVICES AND METHODS <BR>
    Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events
    (e.g., acute myocardial infarction).</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/260,318</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    15,<BR>
    2041</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMBULATORY
    ELECTROCARDIOGRAM PATCH DEVICES AND METHODS <BR>
    Cardiac monitoring patch devices (e.g., an ECG patch for 12-lead detection) for remote detection and/or diagnosis of cardiac events
    (e.g., acute myocardial infarction).</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/494,806<BR>
    US 11,445,963</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct
    5,<BR>
    2041</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/948,099</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct
    5,<BR>
    2041</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (AU)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022358735</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    5,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (CA)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3233979</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    5,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (CN)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202280080024.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    5,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (EP)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22879447.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    5,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (JP)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024520678</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    5,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (KR)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2024-7014745</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    5,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHOD
    AND APPARATUS FOR RECONSTRUCTING ELECTROCARDIOGRAM (ECG) DATA <BR>
    Synthesizing (generating) 12-lead ECG dataset from 3-lead ECG data.</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/726,497<BR>
    US 11,529,085</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr
    21,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS
    FOR GENERATING AN ELECTROCARDIOGRAM<BR>
    Wrist-worn device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods
    of using a wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/068,481<BR>
    US 11,969,251</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr
    21,<BR>
    2042</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS
    FOR GENERATING AN ELECTROCARDIOGRAM<BR>
    Wrist-worn device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods
    of using a wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; width: 9%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    Type</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 14%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    No. Pat. No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 14%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 12%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Predicted
    Expiration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 47%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    Summary</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/608,813</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 21, 2042</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM Wrist-worn
    device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a
    wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (AU)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023255677</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 18, 2043</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM Wrist-worn
    device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a
    wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (CA)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3249211</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 18, 2043</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM Wrist-worn
    device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a
    wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/362,527 US 10,980,433</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct 12, 2038</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HEALTH MONITORING AND GUIDANCE Methods, systems and
    software for the determination of stress states utilizing PPG sensors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/368,568 US 11,412,972</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 19, 2040</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DETECTION OF ATRIAL FIBRILLATION Methods and software
    for determining atrial fibrillation utilizing PPG sensors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/368,571 US 11,234,658</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 5, 2039</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PHOTOPLETHYSMOGRAM DATA ANALYSIS AND PRESENTATION Methods,
    systems and software for the creation of ECG-type waveforms from PPG sensor data.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (US)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/887,160 US 12,290,368</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 12, 2039</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DETECTION OF ATRIAL FIBRILLATION Methods and software
    for determining atrial fibrillation utilizing PPG sensors.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (EP)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP 19724961.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2039</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PHOTOPLETHYSMOGRAM DATA ANALYSIS AND PRESENTATION Methods,
    systems and software for the creation of ECG-type waveforms from PPG sensor data.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (KR)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR 10-2020-7031103 KR 10-2770226</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2039</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PHOTOPLETHYSMOGRAM DATA ANALYSIS AND PRESENTATION Methods,
    systems and software for the creation of ECG-type waveforms from PPG sensor data.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (EP)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23792727.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 18, 2043</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM Wrist-worn
    device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a
    wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility (JP)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024-561832</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr 18, 2043</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM Wrist-worn
    device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods of using a
    wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    Type</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    No.<BR>
    Pat. No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Predicted<BR>
    Expiration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; padding-top: 0.7pt; padding-right: 0.7pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    Summary</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (KR)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2024-7037610</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Apr
    18, 2043</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPARATUS
    FOR GENERATING AN ELECTROCARDIOGRAM<BR>
    Wrist-worn device can be taken off of the wrist and held against the chest to detect three orthogonal cardiac leads, and methods
    of using a wrist-worn device to detect the three orthogonal cardiac leads.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/985,015</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
    13, 2040</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMPACT
    MOBILE THREE-LEAD CARDIAC MONITORING DEVICE <BR>
    Compact, mobile three-lead cardiac monitoring devices for remote detection and/or diagnosis of cardiac events.</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19/059,242</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/20/2045</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WEARABLE
    HEART MONITOR BUFFERING MECHANISM SYSTEM AND METHOD<BR>
    Wearable devices with onboard computing power capable of pre-processing data and communicating a modified data packet(s).</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19/059,240</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/20/2045</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTIFICIAL
    INTELLIGENCE BASED SYSTEM FOR PERSONALIZED ELECTROCARDIOGRAM MONITORING AND ALERTING<BR>
    Personalized ECG monitoring incorporating machine-learning algorithms.</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19/298,084</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Published</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov
    18,2039</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HAND
    HELD DEVICE FOR AUTOMATIC CARDIAC RISK AND DIAGNOSTIC ASSESSMENT<BR>
    Method and apparatus for performing automatic cardiac diagnosis.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utility
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19/412,849</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dec
    11, 2036</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ELECTROCARDIOGRAM
    PATCH DEVICES AND METHODS</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prov
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/935,030</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEM
    AND METHOD FOR HEARTBEAT DETECTION USING A TRANSITIONAL ECG PATCH<BR>
    Methods, systems, and devices for detecting sleep apnea using a wearable ECG patch.</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prov
    (US)</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/864,948</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; padding-top: 0.7pt; padding-right: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    AND SYSTEMS FOR AGGREGATING ECG MODEL OUTPUTS ACROSS TIME AND LEADS<BR>
    Processing and interpretation of multi-lead ECG signals using AI, algorithmic, machine learning or signal analysis techniques.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have entered, and generally plan to continue to enter into, non-disclosure, confidentiality and intellectual property assignment agreements
with all new employees as a condition of employment. In addition, we intend to generally enter into confidentiality and non-disclosure
agreements with consultants, manufacturers&rsquo; representatives, distributors, suppliers, and others to attempt to limit access to,
use and disclosure of our proprietary information. There can be no assurance, however, that these agreements will provide meaningful
protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
ownership of all filed patents is assigned to HeartBeam, Inc.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Research
and Development</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are focused on creating innovative, user-friendly ambulatory solutions, that are always with the patient, assisting physicians in monitoring
and diagnosing cardiac disease in patients. We believe that our success in developing initial products, underscored by our emphasis on
user-friendly solutions, will set a solid foundation for our future endeavors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that our R&amp;D team, primarily based in the US and Belgrade, Serbia, is a testament to our commitment to excellence and innovation
and is comprised of seven employees, plus consultants, with expertise in the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Healthcare
                                            IT platform development, biomedical engineering, electrical engineering with expertise in
                                            machine learning (ML), signal processing and ECG analysis from the medical device industry,
                                            as well as specialties in wireless communication,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Of
                                            note, we have seven (7) Physicists and Electrical Engineers (all Ph.D. E.E. or Ph.D. Physics)
                                            credited with our key inventions and patents.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Looking
ahead, we anticipate further enhancing our efforts in harnessing signal processing and artificial intelligence (AI) to broaden our diagnostic
solutions across a spectrum of cardiac conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
core technology, a cable-free ECG that can measure the heart&rsquo;s electrical activity in three distinct directions, is a platform
technology that we believe is poised to revolutionize diagnostic solutions for cardiovascular patients. Potential applications include
a synthesized 12L-capable patch ECG monitor, offering significant diagnostic advantages through its 12L capability over existing single-lead
ECG patch products. This innovation aims to provide standard of care 12L ECG capabilities in a form factor like current single-lead ECG
patches, which we believe addresses a critical gap in the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
further potential application is a synthesized 12L ECG smartwatch-based monitor, offering significant diagnostic advantages through its
12L capability over existing single-lead ECG smartwatch solutions. The plan for this monitor is to eliminate the need for dedicated ECG
devices, offering synthesized 12L ECG capabilities directly from a smartwatch. Combining our unique and data rich set of signals with
a smartwatch, we believe, will enable the detection of heart attacks and complex arrhythmias with unprecedented convenience and efficiency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both
the patch and smartwatch-based monitor technologies are covered by patents that we believe provide us with a strong position to expand
beyond the current platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
AI team, comprising industry leading experts, developed a roadmap for AI-based tool development. These tools will combine state-of-the-art
AI models and techniques applied to our unique and data-rich set of signals. Results of our initial AI development indicate the potential
to significantly enhance ambulatory diagnostic capabilities over what is currently available. It is expected that AI development efforts
will quickly become one of our major R&amp;D efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
we continue to advance our synthesized 12L technology, evidenced by our recently issued and allowed patents with potentially disruptive
market impacts, our initial product will leverage rule-based algorithms, including signal processing and ECG synthesis. Concurrently,
we are developing a number of AI-based cardiac disease detection algorithms to become the cornerstone of our commercialized systems.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Future
Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
core technology - the approach to capturing the heart&rsquo;s electrical activity in three distinct directions - is a platform technology
that can provide diagnostic solutions to a variety of cardiovascular patients. Our plans call for expanding solutions that diagnose all
major cardiac conditions that are diagnosed by ECGs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have now developed a working prototype of a synthesized 12-lead capable patch ECG monitor that will provide advantages over existing
single-lead ECG patch products such as the Zio Monitor from iRhythm Technologies, Inc. Our approach will offer a synthesized 12-lead
ECG with a patch that is very similar, in dimensions and look and feel, to the currently available single lead ECG patches. We believe
providing standard of care 12-lead ECG capabilities will have significant diagnostic advantages over a single lead patch.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ea028535401_img5.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
also plan to integrate a synthesized 12-lead ECG smartwatch-based monitor intended for detection of heart attacks and complex cardiac
arrhythmias. This invention is intended to eliminate the need for a dedicated ECG device while offering a synthesized 12-lead ECG capability
enabling heart attack and complex arrhythmia detection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have developed initial deep learning algorithms, focused on the ability to detect various cardiac arrhythmias. Recent results demonstrating
performance in the classification of atrial arrhythmias were presented at HRX 2025, building on prior data releases at the European Heart
Rhythm Association in April 2024 and at the Heart Rhythm Society, in May 2024. We believe that, when combined with our Products, HeartBeam&rsquo;s
AI will provide additional value to patients and physicians in several ways, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Providing
                                            automated classification of cardiac conditions, including common arrhythmias,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Potentially
                                            enhancing user experience and simplify the onboarding process, and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
                                            the longer run, we believe that applying deep learning algorithms on top of the rich data,
                                            especially with the longitudinal dataset from patients taking repeated readings, may result
                                            in unsurpassed predictive and diagnostic capabilities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam
was incorporated as a C corporation under the laws of the State of Delaware on June 11, 2015. We do not own any subsidiaries. Our corporate
offices are located at 2118 Walsh Avenue, Suite 210, Santa Clara, CA 95050. Our telephone number is (408) 899-4443. The address of our
website is <I>https://www.heartbeam/</I>. The inclusion of our website address in this prospectus does not include or incorporate by
reference the information on our website into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_003"></A>OFFERING
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>This
summary highlights certain information about this offering and selected information contained elsewhere in or incorporated by reference
into this prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before
deciding whether to invest in securities. For a more complete understanding of our company and this offering, we encourage you to read
and consider carefully the more detailed information in this prospectus supplement and the accompanying base prospectus, including the
information incorporated by reference into this prospectus supplement and the accompanying base prospectus, and the information referred
to under the heading &ldquo;RISK FACTORS&rdquo; in this prospectus supplement on page S-19 and on page 7 of the accompanying base prospectus,
and in the documents incorporated by reference into this prospectus supplement and the accompanying base prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR><TD STYLE="vertical-align: top; width: 27%; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Issuer</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 72%; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam,
    Inc.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common stock offered
    by us</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;] shares</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-Funded Warrants
    offered by us</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
    are also offering, in lieu of shares of Common Stock, Pre-Funded Warrants to purchase up to [&#9679;] shares of Common Stock to any
    purchasers whose purchase of shares of Common Stock in this offering would otherwise result in such investor, together with its affiliates
    and related parties, beneficially owning more than 4.99% of our outstanding Common Stock immediately following the consummation of
    this offering. The purchase price of each Pre-Funded Warrant is equal to the price at which the share of Common Stock is being sold
    in this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants will
    be exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded
    Warrants and the shares of Common Stock issuable upon the exercise thereof are being registered on the registration statement of
    which this prospectus supplement is a part.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Underwriter Warrants
    offered by us</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
    the closing of this offering, we have agreed to issue to the underwriter, or its designees, Underwriter Warrants to purchase up to
    [&#9679;] shares of Common Stock, equal to an aggregate of % of the total number of shares of Common Stock and Pre-Funded Warrants
    sold in this offering (the &ldquo;Underwriter Warrants&rdquo;). The Underwriter Warrants will be exercisable at a per share exercise
    price equal to [&#9679;]% of the offering price per share sold in this offering, or $[&#9679;]. The Underwriter Warrants will be
    exercisable immediately upon issuance, in whole or in part, at any time on or after the date of issuance and will be exercisable for
    a period of five years from the date of this prospectus supplement. The Underwriter Warrants and the shares of common stock issuable
    upon the exercise thereof are being registered on the registration statement of which this prospectus supplement is a
    part.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common stock outstanding
    prior to the offering<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 8pt">41,131,835 shares</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common stock to
    be outstanding after this offering<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;]
    shares (or shares of Common Stock if the underwriters exercise their option to purchase additional shares in full) after giving effect
    to the exercise of all Pre-Funded Warrants sold in this offering and no exercise of any Underwriter Warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

</DIV>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common Stock
    Trading symbol</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 72%"><P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            Common Stock is traded on Nasdaq Capital Market under the symbol &ldquo;BEAT&rdquo;. There
                                            is no established trading market for the Pre-Funded Warrants, and we do not expect a trading
                                            market to develop. We do not intend to list the Pre-Funded Warrants on any securities exchange
                                            or nationally recognized trading system. Without a trading market, the liquidity of the Pre-Funded
                                            Warrants will be extremely limited.&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    estimate that the net proceeds to us from this offering will be approximately $[ million], after deducting underwriting discounts
    and commissions and estimated expenses payable by us. We intend to use the net proceeds from this offering for general corporate
    purposes, working capital purposes and capital expenditures. See &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    investment involves a high degree of risk. See &ldquo;Risk Factors&rdquo; and other information included or incorporated by reference
    in this prospectus supplement beginning on page S-19 and the accompanying base prospectus beginning on page 7 for a discussion of
    certain factors you should carefully consider before deciding to invest in shares of our common stock.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment Option</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                            have granted the underwriter an over-allotment option. This option, which is exercisable
                                            from time to time, for up to 30 days after the date of this prospectus supplement, permits
                                            the underwriter to purchase up to an aggregate of [&#9679;] additional shares of common
                                            stock. The purchase price to be paid per additional share of common stock shall be equal
                                            to the public offering price of one share of common stock equal to $[&#9679;], less the
                                            underwriting discount.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            number of shares of Common Stock outstanding is based on shares of Common Stock issued and
                                            outstanding as of March 31, 2026 and excludes the following:</FONT></P></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,979,452 shares of Common Stock issuable upon the exercise of outstanding
stock options having a weighted average exercise price of $2.09 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">501,488 shares of Common Stock issuable upon vesting of RSUs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">5,827,035<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> shares of Common
    Stock issuable upon the exercise of outstanding warrants having a weighted average exercise price of $4.42 per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,495,622 shares of Common
    Stock reserved for future issuance under the Company&rsquo;s 2022 Equity Incentive Plan (the &ldquo;2022 Equity Plan&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as otherwise indicated herein, all information in this prospectus reflects or assumes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the outstanding
    options described above; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">no
                                    exercise by the Underwriter of the over-allotment option and Underwriter Warrants issued as part
                                    of its compensation.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></DIV>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investment
in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider
the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form
10-Q or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by
reference into this prospectus, as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), and the risk factors and other information contained in the applicable prospectus supplement before acquiring any of such
securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Risks
Relating to this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Management
and our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
described in Note 2 of our audited financial statements incorporated by reference herein, we believe that our existing working capital
is insufficient to fund operations for the next twelve months following the issuance of the annual report. These factors raise substantial
doubt regarding our ability to continue as a going concern. Our financial statements do not include any adjustments that may result from
the outcome of this uncertainty. If we cannot raise the necessary capital to continue as a viable entity, we could experience a material
adverse effect on our business and our stockholders may lose some or all of their investment in us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
can provide no assurances that any additional sources of financing will be available to us on favorable terms, if at all. Our forecast
of the period of time through which our current financial resources will be adequate to support our operations and the costs to support
our general and administrative, selling and marketing and research and development activities are forward-looking statements and involve
risks and uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
you purchase securities in this offering, you</I></B>&nbsp;<B><I>will experience immediate and substantial dilution in the book value
of your shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Because
the price per share of common stock being offered in this offering is expected to be substantially higher than the net tangible book
value per share of our common stock, you may experience substantial dilution to the extent of the difference between the effective offering
price per share of common stock you pay in this offering and the net tangible book value per share of our common stock immediately after
this offering. Our net tangible book value as of December 31, 2025, was approximately $2.6 million, or $0.06 per share of common stock.
Net tangible book value per share is equal to our total tangible assets minus total liabilities, all divided by the number of shares
of common stock outstanding. See the section entitled &ldquo;Dilution&rdquo; on page S-23 below for a more detailed illustration of the
dilution you may incur if you participate in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
management team may invest or spend the proceeds raised in this offering in ways with which you may not agree or which may not yield
a significant return.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
management will have broad discretion over the use of proceeds from this offering. We currently intend to use the net proceeds of this
offering as described in the section entitled &ldquo;Use of Proceeds.&rdquo; However, our management will have broad discretion in the
application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this
offering. Accordingly, you are relying on the judgment of our management with regard to the use of these net proceeds, and you will not
have the opportunity, as part of your investment decision, to assess whether the proceeds will be used appropriately. The failure by
management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business,
cause the price of our common stock to decline, and delay the development of our product candidates. Pending their use, we may invest
the net proceeds from this offering in short-term, interest-bearing instruments. These investments may not yield a favorable return,
or any return, to us or our stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>We
will likely issue additional common stock in the future, which would dilute the holdings of our existing stockholders.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the future, we will likely issue additional shares of our common stock or securities convertible into or exchangeable or exercisable
for our common stock, resulting in the dilution of the ownership interests of our stockholders. We may issue additional shares of our
common stock or securities convertible into or exchangeable or exercisable for our common stock in connection with hiring or retaining
personnel, future acquisitions or future capital-raising transactions or other business purposes. Moreover, the exercise of our existing
outstanding warrants and stock options, which are exercisable for or convertible into shares of our common stock, would dilute our existing
holders of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Holders
of Pre-Funded Warrants purchased in this offering will have no rights as holders of common stock until such holders exercise their Pre-Funded
Warrants and acquire our common stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until
holders of Pre-Funded Warrants acquire shares of our common stock upon exercise of the Pre-Funded Warrants, holders of Pre-Funded Warrants
will have no rights with respect to the shares of our common stock underlying such Pre-Funded Warrants. Upon exercise of the Pre-Funded
Warrants, the holders will be entitled to exercise the rights of a holder of common stock only as to matters for which the record date
occurs after the exercise date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Significant
holders or beneficial holders of shares of our common stock may not be permitted to exercise the Pre-Funded Warrants that they hold.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent
that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% of our outstanding common stock
immediately after exercise, which percentage may be changed at the holder&rsquo;s election to a higher or lower percentage not in excess
of 9.99%. As a result, the holder may not be able to exercise its Pre-Funded Warrants for shares of our common stock at a time when it
would be financially beneficial for the holder to do so. In such a circumstance, the holder could seek to sell its Pre-Funded Warrants
to realize value, but the holder may be unable to do so in the absence of an established trading market and due to applicable transfer
restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>If
we are unable to generate sustainable operating profit and sufficient cash flows, then our future success will depend on our ability
to raise capital.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to seek additional financing and evaluate financing alternatives in order to meet our cash requirements for the foreseeable future.
We cannot be certain that raising additional capital, whether through selling additional debt or equity securities or obtaining a line
of credit or other loan, will be available to us or, if available, will be on terms acceptable to us. If we issue additional securities
to raise funds, these securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders
may experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current
product development programs, cut operating costs, forego future development and other opportunities or even terminate our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_005"></A>SPECIAL
NOTICE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus supplement and any accompanying prospectus, including the documents that we incorporate by reference, contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section
21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). These forward-looking statements are intended
to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not
relate strictly to historical or current facts. Forward-looking statements involve risks and uncertainties and include statements regarding,
among other things, our growth strategies and opportunities, anticipated trends in our market, our anticipated needs for working capital,
and our expectations regarding our business strategy, business prospects, operating results, operating expenses, working capital, liquidity,
and capital expenditure requirements. Important assumptions underlying the forward-looking statements include, among others, demand for
our products, the cost, terms, and availability of components, pricing levels, the timing and cost of capital expenditures, competitive
conditions, and general economic conditions. Forward-looking statements are generally identifiable by use of the words &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo;
&ldquo;projects,&rdquo; &ldquo;continuing,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;expects,&rdquo; &ldquo;management believes,&rdquo; &ldquo;we
believe,&rdquo; &ldquo;we intend&rdquo; or the negative of these words or other variations on these words or comparable terminology.
In particular, these include statements relating to future actions, prospective products, market acceptance, future performance or results
of current and anticipated products, sales efforts, expenses, and the outcome of contingencies such as legal proceedings and financial
results. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">These
statements are based on our management&rsquo;s current expectations, beliefs and assumptions concerning future events affecting us, which
in turn are based on currently available information. These assumptions could prove inaccurate. They are subject to risks and uncertainties
known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.
Although we believe that the estimates and projections reflected in the forward-looking statements are reasonable, our expectations may
prove to be incorrect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should read this prospectus supplement, the accompanying prospectus and the documents that we incorporate by reference herein and therein
and have filed as exhibits to the registration statement, of which this prospectus supplement is part, completely and with the understanding
that our actual future results may be materially different from what we expect. You should assume that the information appearing in this
prospectus supplement and any accompanying prospectus is accurate as of the date on the front cover of this prospectus supplement. Because
the risk factors included in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference
herein and therein, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements
made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which it is made, and except as may be required under applicable securities laws, we undertake no obligation
to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect
the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors
will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination
of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the
information presented in this prospectus supplement and the accompanying prospectus and the documents that we incorporate by reference
herein and therein, and particularly our forward-looking statements, by these cautionary statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B><A NAME="S_006"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
estimate that the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering
expenses payable by us, will be approximately $[&nbsp;&nbsp; ] (or $[&nbsp;&nbsp; ] if the over-allotment option is exercised in full).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We currently intend to use the net proceeds from this offering, if any, to drive commercialization of the Company&rsquo;s FDA-cleared
12-lead synthesized ECG system; advance development of its 12-lead ECG extended-wear patch and heart attack detection initiatives; further
enhance its AI capabilities; and for working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated
growth of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to be received
upon the completion of this offering. The amounts and timing of the actual expenditures will depend on numerous factors, including the
status of our product development efforts, sales and marketing activities, technological advances, amount of cash generated or used in
our operations and competition. Accordingly, our management will have broad discretion in the application of the net proceeds and investors
will be relying on the judgment of its management regarding the application of the proceeds of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_007"></A>MARKET
PRICE OF OUR COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock and warrants are presently listed on The Nasdaq Capital Market under the symbol &ldquo;BEAT&rdquo; and &ldquo;BEATW&rdquo;,
respectively. On April [&#9679;], 2026, the last reported sale price of our common stock was $[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B><A NAME="S_008"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have never declared or paid cash dividends on our capital stock. We intend to retain our future earnings, if any, for use in our business
and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the
discretion of our board of directors after taking into account various factors, including our financial condition, operating results,
current and anticipated cash needs and plans for expansion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B><A NAME="S_009"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth our cash and cash equivalents and capitalization as of December 31, 2025:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">on
                                    an as adjusted basis to reflect the sale of [&#9679;] shares of common stock and Pre-Funded Warrants
                                    (after giving effect to the exercise of all Pre-Funded Warrants sold) in this offering at the public
                                    offering price of $[&#9679;] per share, after deducting the underwriting discounts and commissions
                                    and estimated offering expenses payable by us.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should read this table along with our unaudited consolidated financial statements and related notes as of and for the twelve months ended
December 31, 2025, as well as the other financial information incorporated by reference in this prospectus supplement and the accompanying
prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">($
    in thousands)</FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Actual</FONT></TD><TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
    Adjusted</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,380</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;]</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders&rsquo;
    equity:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred stock
    - $0.0001 par value; 10,000,000 authorized; 0 shares outstanding at December 31, 2025</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common stock -
    $0.0001 par value 100,000,000 shares authorized; 40,117,404 shares issued and outstanding at December 31, 2025</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;]</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">79,887</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;]</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(77,288</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;]</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Stockholders&rsquo; Equity</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,603</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Capitalization</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,777</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&#9679;]</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
December 31, 2025, the number of shares of common stock outstanding in the table above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,119,589 shares of Common
    Stock issuable upon the exercise of outstanding stock options having a weighted average exercise price of $2.15 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457,522 shares of Common
    Stock issuable upon vesting of RSUs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,827,035 shares of Common
    Stock issuable upon the exercise of outstanding warrants having a weighted average exercise price of $4.42 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,440,666 shares of Common
    Stock reserved for future issuance under the Company&rsquo;s 2022 Equity Plan; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">970,467
                                    related to At-the-Market (ATM) sales agreement with Public Ventures (&ldquo;ATM Shares&rdquo;) issued
                                    between January 1, 2026 &ndash; March 31, 2026.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as otherwise indicated herein, all information in this prospectus assumes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the outstanding
    options described above; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise by the Underwriter
    of the over-allotment option or the warrants issued to the Underwriter as compensation in connection with this Offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_010"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
you invest in our Common Stock in this offering, your ownership interest will be diluted to the extent of the difference between the
assumed offering price per share of its Common Stock and the as adjusted net tangible book value per share of its Common Stock immediately
after the offering. Historical net tangible book value per share represents the amount of the Company&rsquo;s total tangible assets less
total liabilities, divided by the number of shares of its Common Stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
historical net tangible book value (deficit) of our Common Stock as of December 31, 2025, was approximately $2.6 million or $0.06 per
share based upon shares of Common Stock outstanding on such date. Historical net tangible book value (deficit) per share represents the
amount of its total tangible assets reduced by the amount of its total liabilities, divided by the total number of shares of Common Stock
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">After
giving effect to the sale of all of the [&#9679;] of shares of Common Stock (which assumes the exercise of all Pre-Funded Warrants sold
in this offering and no exercise of the Underwriter Warrants) offered in this offering at an assumed public offering price of $[&#9679;]
per share after deducting estimated underwriting fees and estimated offering expenses net tangible book value as of [&#9679;], 2026 would
have been $[&#9679;] or $[&#9679;] per share. This represents an immediate increase in net tangible book value of $[&#9679;] per share,
to the existing stockholders, and an immediate dilution in net tangible book value of $[&#9679;] per share to new investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table illustrates this per share dilution of shares of Common Stock sold in this offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price per share</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 88%; padding-left: 9.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
    net tangible book value per share as of December 31, 2025</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.06</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible
    book value per share attributable to this offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted net tangible
    book value per share after giving effect to this offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<FONT STYLE="font-size: 10pt">&#9679;]</FONT></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to
    new investors in this offering</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[<FONT STYLE="font-size: 10pt">&#9679;]</FONT></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
foregoing discussion and tables above are based on 40,117,404 shares of Common Stock issued and outstanding as of December 31, 2025,
and excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
December 31, 2025, the number of shares of common stock outstanding in the table above excludes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,119,589 shares of Common
    Stock issuable upon the exercise of outstanding stock options having a weighted average exercise price of $2.15 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457,522 shares of Common
    Stock issuable upon vesting of RSUs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,827,035 shares of Common
    Stock issuable upon the exercise of outstanding warrants having a weighted average exercise price of $4.42 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,440,666 shares of Common
    Stock reserved for future issuance under the Company&rsquo;s 2022 Equity Incentive Plan (the &ldquo;2022 Equity Plan&rdquo;); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">970,467&nbsp;related
                                    to ATM Shares issued between January 26 &ndash; March 31, 2026.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as otherwise indicated herein, all information in this prospectus reflects or assumes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise of the outstanding
    options described above;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no exercise by the Underwriter
    of the over-allotment option or the warrants issued to the Underwriter as compensation in connection with this Offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_011"></A>DESCRIPTION
OF SECURITIES WE ARE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
this offering, we are offering [&#9679;] maximum of shares of our Common Stock at public offering price of $[&#9679;] per share. To the
extent that the purchase of shares of Common Stock would otherwise result in the purchaser&rsquo;s beneficial ownership exceeding 4.99%
of our outstanding Common Stock immediately following the consummation of this offering, we are also offering the opportunity to purchase
Pre-Funded Warrants in lieu of shares of Common Stock. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
material terms and provisions of our Common Stock are described under the caption &ldquo;Description of Capital Stock&rdquo; starting
on page 7 of the accompanying base prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-Funded
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following summary of certain terms and provisions of the Pre-Funded Warrants that are being offered hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the Pre-Funded Warrant, the form of which will be filed as an exhibit to a Current
Report on Form 8-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus
supplement forms a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for
a complete description of the terms and conditions of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Duration
and exercise price.&nbsp;</I></B>Each Pre-Funded Warrant offered hereby will have an initial exercise price per share equal to $0.001.
The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock
dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Exercisability.&nbsp;</I></B>The
Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of
a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s
Pre-Funded Warrant to the extent that the holder would own more than 4.99% of the outstanding shares of common stock immediately after
exercise, except that upon at least 61 days&rsquo; written prior notice from the holder to us, the holder may increase or decrease the
amount of ownership of outstanding shares of common stock after exercising the holder&rsquo;s Pre-Funded Warrants up to 9.99% of the
number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the Pre-Funded Warrants. No fractional shares of common stock will be issued in connection with the exercise
of a Pre-Funded Warrant. In lieu of fractional shares, we will either pay the holder an amount in cash equal to the fractional amount
multiplied by the exercise price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Cashless
exercise.&nbsp;</I></B>If at the time of exercise, there is no effective registration statement registering the issuance of the shares
upon exercise of the Pre-Funded Warrants, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise
in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the
net number of shares of common stock determined according to a formula set forth in the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Fundamental
transactions.&nbsp;</I></B>In the event of any fundamental transaction, as described in the Pre-Funded Warrants and generally including
any merger with or into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification
of our shares of common stock, then upon any subsequent exercise of a Pre-Funded Warrant, the holder will have the right to receive as
alternative consideration, for each share of common stock that would have been issuable upon such exercise immediately prior to the occurrence
of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation or of our company, if
it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction by a holder of the
number of shares of common stock for which the Pre-Funded Warrant is exercisable immediately prior to such event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Transferability.&nbsp;</I></B>Subject
to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without our consent. The ownership
of the Pre-Funded Warrants and any transfers of the Pre-Funded Warrants will be registered in a warrant register.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Exchange
listing.&nbsp;</I></B>There is no established trading market for the Pre-Funded Warrants. We do not intend to list the Pre-Funded Warrants
on any securities exchange or nationally recognized trading system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>No
rights as a stockholder.&nbsp;</I></B>Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&rsquo;s ownership
of shares of our common stock, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of our common stock,
including any voting rights, until such Pre-Funded Warrant holders exercise their Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Underwriter
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following summary of certain terms and provisions of the Underwriter Warrants that are being offered hereby is not complete and is subject
to, and qualified in its entirety by, the provisions of the Underwriter Warrant, the form of which will be filed as an exhibit to a Current
Report on Form 8-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus
supplement forms a part. You should carefully review the terms and provisions of the form of Underwriter Warrant for a complete description
of the terms and conditions of the Underwriter Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
the closing of this offering, we have agreed to issue to the underwriter, or its designees, Underwriter Warrants to purchase up to
[&#9679;] shares of Common Stock equal to an aggregate of [&#9679;]% of the total number of shares of common stock and Pre-Funded
Warrants sold in this public offering. The Underwriter Warrants will be exercisable at a per share exercise price equal to [&#9679;]% of the offering price per share sold in this offering, or $[&#9679;]. The Underwriter Warrants will be exercisable immediately
upon issuance, in whole or in part, at any time on or after the date of issuance, and will be exercisable for a period of five years
from the date of this prospectus supplement. See &ldquo;<I>Underwriting &mdash; Underwriter Warrants</I>&rdquo; on page S-27 of this
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
transfer agent and registrar for our common stock is VStock Transfer, LLC with an address at 18 Lafayette Pl, Woodmere, NY 11598.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B><A NAME="S_012"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to enter into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, acting as
the sole book-running manager (sometimes referred to as the &ldquo;underwriter&rdquo;). Subject to the terms and conditions of the underwriting
agreement, the underwriter will agree to purchase, and we will agree to sell to it, the number of securities listed next to its name
at the public offering price, less the underwriting discounts and commissions, as set forth on the cover page of this prospectus supplement
and as indicated below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Underwriter</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of <BR> Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Pre-Funded Warrants</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Titan Partners
    Group LLC, a division of American Capital Partners, LLC</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriting agreement provides that the obligations of the underwriter to pay for and accept delivery of the shares of common stock
and Pre-Funded Warrants offered by this prospectus supplement are subject to various conditions and representations and warranties, including
the approval of certain legal matters by its counsel and other conditions specified in the underwriting agreement. The shares of common
stock and Pre-Funded Warrants are offered by the underwriter, subject to prior sale, when, as and if issued to and accepted by the underwriter.
The underwriter reserves the right to withdraw, cancel or modify the offer to the public and to reject orders in whole or in part. The
underwriter is obligated to take and pay for all of the shares of common stock and warrants offered by this prospectus supplement if
any of the securities are taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have agreed to indemnify the underwriter and certain of its affiliates and controlling persons (within the meaning of Section 15 of the
Securities Act or Section 20 of the Securities and Exchange Act of 1934, as amended), among others, against specified liabilities, including
liabilities under the Securities Act of 1933, as amended, and to contribute to payments the underwriter may be required to make in respect
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Discounts
and Commissions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriter proposes to sell the shares of common stock and Pre-Funded Warrants directly to the public at the public offering price set
forth on the cover page of this prospectus supplement. After the offering to the public, the offering price and other selling terms may
be changed by the underwriter without changing the proceeds we will receive from the underwriter. Any securities sold by the underwriter
to securities dealers will be sold at the public offering price less a selling concession not in excess of $[&#9679;] per lot of one
share and $[&#9679;] per lot of Pre-Funded Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table summarizes the public offering price, underwriting commissions and proceeds before expenses to us. The underwriting discount
is [&#9679;]% of the gross proceeds received at the closing of the offering from the sale of the securities in the offering. We have
also agreed to reimburse the underwriter at closing for reasonable, documented out-of-pocket expenses actually incurred by the underwriter,
up to $[&#9679;], including the fees and disbursements of the underwriter&rsquo;s legal counsel. We estimate that our total offering
expenses for this offering, net of the underwriting discounts and commissions, will be approximately $[&#9679;]. We have also agreed
to pay a non-accountable expense allowance equal to [&#9679;]% of the gross proceeds received at the closing if the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price
    Per<BR>
    Pre-Funded<BR>
    Warrant</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    </B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 67%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">[&#9679;]</FONT></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions ([&#9679;] %)<SUP>(1)</SUP></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                            have also agreed to reimburse the underwriters for certain expenses and to pay to the representative
                                            at the closing of the offering a non-accountable expense allowance equal to [&#9679;]% of
                                            the gross proceeds of this offering.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
total estimated expenses of the offering, including registration, filing and listing fees, printing fees, legal and accounting expenses,
and non-accountable expense, but excluding underwriting discounts and commissions, are approximately $[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have granted the underwriter an over-allotment option. This option, which is exercisable from time to time, for up to 30 days after the
date of this prospectus supplement, permits the underwriter to purchase up to an aggregate of [&#9679;] additional shares of common stock.
The purchase price to be paid per additional share of common stock shall be equal to the public offering price of one share of common
stock equal to $[&#9679;], less the underwriting discount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Underwriter
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
the closing of this offering, we have agreed to issue to the underwriter, or its designees, warrants (the &ldquo;Underwriter Warrants&rdquo;)
to purchase a number of shares of common stock equal to an aggregate of [&#9679;] % of the total number of shares of common stock sold
in this offering. The underwriter warrants will be exercisable at a per share exercise price equal to [&#9679;]% of the offering price
of the shares of common stock sold in this offering, or $[&#9679;] per share. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Underwriter Warrants will be exercisable immediately upon issuance, in whole or in part, at any time on or after the date of issuance,
and will be exercisable for a period of five years from the date of this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriter does not intend to confirm sales of the shares of common stock offered hereby to any accounts over which it has discretionary
authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the underwriting agreement, we have agreed to indemnify the underwriter against certain liabilities, including liabilities under the
Securities Act, or to contribute to payments that the underwriter or such other indemnified parties may be required to make in respect
of those liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Without
the prior written consent of the underwriter, for a period of 75 days following the date of the closing of this offering (the &ldquo;Lock-Up
Period&rdquo;), we have agreed not to (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any
shares of common stock or common stock equivalents without the prior written consent of the underwriter; (ii) file or caused to be filed
any registration statement with the SEC relating to the offering of any shares of common stock or common stock equivalents or any securities
convertible into or exercisable or exchangeable for shares of common stock or common stock equivalents; or (iii) enter into any swap
or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of common stock or
common stock equivalents, whether any such transaction described in clause (i), (ii), or (iii) above is to be settled by delivery of
shares of common stock or common stock equivalents, in cash or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, each of our directors and officers has entered into a lock-up agreement with the Company. Under the lock-up agreements, without
the prior written consent of the underwriter, during the Lock-Up Period the foregoing persons may not, offer, sell, contract to sell,
hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to,
result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the
undersigned or any Affiliate of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly
or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning
of Section 16 of the Exchange Act, with respect to, any shares of Common Stock of the Company or securities convertible, exchangeable
or exercisable into, shares of Common Stock of the Company beneficially owned, held or hereafter acquired by the undersigned (the &ldquo;Securities&rdquo;)
or make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect
to the registration of any shares of Common Stock or Common Stock Equivalents or publicly disclose the intention to do any of the foregoing.
These restrictions on future dispositions by our directors and officers are subject to certain exceptions for transfers of Securities,
including, but not limited to, transfers (i) as a bona fide gift or gifts, (ii) to the immediate family of the transferor, (iii) to any
trust for the direct or indirect benefit of such person or the immediate family of the transferor, (iv) to any beneficiary of the transferor
pursuant to a will or other testamentary document or applicable laws of descent and (v) to any corporation, partnership, limited liability
company or other entity all of the beneficial ownership interests of which are held by the transferor or the immediate family of the
transferor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock is listed on The Nasdaq Capital Market under the trading symbol &ldquo;BEAT.&rdquo; There is no established trading market
for the Pre-Funded Warrants, and we do not expect a trading market to develop. We do not intend to list the Pre-Funded Warrants on any
securities exchange or nationally recognized trading system. Without a trading market, the liquidity of the Pre-Funded Warrants will
be extremely limited. We have submitted an application to The Nasdaq Capital Market to list the shares of common stock offered hereby,
including shares of common stock issuable upon exercise of the Pre-Funded Warrants and the Underwriter Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Price
Stabilization, Short Positions and Penalty Bids</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
order to facilitate the offering of our securities, the underwriter may engage in transactions that stabilize, maintain or otherwise
affect the price of our securities. In connection with the offering, the underwriter may purchase and sell our securities in the open
market. These transactions may include short sales, purchases on the open market to cover positions created by short sales and stabilizing
transactions. Short sales involve the sale by the underwriter of a greater number of securities than they are required to purchase in
the offering. [&ldquo;Covered&rdquo; short sales are sales made in an amount not greater than the underwriter&rsquo;s option to purchase
additional securities in the offering. The underwriter may close out any covered short position by either exercising the over-allotment
option to purchase securities or purchasing securities in the open market. In determining the source of securities to close out the covered
short position, the underwriter will consider, among other things, the price of securities available for purchase in the open market
as compared to the price at which they may purchase securities through the over-allotment option to purchase securities. &ldquo;Naked&rdquo;
short sales are sales in excess of the over-allotment option to purchase securities. The underwriter must close out any naked short position
by purchasing securities in the open market. A naked short position is more likely to be created if the underwriter is concerned that
there may be downward pressure on the price of our securities in the open market after pricing that could adversely affect investors
who purchase in the offering.] Stabilizing transactions consist of various bids for or purchases of securities made by the underwriter
in the open market before the completion of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Similar
to other purchase transactions, the underwriter&rsquo;s purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As result,
the price of our securities may be higher than the price that might otherwise exist in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriter makes no representation or prediction as to the direction or magnitude of any effect that the transactions described above
may have on the price of our securities. In addition, neither we nor the underwriter make any representation that the underwriter will
engage in these transactions or that these transactions, once commenced, will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Electronic
Offer, Sale and Distribution of Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus supplement and accompanying base prospectus in electronic format may be made available on the websites maintained by the underwriter
or selling group members, if any, participating in the offering. The underwriter may agree to allocate a number of securities to selling
group members for sale to their online brokerage account holders. Internet distributions will be allocated by the selling group members
that may make internet distributions on the same basis as other allocations. Other than this prospectus supplement and accompanying base
prospectus in electronic format, the information on the underwriter&rsquo;s or selling group member&rsquo;s website and any information
contained in any other website maintained by the underwriter or selling group member is not part of this prospectus supplement, accompanying
base prospectus or the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, the underwriter and/or its affiliates may provide in the future, various advisory, investment and commercial banking and
other services to us in the ordinary course of business, for which they will receive customary fees and commissions. However, except
as disclosed in this prospectus, we have no present arrangements with the underwriter or any of its affiliates for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
terms and the public offering prices of the securities offered hereby were determined by negotiations between us and the underwriter.
Among the factors considered in determining the public offering price were our future prospects and those of our industry in general,
our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales
ratios, market prices of our securities and the securities of other public companies, market conditions, and certain financial and operating
information of companies engaged in activities similar to ours. Neither we nor the underwriter can assure investors that an active trading
market for the securities will develop or that, after the offering, the securities will trade in the public market at or above the public
offering price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered
by this prospectus supplement and accompanying base prospectus in any jurisdiction where action for that purpose is required. The securities
offered by this prospectus supplement and accompanying base prospectus may not be offered or sold, directly or indirectly, nor may this
prospectus supplement and accompanying base prospectus or any other offering material or advertisements in connection with the offer
and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance
with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform
themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement and accompanying
base prospectus. This prospectus supplement and accompanying base prospectus does not constitute an offer to sell or a solicitation of
an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Australia</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus supplement is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the
Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under
Chapter 6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus supplement is only
made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under
one or more exemptions set out in section 708 of the Australian Corporations Act, (ii) this prospectus supplement is made available in
Australia only to those persons as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that
by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted
under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree
within 12 months after its transfer to the offeree under this prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Canada</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors,
as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies
for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that
the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation
of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation
of the purchaser&rsquo;s province or territory for particulars of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Cayman
Islands</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
invitation, whether directly or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>European
Economic Area &mdash; Belgium, Germany, Luxembourg and Netherlands</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under
the Directive 2003/71/EC, the Prospectus Directive, as implemented in Member States of the European Economic Area (each, a Relevant Member
State), from the requirement to produce a prospectus for offers of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following
exemptions under the Prospectus Directive as implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp; &nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to legal entities that
    are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is
    solely to invest in securities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to any legal entity that
    has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more than
    &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover
    of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to fewer than 100 natural
    or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive) subject to obtaining
    the prior consent of us or any underwriter for any such offer; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in any other circumstances
    falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement
    for the publication by us of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>France</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers)
in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code Monetaire et Financier) and Articles
211-1 et seq. of the General Regulation of the French Autorite des marches financiers (AMF). The securities have not been offered or
sold and will not be offered or sold, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval
in France and, accordingly, may not be distributed or caused to be distributed, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Such
offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifies) acting
for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D.744-1, D.754-1; and
D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors
(cercle restreint d&rsquo;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg;
and D.411-4, D.744-1, D.754-1; and D.764-1 of the French Monetary and Financial Code and any implementing regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly
or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3
of the French Monetary and Financial Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Ireland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed
with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities
in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005, or the Prospectus Regulations. The securities
have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering,
except to (i) qualified investors as defined in Regulation 2(1) of the Prospectus Regulations and (ii) fewer than 100 natural or legal
persons who are not qualified investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
securities offered by this prospectus supplement have not been approved or disapproved by the Israeli Securities Authority (the &ldquo;ISA&rdquo;)
nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public
in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering
or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered
an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities
offered by this prospectus supplement is subject to restrictions on transferability and must be effected only in compliance with the
Israeli securities laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Italy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione
Nazionale per le Society e la Borsa, &ldquo;CONSOB&rdquo;) pursuant to the Italian securities legislation and, accordingly, no offering
material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer
within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (Decree No. 58), other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to Italian qualified investors,
    as defined in Article 100 of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999 (Regulation
    no. 11971) as amended (Qualified Investors); and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in other circumstances
    that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of Regulation No. 11971
    as amended.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements
where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made by investment firms,
    banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of
    1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable laws; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in compliance with all
    relevant Italian securities, tax and exchange controls and any other applicable laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules
provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply
with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring
the securities for any damages suffered by the investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Japan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan
(Law No. 25 of 1948), as amended (the FIEL) pursuant to an exemption from the registration requirements applicable to a private placement
of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations
promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities
may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities
is conditional upon the execution of an agreement to that effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Portugal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
document is not being distributed in the context of a public offer of financial securities (oferta publica de valores mobiliarios) in
Portugal, within the meaning of Article 109 of the Portuguese Securities Code (Codigo dos Valores Mobiliarios). The securities have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other
offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission
(Comissao do Mercado de Valores Mobiliarios) for approval in Portugal and, accordingly, may not be distributed or caused to be distributed,
directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under
the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &ldquo;qualified
investors&rdquo; (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute
it or the information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Sweden</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority).
Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances
that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel
med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &ldquo;qualified investors&rdquo; (as
defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the
information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Switzerland</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange
or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance
prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under
art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither
this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available
in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neither
this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial
Market Supervisory Authority (FINMA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
document is personal to the recipient only and not for general circulation in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>United
Arab Emirates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neither
this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates
or any other governmental authority in the United Arab Emirates, nor have we received authorization or licensing from the Central Bank
of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the
United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating
to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the
United Arab Emirates by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>United
Kingdom</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Conduct
Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as
amended (FSMA) has been published or is intended to be published in respect of the securities. This document is issued on a confidential
basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may
not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances
which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published
or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the
issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be
communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters
relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005 (FPO), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies,
unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &ldquo;relevant persons&rdquo;).
The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged
in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_013"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
validity of the shares of common stock offered hereby will be passed upon for us by Lucosky Brookman LLP. Certain legal matters will
be passed upon for the Underwriter by Sullivan &amp; Worcester LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_014"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
financial statements of HeartBeam, Inc as of and for the year ended December 31, 2025, has been audited by CBIZ CPAs P.C., an independent
registered public accounting firm, as stated in their report which includes an explanatory paragraph as to the Company&rsquo;s ability
to continue as a going concern, which is incorporated herein by reference. Such financial statements have been incorporated by reference
in reliance upon the report pertaining to such financial statements of such firm given upon their authority as experts in accounting
and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
financial statements of HeartBeam, Inc. as of and for the year ended December 31, 2024, has been audited by Marcum LLP, an independent
registered public accounting firm, as stated in their report which includes an explanatory paragraph as to the Company&rsquo;s ability
to continue as a going concern, which is incorporated herein by reference. Such financial statements have been incorporated by reference
in reliance upon the report pertaining to such financial statements of such firm given upon their authority as experts in accounting
and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="S_015"></A>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
SEC&rsquo;s rules allow us to &ldquo;incorporate by reference&rdquo; information into this prospectus, which means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference
is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede
that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
incorporate by reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &ldquo;Exchange Act&rdquo; in this prospectus, between
the date of this prospectus and the termination of the offering of the securities described in this prospectus. We are not, however,
incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that are not
deemed &ldquo;filed&rdquo; with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits
furnished pursuant to Item 9.01 of Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus supplement incorporates by reference the documents listed below, other than those documents or the portions of those documents
deemed to be furnished and not filed in accordance with SEC rules:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1779372/000119312526104080/beat-20251231.htm">Form
    10-K</A> for the fiscal year ended December 31, 2025, filed with the SEC on March 12, 2026; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our
    securities contained in our Registration Statement on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1779372/000121390021058171/ea150371-8a12b_heartbeaminc.htm"><FONT STYLE="font-size: 10pt">Form
    8-A</FONT></A> <FONT STYLE="font-size: 10pt">filed with the SEC on November 10, 2021, including any amendment or report filed for
    the purpose of updating such description.</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination
of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior
to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will
also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports
and documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
may request a free copy of any of the documents incorporated by reference in this prospectus (other than exhibits, unless they are specifically
incorporated by reference in the documents) by writing or telephoning us at the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Robert
Eno<BR>
Chief Executive Officer<BR>
2118 Walsh Avenue, Suite 210<BR>
Santa Clara, CA 95050<BR>
Telephone: 408-899-4443</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibits
to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus and
any accompanying prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>HeartBeam,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>$100,000,000
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Debt
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Units
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may offer and sell up to $100,000,000 in the aggregate of the securities identified above from time to time in one or more offerings.
This prospectus provides you with a general description of the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering
and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus
with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement before you invest in
any of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters,
dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are
involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement
between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement.
See the sections of this prospectus entitled &ldquo;About this Prospectus&rdquo; and &ldquo;Plan of Distribution&rdquo; for more information.
No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms
of the offering of such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>INVESTING
IN OUR SECURITIES INVOLVES RISKS. SEE THE &ldquo;<U>RISK FACTORS</U>&rdquo; ON PAGE 7 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED
IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock and warrants are listed on The Nasdaq Capital Market under the symbol &ldquo;BEAT&rdquo; and &ldquo;BEATW&rdquo;, respectively.
On March 12, 2026, the last reported sale price of our common stock on The Nasdaq Capital Market was $1.47 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
date of this prospectus is&nbsp;March 17, 2026.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_001">ABOUT
    THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">ii</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_002">THE COMPANY</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_003">RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_004">SPECIAL
    NOTE REGARDING FORWARD LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_005">USE OF
    PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_006">DESCRIPTION
    OF CAPITAL STOCK</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">7</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_007">DESCRIPTION
    OF DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">10</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_008">DESCRIPTION
    OF WARRANTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">16</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_009">DESCRIPTION
    OF RIGHTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_010">DESCRIPTION
    OF UNITS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_011">PLAN OF
    DISTRIBUTION</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">18</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_012">LEGAL
    MATTERS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_013">EXPERTS</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_014">WHERE
    YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#k_015">INCORPORATION
    BY REFERENCE</A></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_001"></A><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;),
using a &ldquo;shelf&rdquo; registration process. By using a shelf registration statement, we may sell securities from time to time and
in one or more offerings up to a total dollar amount of $100,000,000 as described in this prospectus. Each time that we offer and sell
securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being
offered and sold and the specific terms of that offering. The prospectus supplement may also add, update or change information contained
in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable
prospectus supplement, you should rely on the prospectus supplement. Before purchasing any securities, you should carefully read both
this prospectus and the applicable prospectus supplement, together with the additional information described under the headings &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation by Reference.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent
information, you should not rely on it. We will not make an offer to sell these securities in any jurisdiction where the offer or sale
is not permitted. You should assume that the information appearing in this prospectus and the applicable prospectus supplement to this
prospectus is accurate as of the date on its respective cover, and that any information incorporated by reference is accurate only as
of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations
and prospects may have changed since those dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">When
we refer to &ldquo;BEAT,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and the &ldquo;Company&rdquo; in this prospectus,
we mean HeartBeam, Inc., unless otherwise specified. When we refer to &ldquo;you,&rdquo; we mean the holders of the applicable series
of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_002"></A><B>THE
COMPANY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
History and Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam
was incorporated as a C corporation under the laws of the State of Delaware on June&nbsp;11, 2015. We do not own any subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Company
Overview</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam
is a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver
innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and
monitoring of cardiac disease outside of a healthcare facility. Our ability to develop higher resolution Electrocardiogram (&ldquo;ECG&rdquo;)
solutions is achieved through the development of our proprietary and patented technology platform that allows us to collect the heart&rsquo;s
electrical activity from three dimensions and synthesize a 12-Lead (&ldquo;12L&rdquo;) ECG from these signals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe our Products (&ldquo;Products&rdquo; or &ldquo;Product&rdquo;) and services will benefit many stakeholders, including patients,
healthcare providers, and healthcare payors, and will also address the rapidly growing field of ambulatory cardiac monitoring. As part
of our long-term vision, we believe that we are uniquely positioned to play a central role in high-risk Coronary Artery Disease (&ldquo;CAD&rdquo;)
monitoring, given positive, proof-of-concept data from the initial feasibility studies that demonstrated comparable performance of the
HeartBeam System and the standard 12L ECG in ischemia detection. CAD patients are at increased risk for a heart attack or Myocardial
Infarction (&ldquo;MI&rdquo;). Additionally, our unique portable form-factor will make high-fidelity insights easily accessible, wherever
patients are, compared to a standard 12L ECG, which is typically limited to a healthcare setting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
initial product and service offering is the HeartBeam System. The HeartBeam System is the first U.S. Food and Drug Administration (&ldquo;FDA&rdquo;)
cleared cable-free, ambulatory ECG that captures the heart&rsquo;s electrical signals from three dimensions for high-fidelity data collection
and advanced diagnostics for arrhythmia assessment. The HeartBeam System is comprised of a credit card sized 3D ECG recording device,
a patient application, a physician portal, and powerful cloud-based algorithms. Unlike any single-lead or 6-lead consumer device, HeartBeam&rsquo;s
patented cable-free technology captures the heart&rsquo;s electrical signals in three non-coplanar dimensions and synthesizes them into
a familiar 12L ECG display, using a personalized transformation matrix. This allows patients to obtain a 12L ECG reading for their arrhythmia
from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind. The synthesized 12-lead
ECG is promptly reviewed by an on-demand, board-certified cardiologist.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam&rsquo;s
credit card sized 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software
received FDA clearance in December 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are focused on advancing several key initiatives as part of our growth strategy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Limited
                                            Launch</B>: On the back of our recent FDA Clearance for the HeartBeam System, we are initiating
                                            a market introduction in early 2026, focusing on select concierge and preventive cardiology
                                            groups that have proactively signaled strong interest in adopting HeartBeam&rsquo;s technology.
                                            This limited market release will enable the Company to validate real world performance and
                                            establish reference sites for broader commercialization.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Heart
                                            Attack Detection</B>: We are pursuing an expansion of our cleared indications through a heart
                                            attack detection indication, supported by compelling proof-of-concept data and representing
                                            a major expansion opportunity to tens of millions of patients in the U.S.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Extended
                                            Wear Patch</B>: We are making significant advancements with an on-demand 12L ECG extended
                                            wear monitor. The Company has developed a working prototype of its novel 12L patch, which
                                            has the potential to be a best-in-class offering in an existing multi-billion-dollar market
                                            with reimbursement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Longitudinal
                                            Data and AI</B>: The Company believes it has the ability to unlock the power of the unique
                                            data-rich repository generated from our 3D ECG platform and deep learning algorithms. As
                                            adoption grows, the ability for patients to record synthesized 12L ECGs over time will create
                                            the opportunity to build AI-based screening and prediction algorithms that go beyond what
                                            is possible with single-timepoint ECGs or traditional wearables.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2025, we had 16 employees. In January 2026, the Company hired a Chief Commercial Officer, Bryan Humbarger, bringing total
headcount to 17 employees. Bryan brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies.
While initially focused on launching the Company&rsquo;s FDA-cleared 12L system for arrhythmia assessment, he will lead the Company&rsquo;s
broader commercialization strategy across key growth initiatives, including heart attack detection and the 12L ECG extended wear patch.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to strike a balance of managing our headcount in line with cash resources, while also, at the appropriate time, hiring or engaging
additional full-time professionals, employees, and / or consultants in alignment with our growth strategy. To that end, the Company does
not anticipate the need to hire a large sales force during the initial launch of its HeartBeam System. We believe that a few well-placed
resources will help provide the data points required to effectively invest into a broader launch based around a path to profitable growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
the market is highly competitive for attracting and retaining highly qualified professionals in our industry, we continue our endeavor
to find such candidates for our Company. Our management team and additional personnel that we may hire in the future will be primarily
responsible for executing and implementing growth opportunities, making tactical decisions related to our strategy and pursuing opportunities
to invest in new technologies through strategic partnerships and acquisitions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Market
Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chronic
diseases are the number one burden on the healthcare system, driving up costs each year, and cardiovascular illnesses are one of the
top contributors. Regulators, payors, and providers are focused on earlier diagnosis and improved management of these conditions to drive
better outcomes at lower cost. One way to accomplish this is through the use of Connected Medical Devices - solutions that use technology
to provide healthcare services remotely and aim to reduce healthcare expenditures while allowing patients to engage with clinicians and
better self-manage their care. The Connected Medical Device Market size is estimated at $66 billion in 2024, and is expected to reach
$133 billion by 2029, growing at a compounded annual growth (&ldquo;CAGR&rdquo;) of 15% during the forecast period (2024-2029).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cardiovascular
disease is the most expensive disease to manage and is estimated to be responsible for one in every eight healthcare dollars spent in
the US, projected to cost the US healthcare system $1 trillion by 2035. As cardiovascular disease is the leading cause of death worldwide,
early detection, diagnosis, and management of chronic cardiac conditions are necessary to relieve the increasing burden on the healthcare
system. Diagnostic tests such as ECGs are used to detect, diagnose, and track numerous cardiovascular conditions. The market for cardiac
monitoring technologies, such as Holter monitors, patch-based cardiac monitoring technologies, and any other ECG-based technology used
for clinical diagnosis is projected to reach approximately $18 billion by 2030, a CAGR of approximately 8%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">With
advances in mobile communications, diagnostic monitoring of cardiac conditions is increasingly occurring outside the hospital. Global
sales of patient monitoring devices in 2021 were $42 billion. With a CAGR of approximately 11% from 2022 to 2032, the market is projected
to reach a valuation of $125 billion by 2032. The adoption of such technology was greatly accelerated by the COVID-19 pandemic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the US, someone has a heart attack every 40 seconds. We believe there are no products on the market that are portable, easy to use, and
always with the patient to provide physicians with timely and highly accurate information about heart conditions that could be detected
with a standard 12L ECG. A tool that is always with the patient and decreases time to intervention would have a significant effect on
saving lives and healthcare dollars. We believe our technology will address this problem by providing convenient, cost-effective cardiac
monitoring solutions, including multiple form factors for the hardware and evolving software and ecosystem for physicians and patient
engagement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Products
and Technology</I></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">HeartBeam&rsquo;s
IP and novel technology have resulted in our initial Product, the HeartBeam System. Our HeartBeam System device records cardiac signals
with integrated electrodes rather than cables. The electrocardiogram (ECG) signal collection device is similar in size to a credit card,
is about 1/8 inch (4 mm), and weighs about 1 ounce (28 grams). The core technology consists of a series of patented inventions and associated
algorithms that allow us to capture the heart&rsquo;s electrical activity from three distinct directions and get a complete view of the
heart&rsquo;s electrical activity. As a high-fidelity ECG system, it captures heart signals from three distinct directions for actionable
heart health information and allows physicians to diagnose a wide range of non-urgent complex arrhythmias.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
patented technology, along with a proprietary algorithm, allow us to generate signals similar to a 12L ECG without the need for cables,
unlike a standard 12L ECG machine. In addition, we use the concept of a baseline, through which we will be able to measure the change
in cardiac parameters between an asymptomatic (baseline) recording and the symptomatic recording. The baseline is personalized for every
patient, offering an increase in diagnostic performance as published previously in JACC: Advances (https://www.jacc.org/doi/10.1016/j.jacadv.2023.100454).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Longer-term,
there will be obvious ease-of-use advantages when comparing our credit card-sized device to the current 12L ECG machine. The small form
factor of our device makes it portable and able to be used by a patient at home or elsewhere. The device can be self-applied versus requiring
a trained professional to apply. Additionally, the ease of use will allow for prompt data collection, immediately upon symptom onset
which can be sent a physician to assess the patient&rsquo;s ECG in the context of the patient&rsquo;s baseline ECG, symptoms, and cardiac
health history.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
we commence our commercialization efforts, The HeartBeam System will consist of a number of capabilities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
                                            FDA-cleared, cable-free 12L ECG collection device for the assessment of arrhythmias. The
                                            device captures cardiac signals in 3D through three non-coplanar dimensions and transmits
                                            them via Bluetooth connection to a smartphone. The device&rsquo;s small form factor allows
                                            it to be always with the patient. It is easy to use, as all that is required of the patient
                                            is that the device be pressed against the chest.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                            cloud-based software system that serves four basic functions: (1) performing ECG signal quality
                                            checks, (2) synthesizing a 12L ECG from the 3D ECG, and (3) preparing a summary report for
                                            the physician. To facilitate a more accurate physician interpretation of the data, the software
                                            will also overlay the patient&rsquo;s synthesized baseline 12L ECG waveform on the synthesized
                                            12L ECG waveform from the current reading. To ensure high signal quality, the system checks
                                            for noise levels in the recorded signals. Those signals that can be effectively filtered
                                            are accepted and those that have a noise level above an empirically established threshold
                                            are rejected. If a recorded signal is rejected, the user is asked to repeat the recording.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                            web-based physician portal capable of displaying the following relevant information for the
                                            physician to analyze: patient history, symptoms, synthesized 12L ECG, and recorded 3 leads.
                                            Our physician portal assists physicians with their diagnostic interpretation by providing
                                            both the baseline 12L synthesized ECG and the 12L synthesized ECG that is under evaluation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
                                            dedicated team of cardiologists, offering 24/7/365 services in order to provide a recommended
                                            course of action to patients based on the ECG signals, symptoms, and patient history. The
                                            patient will have the option of having a consult with a medical professional.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe this is the first patient-friendly, portable device of its kind to be cleared by the FDA and our two FDA clearance are major
milestones for the Company. In addition, our FDA Clearances provide the regulatory foundation for subsequent products and expanded indications.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Future
versions of our Products may include an expansion of our cleared indications through a heart attack detection indication, an on-demand
12L ECG extended wear patch monitor, and AI-based screening and prediction algorithms.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company believes it has the ability to unlock the power of the unique data-rich repository generated from our 3D ECG platform and deep
learning algorithms. As adoption grows, the ability for patients to record synthesized 12L ECGs over time will create the opportunity
to build AI-based screening and prediction algorithms that go beyond what is possible with single-timepoint ECGs or traditional wearables.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
custom software and hardware of our Products are classified as Class II medical devices by the FDA. Premarket review and clearance by
the FDA for Class II devices is generally accomplished through the 510(k) premarket notification process or De Novo process. Given the
proposed intended use of our device, the 510(k) submission or De Novo process is expected to require clinical data to support future
FDA clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Market
Opportunity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ECGs
are key diagnostic tests utilized in the diagnosis and monitoring of cardiovascular disease, the number one cause of death worldwide.
According to the American Heart Association, there were approximately 130 million adults living with cardiovascular disease and approximately
20 million adults with diagnosed CAD in the US. The prevalence of these cardiac conditions and thus the market size is increasing, due
to an aging population and lifestyle choices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Every
40 seconds someone in the US has a heart attack, or MI. Unfortunately, there is no way for patients at home to distinguish if the symptoms
they are experiencing are due to an MI, or some other more benign condition such as indigestion. As a result, patients often ignore symptoms
and delay seeking care, which leads to worse outcomes and increased mortality. Shortening that time from symptoms to the door of a medical
facility would reduce complications and save lives. On the other hand, many patients who go to the Emergency Department (ED) with chest
pain are not experiencing an MI. Chest pain is the second most common reason for an ED visit in patients over 45, yet fewer than 20%
of chest pain ED visits result in a diagnosis of a life-threatening condition. These unnecessary ED visits lead to well over $10 billion
in unnecessary healthcare expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ea028535401_img6.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
ECGs are conducted in a healthcare facility setting using a 12L ECG machine, the gold standard. ECGs taken outside of healthcare facilities
are expected to grow more quickly than in-hospital ECGs. Monitoring cardiac patients outside of a hospital is a fast-growing trend, as
it is less expensive and provides a better patient experience. However, while ambulatory cardiac monitoring devices are often much easier
for patients to use, they have fewer leads than the gold standard and therefore cannot offer as comprehensive a picture of cardiac health.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
a standard 12L ECG readout is of great medical value, it is simply impractical to have a standard 12L machine next to patients when they
experience symptoms outside the clinical setting, since recording the event requires attaching multiple electrodes to the patient&rsquo;s
body with professional assistance. While existing technologies use predominantly single lead ECG devices to monitor arrhythmias, these
technologies do not provide information to the physician on the presence of life-threatening conditions such as acute coronary syndrome
(ACS) including MIs, also known as heart attacks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe our technology will address these market needs and has several key attributes that make it a good fit for these patients. Our
Product can be used anywhere when symptoms occur and offers the potential for lifelong patient usage. The device is practically always
near the patient and ready to be used for recording a cardiac event. It enables real-time transmission of the ECG signals and in the
future, a synthesized 12L ECG. We believe physicians will typically prescribe our solution to chronic cardiovascular patients for long
term monitoring, thereby enabling prolonged data collection and delivering a more complete picture for diagnosis. This will also enable
the use of artificial intelligence (AI) on our future database that will have a unique set of longitudinal ECG signals and synthesized
12L ECGs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
we believe our ECG platform will demonstrate 12L equivalence and clinical and cost-effectiveness advantages, coupled with a patent protected
technology, we believe this might open multiple licensing and/or partnering opportunities with players in the ECG, cardiac monitoring
patch and smart watch verticals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Market
Strategy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
goal is to establish our Products as key solutions for concierge practices consisting of internal medicine and cardiology specialty,
as well as cardiology practices. Our efforts to enter the market involve establishing clinical evidence and demonstrating the cost-effectiveness
of adopting our Products. The initial geographic market for HeartBeam System is the US, and the Company will remain opportunistic in
addressing international market opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
primary customers are concierge physicians, preventative cardiology practices and the cardiology departments of hospitals. Healthcare
insurers are another important customer, as they will potentially benefit from the reduced costs to the healthcare system. We are working
to develop new clinical studies and publish results of completed clinical studies and plan to demonstrate real world cost-effectiveness
of the use of the solution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
initial targets for the HeartBeam System are market segments that see value in an easy-to-use medical-grade ECG device. These will be
segments in which payment for the device will be outside of the established reimbursement system. These target segments may include concierge
practices, the hospital-at-home segment and use in clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
long-term strategy is to generate sufficient evidence of clinical efficacy and cost-effectiveness and partner with health insurance companies
(payers) to seek coverage for the HeartBeam System solution. We expect to be able to demonstrate significant clinical benefits for patients
and savings to Payers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
primary marketing strategy will focus on the medical community with continued validation of clinical efficacy and cost-effectiveness
and the establishment of reference sites. We will also create educational materials and provide other support to help educate our customers&rsquo;
patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are currently speaking with concierge practices and hospitals in large healthcare systems to educate them about our Product. These are
sophisticated customers who already understand the benefit of the patient having access to a 12L ECG at home, and we plan to use technical
presentations, peer-reviewed clinical data, and demonstration projects to achieve penetration of this market. We plan to continue to
utilize the expertise of our medical advisory board, conduct clinical trials with leading cardiologists to increase the body of evidence,
and establish reference sites among these customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
expect our value proposition will be progressively increased as we gradually add additional functionality to our monitoring solutions
and drive down the cost by increasing scale and automation. We expect our HeartBeam System to eventually incorporate algorithms with
the capabilities of detecting heart conditions that can be detected via a standard 12L ECG device. Additionally, as we collect rich longitudinal
data sets from our patients, we expect to train AI algorithms that could potentially have predictive capabilities regarding different
heart conditions. Over time and with scale, we expect that our costs per user will decrease and that we will provide more and better
services to our patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
our initial markets, we plan to establish a small, direct sales network with relationships and experience selling to our target markets.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Clinical
Data</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
technology is backed by robust clinical data, including the VALID-ECG pivotal study. The results of this pivotal study were presented
at the Heart Rhythm Society conference in April 2025. The study evaluated the mean difference in ECG intervals and amplitudes between
HeartBeam&rsquo;s synthesized 12L ECG and a simultaneously collected standard 12L ECG. Intervals and amplitudes are important in assessing
non-life-threatening arrhythmias. Data showed a 93.4% overall diagnostic agreement, indicating that HeartBeam&rsquo;s synthesized 12L
ECG can support manual detection of arrhythmias in a manner consistent with standard 12L ECGs. The VALID-ECG pivotal study was a multicenter
trial that enrolled 198 patients across five clinical sites in the US, including Allegheny Health Network, Atlanta Heart Specialists,
Mount Sinai Hospital, Northwell Health and Piedmont Heart Institute. Efforts were made to enroll patients with a diverse demographic
profile reflective of the intended use population in the United States.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
landmark clinical study on the Company&rsquo;s technology was published in the August 2023 issue of the journal JACC: Advances. The publication,
&ldquo;Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit Card-Size Personal Device Integration&rdquo; demonstrated
that HeartBeam technology detects the presence of a coronary occlusion, the cause of heart attacks, with the same accuracy as a standard
12L ECG. The study showed that the automated analysis of the 3L ECG and 12L ECG signals had similar performance in determining whether
a coronary artery was occluded. Also in the study, the human interpretation of the 12L ECGs had significant intra- and inter-observer
variability, which does not occur with automated readings. The study also showed that the presence of the &ldquo;normal baseline&rdquo;
recording, a novel feature that is integral to HeartBeam&rsquo;s 3L ECG technology, dramatically improved the accuracy of interpretation,
increasing the Area Under the Curve, a standard measure of diagnostic performance, from 0.72 to 0.95. This is particularly important
since physicians who are analyzing 12L ECGs often do not have access to a normal baseline, implying that the HeartBeam System could outperform
this approach. The study was a collaboration of Harvard Medical School Faculty at Beth Israel Deaconess Medical Center in Boston, MA,
and Clinical Center of Serbia in Belgrade.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Data
on the HeartBeam deep learning algorithm was presented at two prestigious Electrophysiology conferences: the European Heart Rhythm Society,
held in Berlin, Germany in April 2024 and the Heart Rhythm Society, held in Boston, MA in May 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
key data from two pilot studies were presented at American Heart Association meeting in November 2024. The studies demonstrated early
evidence of (1) clinical equivalence of the HeartBeam Synthesized 12L ECG to a standard 12L ECG for diagnosis of arrhythmia and (2) the
use of the technology for heart attack detection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Intellectual
Property</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s patent portfolio includes twenty-four (24) issued patents worldwide, consisting of sixteen (16) issued patents in the
United States and eight (8) issued patents outside of the United States, including one (1) European patent granted with unitary effect
under the Unitary Patent system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
the United States, the Company also has twelve (12) additional pending patent applications. Outside the United States, the Company has
twenty-two (22) pending patent applications in jurisdictions including Canada, China, the European Union, Japan, South Korea, and Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s issued patents are expected to expire between April 11, 2036, and April 21, 2042. The pending applications, regardless
of publication status, are projected to expire between April 11, 2036, and February 20, 2045.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
our quest to redefine the landscape of digital health through our innovative, user-friendly ambulatory solutions, our primary objective
remains steadfast: to deliver high medical value through products that are always with the patient, assisting physicians in monitoring
and diagnosing cardiac disease in patients. We believe that our success in developing initial products, underscored by our emphasis on
user-friendly solutions, will set a solid foundation for our future endeavors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that our R&amp;D team, primarily based in the US and Belgrade, Serbia, is a testament to our commitment to excellence and innovation
and is comprised of seven employees, plus consultants, with expertise in the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Healthcare
                                            IT platform development, biomedical engineering, electrical engineering with expertise in
                                            machine learning (ML), signal processing and ECG analysis from the medical device industry,
                                            as well as specialties in wireless communication,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Of
                                            note, we have seven (7) Physicists and Electrical Engineers (all Ph.D. E.E. or Ph.D. Physics)
                                            credited with our key inventions and patents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Looking
ahead, we anticipate further enhancing our efforts in harnessing signal processing and artificial intelligence (AI) to broaden our diagnostic
solutions across a spectrum of cardiac conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
core technology, a cable-free ECG that can measure heart&rsquo;s electrical activity in three distinct directions, is a platform technology
that we believe is poised to revolutionize diagnostic solutions for cardiovascular patients. Potential applications include a synthesized
12L capable patch ECG monitor, offering significant diagnostic advantages through its 12L capability over existing single-lead ECG patch
products. This innovation aims to provide standard of care 12L ECG capabilities in a form factor like current single-lead ECG patches,
which we believe addresses a critical gap in the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
further potential application is a synthesized 12L ECG smartwatch-based monitor, offering significant diagnostic advantages through its
12L capability over existing single-lead ECG smartwatch solutions. The plan for this monitor is to eliminate the need for dedicated ECG
devices, offering synthesized 12L ECG capabilities directly from a smartwatch. Combining our unique and data rich set of signals with
a smartwatch, we believe, will enable the detection of heart attacks and complex arrhythmias with unprecedented convenience and efficiency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Both
the patch and smartwatch-based monitor technologies are covered by patents that we believe provide us with a strong position to expand
beyond the current platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
AI team, comprising industry leading experts, developed a roadmap for AI-based tool development. These tools will combine state-of-the-art
AI models and techniques applied to our unique and data rich set of signals. Initial AI development results indicate potential to significantly
enhance ambulatory diagnostic capabilities over what is currently available. It is expected that AI development efforts will quickly
become one of our major R&amp;D efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
we continue to advance our synthesized 12L technology, evidenced by our recently issued and allowed patents with potentially disruptive
market impacts, our initial product will leverage rule-based algorithms, including signal processing and ECG synthesis. Concurrently,
we are developing a number of AI-based cardiac disease detection algorithms to become the cornerstone of our commercialized systems.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Future
Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
core technology - the approach to capturing heart&rsquo;s electrical activity in three distinct directions, adopted and invented by our
research team - is a platform technology that can provide diagnostic solutions to a variety of cardiovascular patients. Our plans call
for expanding solutions that diagnose all major cardiac conditions that are diagnosed by ECGs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
future plans include the development of a synthesized 12-lead capable patch ECG monitor that will provide advantages over existing single-lead
ECG patch products such as the Zio Monitor from iRhythm Technologies, Inc. Our approach will offer a synthesized 12-lead ECG with a patch
that is very similar, in dimensions and look and feel, to the currently available single lead ECG patches. We believe providing standard
of care 12-lead ECG capabilities will have significant diagnostic advantages over a single lead patch.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
also plan to integrate a synthesized 12-lead ECG smartwatch-based monitor intended for detection of heart attacks and complex cardiac
arrhythmias. This invention is intended to eliminate the need for a dedicated ECG device while offering a synthesized 12-lead ECG capability
enabling heart attack and complex arrhythmia detection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
our initial Product is powered by a software expert system that serves as a diagnostic aid to a physician, our plan is to develop an
AI based diagnostic system that will supplement our diagnostic expert system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
corporate offices are located at 2118 Walsh Avenue, Suite 210, Santa Clara, CA&nbsp;95050. Our telephone number is (408)&nbsp;899-4443.
The address of our website is <I>https:</I>//<I>www.heartbeam</I>/. The inclusion of our website address in this prospectus does not
include or incorporate by reference the information on our website into this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_003"></A><B>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Investment
in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider
the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form
10-Q or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by
reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information
contained in the applicable prospectus supplement before acquiring any of such securities. The occurrence of any of these risks might
cause you to lose all or part of your investment in the offered securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_004"></A><B>SPECIAL
NOTICE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus contains forward-looking statements that involve risks and uncertainties, principally in the sections entitled &ldquo;Risk
Factors.&rdquo; All statements other than statements of historical fact contained in this prospectus, including statements regarding
future events, our future financial performance, business strategy and plans and objectives of management for future operations, are
forward-looking statements. We have attempted to identify forward-looking statements by terminology including &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo;
&ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;should,&rdquo;
or &ldquo;will&rdquo; or the negative of these terms or other comparable terminology. Although we do not make forward looking statements
unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions
and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &ldquo;Risk Factors&rdquo; or
elsewhere in this prospectus, which may cause our or our industry&rsquo;s actual results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forward-looking
statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the
times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available
at the time they are made and/or management&rsquo;s good faith belief as of that time with respect to future events, and are subject
to risks and uncertainties that could cause actual performance or results to differ materially from what is expressed in or suggested
by the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forward-looking
statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no
obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting
forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking
statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_005"></A><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_006"></A><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following description of the Company&rsquo;s capital stock and provisions of its Certificate of Incorporation and Bylaws are summaries
and are qualified by reference to the Company&rsquo;s Certificate of Incorporation and Bylaws, which have been publicly filed with the
SEC. See &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation by Reference.&rdquo;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Authorized
and Outstanding Capital Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company is authorized to issue 110,000,000 shares of capital stock, consisting of 100,000,000 shares of Common Stock, par value $0.0001
per share and 10,000,000 shares of Preferred Stock, par value $0.0001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 11, 2026, the Company had 41,087,871 outstanding shares of Common Stock held by approximately 45 shareholders of record. As
of the date thereof, there were no shares of preferred stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Common
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
holders of our Common Stock are entitled to one vote per share. In addition, the holders of our Common Stock will be entitled to receive
dividends ratably, if any, declared by our board of directors out of legally available funds; however, the current policy of the board
of directors is to retain earnings, if any, for operations and growth. Upon liquidation, dissolution or winding-up, the holders of our
Common Stock are entitled to share ratably in all assets that are legally available for distribution. The holders of our Common Stock
have no pre-emptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of our Common Stock
are subject to, and may be adversely affected by, the rights of the holders of any series of preferred stock, which may be designated
solely by action of the board of directors and issued in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Preferred
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Board of Directors will have the authority, without further action by our stockholders, to issue up to 10,000,000&nbsp;shares of preferred
stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges
could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and
the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Common Stock.
The issuance of our preferred stock could adversely affect the voting power of holders of Common Stock and the likelihood that such holders
will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect
of delaying, deferring or preventing a change in control of our company or other corporate action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following summary of certain terms and provisions of the warrants (the &ldquo;Warrants&rdquo;) is not complete and is subject to, and
qualified in its entirety by, the provisions of the warrant agency agreement between us and VStock Transfer, LLC (the &ldquo;Warrant
Agent&rdquo;), and the form of warrant, which have been publicly filed with the SEC.&nbsp;See &ldquo;Where You Can Find More Information&rdquo;
and &ldquo;Incorporation by Reference.&rdquo; As of December&nbsp;31, 2025, there were 3,162,500 Warrants issued and outstanding trading
under BEATW.&nbsp;The exercise price of the Warrants is $6 per share. Each Warrant is exercisable for one share of our Common Stock,
subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar
events affecting our common stock as described herein. A holder may not exercise any portion of a warrant to the extent that the holder,
together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of the outstanding Common Stock
after exercise, as such percentage ownership is determined in accordance with the terms of the Warrants, except that upon notice from
the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. Each warrant will be exercisable immediately
upon issuance and will expire five (5)&nbsp;years after the initial issuance date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to the warrants mentioned above, the Company has issued the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            February&nbsp;18, 2022, the Company issued 58,000&nbsp;warrants to purchase 58,000&nbsp;shares
                                            of common stock at an exercise price of $6.00 per share, with an expiration date of five&nbsp;years
                                            from the date thereof.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            January&nbsp;14, 2022, the Company issued 72,727&nbsp;warrants based on performance metrics
                                            achieved in 2021 to purchase 72,727&nbsp;shares of common stock at an exercise price of $5.50
                                            per share, with an expiration of five&nbsp;years from the date of issuance.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            November&nbsp;15, 2022, the Company issued warrants to the lead underwriter, as portion of
                                            the underwriting compensation payable in connection with the Company&rsquo;s initial public
                                            offering (&ldquo;IPO&rdquo;). The warrants accounted for 7% of the number of common stock
                                            sold in the IPO, which was 192,500&nbsp;warrants, exercisable at a per share exercise price
                                            equal to $7.50 per share and expire five&nbsp;years from the date of issuance. The warrants
                                            were subject to a 180-day lock-up period.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May
    2, 2023, the Company issued 1,666,666 placement agent warrants to purchase shares of Common Stock sold in the offering, with an exercise
    price of $1.875 per share and are exercisable for five years from the date of issuance.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
                                            February 12, 2025, the Company entered into an Underwriting Agreement with Public Ventures
                                            LLC to consummate an offering of 5,882,353 shares of Common Stock at an offering price of
                                            $1.70 per share, which closed on February 14, 2025. In addition, the subscription agreement
                                            granted 588,235 underwriter warrants with an exercise price of exercise price is $2.13. On
                                            February 25, 2025, Public Ventures, LLC exercised its over-allotment option to purchase an
                                            additional 864,033 shares of Common Stock. In addition, the subscription agreement granted
                                            86,403 underwriter warrants with an exercise price of $2.13 as part of this transaction.
                                            In total, the Company issued 674,638 placement agent underwriter warrants to purchase shares
                                            of Common Stock sold in the offering, with an exercise price of $2.13 per share and are exercisable
                                            for five years from the date of issuance, after a 360-day lockup period.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>2022
Equity Incentive Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June&nbsp;15, 2022, our Board of Directors approved the 2022 Equity Incentive Plan (&ldquo;2022 Equity Plan&rdquo;), to attract and retain
the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors, and
consultants, and to promote the success of the Company&rsquo;s business. The 2022 Equity Plan provides for the grant of stock options
and restricted stock awards (&ldquo;RSUs&rdquo;) to purchase common stock. Initially, the aggregate number of shares of our Common Stock
that may be issued pursuant to stock awards under our 2022 Equity Plan was 1,900,000 shares. The 2022 Equity Plan was increased to 5,900,000
at the 2023 annual shareholders&rsquo; meeting, increased to 8,900,000 shares at the 2024 annual shareholders&rsquo; meeting, and subsequently
increased to 11,900,000 shares at the 2025 annual shareholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2025, there are 6,009,055 shares available for issuance under the 2022 Equity Plan. The number of shares available for
issuance under the 2022 Equity Plan will be increased on the first&nbsp;day of each fiscal year beginning with the 2023 fiscal year by
five percent (5%) of the total number of shares of common stock outstanding on the last&nbsp;day of the immediately preceding fiscal
year as defined in the 2022 Equity Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eligible
recipients of option awards are employees, officers, consultants, attorneys, advisors or directors (including non-employee directors)
of the Company or of any parent, subsidiary or affiliate of the Company. The Board of Directors has the authority to grant to any eligible
recipient any options, restricted stock or other awards valued in whole or in part by reference to, or otherwise based on, the Company&rsquo;s
Common Stock; provided, however, that Incentive Options may only be granted to employees of the Company or its subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
provisions of each option granted need not be the same with respect to each option recipient. Option recipients have entered into award
agreements with the Company, in such form as the full Board of Directors has determined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
2022 Equity Plan is administered by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Anti-Takeover
Provisions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following is a summary of certain provisions of Delaware law, our Certificate of Incorporation and our bylaws. This summary does not
purport to be complete and is qualified in its entirety by reference to the corporate law of Delaware and our Certificate of Incorporation
and bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Amended
Certificate of Incorporation and Amended and Restated Bylaws</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
charter documents include provisions that may have the effect of discouraging, delaying or preventing a change in control or an unsolicited
acquisition proposal that a stockholder might consider favorable, including a proposal that might result in the payment of a premium
over the market price for the shares held by our stockholders. Certain provisions are summarized in the following paragraphs.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Effects
of authorized but unissued common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">One
of the effects of the existence of authorized but unissued common stock may be to enable our board of directors to make more difficult
or to discourage an attempt to obtain control of our Company by means of a merger, tender offer, proxy contest or otherwise, and thereby
to protect the continuity of management. If, in the due exercise of its fiduciary obligations, the board of directors were to determine
that a takeover proposal was not in our best interest, such shares could be issued by the board of directors without stockholder approval
in one or more transactions that might prevent or render more difficult or costly the completion of the takeover transaction by diluting
the voting or other rights of the proposed acquirer or insurgent stockholder group, by putting a substantial voting block in institutional
or other hands that might undertake to support the position of the incumbent board of directors, by effecting an acquisition that might
complicate or preclude the takeover, or otherwise.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Special
Meeting of Stockholders and Stockholder Action by Written Consent. </I>A special meeting of the stockholders may be called at any time
by the Board, Chairperson of the Board, Chief Executive Officer or President (in the absence of a Chief Executive Officer) or by one
or more stockholders holding shares in the aggregate entitled to cast not less than 10% of the votes at that meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Section&nbsp;203
of the Delaware General Corporation Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any
interested stockholder for a period of three&nbsp;years after the date that such stockholder became an interested stockholder, with the
following exceptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">before
                                            such date, our board of directors approved either the business combination or the transaction
                                            that resulted in the stockholder becoming an interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">upon
                                            closing of the transaction that resulted in the stockholder becoming an interested stockholder,
                                            the interested stockholder owned at least 85% of the voting stock of the corporation outstanding
                                            at the time the transaction began, excluding for purposes of determining the voting stock
                                            outstanding (but not the outstanding voting stock owned by the interested stockholder) those
                                            shares owned by (i)&nbsp;persons who are directors and also officers and (ii)&nbsp;employee
                                            stock plans in which employee participants do not have the right to determine confidentially
                                            whether shares held subject to the plan will be tendered in a tender or exchange offer; or
                                            on or after such date, the business combination is approved by our board of directors and
                                            authorized at an annual or special meeting of the stockholders, and not by written consent,
                                            by the affirmative vote of at least 66-&frac23;% of the outstanding voting stock that is
                                            not owned by the interested stockholder.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, Section&nbsp;203 defines business combination to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            merger or consolidation involving the corporation and the interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation
                                            involving the interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">subject
                                            to certain exceptions, any transaction that results in the issuance or transfer by the corporation
                                            of any stock of the corporation to the interested stockholder;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            transaction involving the corporation that has the effect of increasing the proportionate
                                            share of the stock or any class or series of the corporation beneficially owned by the interested
                                            stockholder; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
                                            receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges
                                            or other financial benefits by or through the corporation.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
general, Section&nbsp;203 defines an &ldquo;interested stockholder&rdquo; as an entity or person who, together with the person&rsquo;s
affiliates and associates, beneficially owns, or within three&nbsp;years prior to the time of determination of interested stockholder
status did own, 15% or more of the outstanding voting stock of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
Nasdaq Capital Market Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
common stock and warrants are listed on the Nasdaq Capital Market, under the symbol &ldquo;BEAT&rdquo; and &ldquo;BEATW&rdquo;, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Transfer
Agent and Warrant Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
transfer agent, warrant agent and registrar for our common stock is VStock Transfer with an address of 18 Lafayette Place Woodmere, New&nbsp;York
11598.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_007"></A><B>DESCRIPTION
OF DEBT SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
debt securities that we may offer by this prospectus consist of notes, debentures, or other evidences of indebtedness. The debt securities
may constitute either senior or subordinated debt securities, and in either case may be either secured or unsecured. Any debt securities
that we offer and sell will be our direct obligations. Debt securities may be issued in one or more series. All debt securities of any
one series need not be issued at the same time, and unless otherwise provided, a series of debt securities may be reopened, with the
required consent of the holders of outstanding debt securities, for issuance of additional debt securities of that series or to establish
additional terms of that series of debt securities (with such additional terms applicable only to unissued or additional debt securities
of that series). The form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part
and is subject to any amendments or supplements that we may enter into with the trustee(s), however, we may issue debt securities not
subject to the indenture provided such terms of debt securities are not otherwise required to be set forth in the indenture. The material
terms of the indenture are summarized below and we refer you to the indenture for a detailed description of these material terms. Additional
or different provisions that are applicable to a particular series of debt securities will, if material, be described in a prospectus
supplement relating to the offering of debt securities of that series. These provisions may include, among other things and to the extent
applicable, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            title of the debt securities, including, as applicable, whether the debt securities will
                                            be issued as senior debt securities, senior subordinated debt securities or subordinated
                                            debt securities, any subordination provisions particular to the series of debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            limit on the aggregate principal amount of the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            the debt securities are senior debt securities or subordinated debt securities and applicable
                                            subordination provisions, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            the debt securities will be secured or unsecured;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                            other than 100% of the aggregate principal amount, the percentage of the aggregate principal
                                            amount at which we will sell the debt securities, such as an original issuance discount;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            date or dates, whether fixed or extendable, on which the principal of the debt securities
                                            will be payable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            rate or rates, which may be fixed or variable, at which the debt securities will bear interest,
                                            if any, the date or dates from which any such interest will accrue, the interest payment
                                            dates on which we will pay any such interest, the basis upon which interest will be calculated
                                            if other than that of a 360-day year consisting of twelve 30-day&nbsp;months, and, in the
                                            case of registered securities, the record dates for the determination of holders to whom
                                            interest is payable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            place or places where the principal of and any premium or interest on the debt securities
                                            will be payable and where the debt securities may be surrendered for conversion or exchange;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            we may, at our option, redeem the debt securities, and if so, the price or prices at which,
                                            the period or periods within which, and the terms and conditions upon which, we may redeem
                                            the debt securities, in whole or in part, pursuant to any sinking fund or otherwise;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                            other than 100% of the aggregate principal amount thereof, the portion of the principal amount
                                            of the debt securities which will be payable upon declaration of acceleration of the maturity
                                            date thereof or provable in bankruptcy, or, if applicable, which is convertible or exchangeable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            obligation we may have to redeem, purchase or repay the debt securities pursuant to any sinking
                                            fund or analogous provisions or at the option of a holder of debt securities, and the price
                                            or prices at which, the currency in which and the period or periods within which, and the
                                            terms and conditions upon which, the debt securities will be redeemed, purchased or repaid,
                                            in whole or in part, pursuant to any such obligation, and any provision for the remarketing
                                            of the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            issuance of debt securities as registered securities or unregistered securities or both,
                                            and the rights of the holders of the debt securities to exchange unregistered securities
                                            for registered securities, or vice versa, and the circumstances under which any such exchanges,
                                            if permitted, may be made;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            denominations, which may be in United&nbsp;States Dollars or in any foreign currency, in
                                            which the debt securities will be issued, if other than denominations of $1,000 and any integral
                                            multiple thereof;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            the debt securities will be issued in the form of certificated debt securities, and if so,
                                            the form of the debt securities (or forms thereof if unregistered and registered securities
                                            are issuable in that series), including the legends required by law or as we deem necessary
                                            or appropriate, the form of any coupons or temporary global security which may be issued
                                            and the forms of any other certificates which may be required under the indenture or which
                                            we may require in connection with the offering, sale, delivery or exchange of the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                            other than United&nbsp;States Dollars, the currency or currencies in which payments of principal,
                                            interest and other amounts payable with respect to the debt securities will be denominated,
                                            payable, redeemable or repurchasable, as the case may be;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            the debt securities may be issuable in tranches;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            obligations, if any, we may have to permit the conversion or exchange of the debt securities
                                            into common stock, preferred stock or other capital stock or property, or a combination thereof,
                                            and the terms and conditions upon which such conversion or exchange will be effected (including
                                            conversion price or exchange ratio), and any limitations on the ownership or transferability
                                            of the securities or property into which the debt securities may be converted or exchanged;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                            other than the trustee under the indenture, any trustees, authenticating or paying agents,
                                            transfer agents or registrars or any other agents with respect to the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            deletions from, modifications of or additions to the events of default with respect to the
                                            debt securities or the right of the Trustee or the holders of the debt securities in connection
                                            with events of default;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            deletions from, modifications of or additions to the covenants with respect to the debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                            the amount of payments of principal of, and make-whole amount, if any, and interest on the
                                            debt securities may be determined with reference to an index, the manner in which such amount
                                            will be determined;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            the debt securities will be issued in whole or in part in the global form of one or more
                                            debt securities and, if so, the depositary for such debt securities, the circumstances under
                                            which any such debt security may be exchanged for debt securities registered in the name
                                            of, and under which any transfer of debt securities may be registered in the name of, any
                                            person other than such depositary or its nominee, and any other provisions regarding such
                                            debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether,
                                            under what circumstances and the currency in which, we will pay additional amounts on the
                                            debt securities to any holder of the debt securities who is not a United&nbsp;States person
                                            in respect of any tax, assessment or governmental charge and, if so, whether we will have
                                            the option to redeem such debt securities rather than pay such additional amounts, and the
                                            terms of any such option;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            the debt securities will be secured by any collateral and, if so, a general description of
                                            the collateral and the terms of any related security, pledge or other agreements;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            persons to whom any interest on the debt securities will be payable, if other than the registered
                                            holders thereof on the regular record date therefore; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            other material terms or conditions upon which the debt securities will be issued.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
otherwise indicated in the applicable prospectus supplement, we will issue debt securities in fully registered form without coupons and
in denominations of $1,000 and in integral multiples of $1,000, and interest will be computed on the basis of a 360-day year of twelve
30-day&nbsp;months. If any interest payment date or the maturity date falls on a&nbsp;day that is not a business&nbsp;day, then the payment
will be made on the next business&nbsp;day without additional interest and with the same effect as if it were made on the originally
scheduled date. &ldquo;Business&nbsp;day&rdquo; means any calendar&nbsp;day that is not a Saturday, Sunday or legal holiday in New&nbsp;York,
New&nbsp;York, and on which the trustee and commercial banks are open for business in New&nbsp;York, New&nbsp;York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
we inform you otherwise in a prospectus supplement, each series of our senior debt securities will rank equally in right of payment with
all of our other unsubordinated debt. The subordinated debt securities will rank junior in right of payment and be subordinate to all
of our unsubordinated debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
otherwise indicated in the applicable prospectus supplement, the trustee will act as paying agent and registrar for the debt securities
under the indenture. We may act as paying agent under the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
prospectus supplement will contain a description of United&nbsp;States federal income tax consequences relating to the debt securities,
to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Covenants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
applicable prospectus supplement will describe any covenants, such as restrictive covenants restricting us or our subsidiaries, if any,
from incurring, issuing, assuming or guarantying any indebtedness or restricting us or our subsidiaries, if any, from paying dividends
or acquiring any of our or its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Consolidation,
Merger and Transfer of Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
indenture permits a consolidation or merger between us and another entity and/or the sale, conveyance or lease by us of all or substantially
all of our property and assets, provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            resulting or acquiring entity, if other than us, is organized and existing under the laws
                                            of a United&nbsp;States jurisdiction and assumes all of our responsibilities and liabilities
                                            under the indenture, including the payment of all amounts due on the debt securities and
                                            performance of the covenants in the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">immediately
                                            after the transaction, and giving effect to the transaction, no event of default under the
                                            indenture exists; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            have delivered to the trustee an officers&rsquo; certificate stating that the transaction
                                            and, if a supplemental indenture is required in connection with the transaction, the supplemental
                                            indenture comply with the indenture and that all conditions precedent to the transaction
                                            contained in the indenture have been satisfied.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we consolidate or merge with or into any other entity, or sell or lease all or substantially all of our assets in compliance with the
terms and conditions of the indenture, the resulting or acquiring entity will be substituted for us in the indenture and the debt securities
with the same effect as if it had been an original party to the indenture and the debt securities. As a result, such successor entity
may exercise our rights and powers under the indenture and the debt securities, in our name and, except in the case of a lease, we will
be released from all our liabilities and obligations under the indenture and under the debt securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing, we may transfer all of our property and assets to another entity if, immediately after giving effect to the transfer,
such entity is our wholly owned subsidiary. The term &ldquo;wholly owned subsidiary&rdquo; means any subsidiary in which we and/or our
other wholly owned subsidiaries, if any, own all of the outstanding capital stock.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Modification
and Waiver</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the indenture, some of our rights and obligations and some of the rights of the holders of the debt securities may be modified or amended
with the consent of the holders of not less than a majority in aggregate principal amount of the outstanding debt securities affected
by the modification or amendment. However, the following modifications and amendments will not be effective against any holder without
its consent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            change in the stated maturity date of any payment of principal or interest;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            reduction in the principal amount of or interest on any debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                            alteration or impairment of any right to convert at the rate or upon the terms provided in
                                            the indenture;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            change in the currency in which any payment on the debt securities is payable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">an
                                            impairment of a holder&rsquo;s right to sue us for the enforcement of payments due on the
                                            debt securities; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            reduction in the percentage of outstanding debt securities required to consent to a modification
                                            or amendment of the indenture or required to consent to a waiver of compliance with certain
                                            provisions of the indenture or certain defaults under the indenture.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under
the indenture, the holders of not less than a majority in aggregate principal amount of the outstanding debt securities may, on behalf
of all holders of the debt securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">waive
                                            compliance by us with certain restrictive provisions of the indenture; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">waive
                                            any past default under the indenture in accordance with the applicable provisions of the
                                            indenture, except a default in the payment of the principal of or interest on any series
                                            of debt securities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Events
of Default</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
we indicate otherwise in the applicable prospectus supplement, &ldquo;event of default&rdquo; under the indenture will mean, with respect
to any series of debt securities, any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">failure
                                            to pay interest on any debt security for 30&nbsp;days after the payment is due;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">failure
                                            to pay the principal of any debt security when due, either at maturity, upon redemption,
                                            by declaration or otherwise;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">failure
                                            on our part to observe or perform any other covenant or agreement in the indenture that applies
                                            to the debt securities for 90&nbsp;days after we have received written notice of the failure
                                            to perform in the manner specified in the indenture; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">certain
                                            events of bankruptcy, insolvency or reorganization.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Remedies
Upon an Event of Default</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an event of default occurs and continues, the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding
debt securities of such series may declare the entire principal of all the debt securities to be due and payable immediately, except
that, if the event of default is caused by certain events in bankruptcy, insolvency or reorganization, the entire principal of all of
the debt securities of such series will become due and payable immediately without any act on the part of the trustee or holders of the
debt securities. If such a declaration occurs, the holders of a majority of the aggregate principal amount of the outstanding debt securities
of such series can, subject to conditions, rescind the declaration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
indenture requires us to furnish to the trustee not less often than annually, a certificate from our principal executive officer, principal
financial officer or principal accounting officer, as the case may be, as to such officer&rsquo;s knowledge of our compliance with all
conditions and covenants under the indenture. The trustee may withhold notice to the holders of debt securities of any default, except
defaults in the payment of principal of or interest on any debt securities if the trustee in good faith determines that the withholding
of notice is in the best interests of the holders. For purposes of this paragraph, &ldquo;default&rdquo; means any event which is, or
after notice or lapse of time or both would become, an event of default under the indenture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
trustee is not obligated to exercise any of its rights or powers under the indenture at the request, order or direction of any holders
of debt securities, unless the holders offer the trustee satisfactory security or indemnity. If satisfactory security or indemnity is
provided, then, subject to other rights of the trustee, the holders of a majority in aggregate principal amount of the outstanding debt
securities may direct the time, method and place of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">conducting
                                            any proceeding for any remedy available to the trustee; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">exercising
                                            any trust or power conferred upon the trustee.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
holder of a debt security will have the right to begin any proceeding with respect to the indenture or for any remedy only if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            holder has previously given the trustee written notice of a continuing event of default;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            holders of not less than a majority in aggregate principal amount of the outstanding debt
                                            securities have made a written request of, and offered reasonable indemnity to, the trustee
                                            to begin such proceeding;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            trustee has not started such proceeding within 60&nbsp;days after receiving the request;
                                            and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">no
                                            direction inconsistent with such written request has been given to the trustee under the
                                            indenture.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">However,
the holder of any debt security will have an absolute right to receive payment of principal of and interest on the debt security when
due and to institute suit to enforce this payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Satisfaction
and Discharge; Defeasance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Satisfaction
and Discharge of Indenture. </I>Unless otherwise indicated in the applicable prospectus supplement, if at any time,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            have paid the principal of and interest on all the debt securities of any series, except
                                            for debt securities which have been destroyed, lost or stolen and which have been replaced
                                            or paid in accordance with the indenture, as and when the same shall have become due and
                                            payable, or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            have delivered to the trustee for cancellation all debt securities of any series theretofore
                                            authenticated, except for debt securities of such series which have been destroyed, lost
                                            or stolen and which have been replaced or paid as provided in the indenture, or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">all
                                            the debt securities of such series not theretofore delivered to the trustee for cancellation
                                            have become due and payable, or are by their terms are to become due and payable within one
                                            year or are to be called for redemption within one year, and we have deposited with the trustee,
                                            in trust, sufficient money or government obligations, or a combination thereof, to pay the
                                            principal, any interest and any other sums due on the debt securities, on the dates the payments
                                            are due or become due under the indenture and the terms of the debt securities,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">then
the indenture shall cease to be of further effect with respect to the debt securities of such series, except for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">rights
                                            of registration of transfer and exchange, and our right of optional redemption;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">substitution
                                            of mutilated, defaced, destroyed, lost or stolen debt securities;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">rights
                                            of holders to receive payments of principal thereof and interest thereon upon the original
                                            stated due dates therefor (but not upon acceleration) and remaining rights of the holders
                                            to receive mandatory sinking fund payments, if any;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            rights, obligations and immunities of the trustee under the indenture; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            rights of the holders of such series of debt securities as beneficiaries thereof with respect
                                            to the property so deposited with the trustee payable to all or any of them.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Defeasance
and Covenant Defeasance. </I>Unless otherwise indicated in the applicable prospectus supplement, we may elect with respect to any debt
securities of any series either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
                                            defease and be discharged from all of our obligations with respect to such debt securities
                                            (&ldquo;defeasance&rdquo;), with certain exceptions described below; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">to
                                            be released from our obligations with respect to such debt securities under such covenants
                                            as may be specified in the applicable prospectus supplement, and any omission to comply with
                                            those obligations will not constitute a default or an event of default with respect to such
                                            debt securities (&ldquo;covenant defeasance&rdquo;).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
must comply with the following conditions before the defeasance or covenant defeasance can be effected:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            must irrevocably deposit with the indenture trustee or other qualifying trustee, under the
                                            terms of an irrevocable trust agreement in form and substance satisfactory to the trustee,
                                            trust funds in trust solely for the benefit of the holders of such debt securities, sufficient
                                            money or government obligations, or a combination thereof, to pay the principal, any interest
                                            and any other sums on the due dates for those payments; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">we
                                            must deliver to the trustee an opinion of counsel to the effect that the holders of such
                                            debt securities will not recognize income, gain or loss for federal income tax purposes as
                                            a result of defeasance or covenant defeasance, as the case may be, to be effected with respect
                                            to such debt securities and will be subject to federal income tax on the same amount, in
                                            the same manner and at the same times as would be the case if such defeasance or covenant
                                            defeasance, as the case may be, had not occurred.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with defeasance, any irrevocable trust agreement contemplated by the indenture must include, among other things, provision
for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">payment
                                            of the principal of and interest on such debt securities, if any, appertaining thereto when
                                            due (by redemption, sinking fund payments or otherwise),</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            payment of the expenses of the trustee incurred or to be incurred in connection with carrying
                                            out such trust provisions,</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">rights
                                            of registration, transfer, substitution and exchange of such debt securities in accordance
                                            with the terms stated in the indenture, and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">continuation
                                            of the rights, obligations and immunities of the trustee as against the holders of such debt
                                            securities as stated in the indenture.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
accompanying prospectus supplement may further describe any provisions permitting or restricting defeasance or covenant defeasance with
respect to the debt securities of a particular series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Global
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
otherwise indicated in the applicable prospectus supplement, each debt security offered by this prospectus will be issued in the form
of one or more global debt securities representing all or part of that series of debt securities. This means that we will not issue certificates
for that series of debt securities to the holders. Instead, a global debt security representing that series will be deposited with, or
on behalf of, a securities depositary and registered in the name of the depositary or a nominee of the depositary. Any such depositary
must be a clearing agency registered under the Exchange&nbsp;Act. We will describe the specific terms of the depositary arrangement with
respect to a series of debt securities to be represented by a global security in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Notices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
will give notices to holders of the debt securities by mail at the addresses listed in the security register. In the case of notice in
respect of unregistered securities or coupon securities, we may give notice by publication in a newspaper of general circulation in New&nbsp;York,
New&nbsp;York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Governing
Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
particular terms of a series of debt securities will be described in a prospectus supplement relating to such series of debt securities.
Any indentures will be subject to and governed by the Trust Indenture Act&nbsp;of&nbsp;1939, as amended, and may be supplemented or amended
from time to time following their execution. Unless otherwise stated in the applicable prospectus supplement, we will not be limited
in the amount of debt securities that we may issue, and neither the senior debt securities nor the subordinated debt securities will
be secured by any of our property or assets. Thus, by owning debt securities, you are one of our unsecured creditors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Regarding
the Trustee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
time to time, we may maintain deposit accounts and conduct other banking transactions with the trustee to be appointed under the indenture
or its affiliates in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_008"></A><B>DESCRIPTION
OF WARRANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may offer to sell warrants from time to time. If we do so, we will describe the specific terms of the warrants in a prospectus supplement.
In particular, we may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series.
We may also issue warrants independently or together with other securities and the warrants may be attached to or separate from those
securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
will evidence each series of warrants by warrant certificates that we will issue under a separate agreement. We will enter into the warrant
agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating
to a particular series of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
will describe in the applicable prospectus supplement the terms of the series of warrants, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            offering price and aggregate number of warrants offered;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            currency for which the warrants may be purchased;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                            applicable, the designation and terms of the securities with which the warrants are issued
                                            and the number of warrants issued with each such security or each principal amount of such
                                            security;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">if
                                            applicable, the date on and after which the warrants and the related securities will be separately
                                            transferable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">in
                                            the case of warrants to purchase debt securities, the principal amount of debt securities
                                            purchasable upon exercise of one warrant and the price at, and currency in which, this principal
                                            amount of debt securities may be purchased upon such exercise;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">in
                                            the case of warrants to purchase common stock or preferred stock, the number of shares of
                                            common stock or preferred stock, as the case may be, purchasable upon the exercise of one
                                            warrant and the price at which these shares may be purchased upon such exercise;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            effect of any merger, consolidation, sale or other disposition of our business on the warrant
                                            agreement and the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            terms of any rights to redeem or call the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            provisions for changes to or adjustments in the exercise price or number of securities issuable
                                            upon exercise of the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            dates on which the right to exercise the warrants will commence and expire;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            manner in which the warrant agreement and warrants may be modified;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">certain
                                            United&nbsp;States federal income tax consequences of holding or exercising the warrants;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            terms of the securities issuable upon exercise of the warrants; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            other specific material terms, preferences, rights or limitations of or restrictions on the
                                            warrants.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holders
may exercise the warrants by delivering the warrant certificate representing the warrants to be exercised together with other requested
information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus
supplement. We will set forth in the applicable prospectus supplement the information that the holder of the warrant will be required
to deliver to the warrant agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
receipt of the required payment and the warrant certificate properly completed and duly executed at the office of the warrant agent or
any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise.
If a holder exercises fewer than all of the warrants represented by the warrant certificate, then we will issue a new warrant certificate
for the remaining amount of warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder
will not have any of the rights of the holders of the securities purchasable upon the exercise of warrants until you exercise them. Accordingly,
holder will not be entitled to, among other things, vote or receive dividend payments or similar distributions on the securities you
can purchase upon exercise of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
information provided above is only a summary of the terms under which we may offer warrants for sale. Accordingly, investors must carefully
review the applicable warrant agreement for more information about the specific terms and conditions of these warrants before investing
in us. In addition, please carefully review the information provided in the applicable prospectus supplement, which contains additional
information that is important for you to consider in evaluating an investment in our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_009"></A><B>DESCRIPTION
OF RIGHTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may issue rights to our stockholders to purchase shares of our common stock or preferred stock described in this prospectus. We may offer
rights separately or together with one or more additional rights, preferred stock, common stock, warrants or any combination of those
securities in the form of units, as described in the applicable prospectus supplement. Each series of rights will be issued under a separate
rights agreement to be entered into between us and a bank or trust company, as rights agent. The rights agent for any rights we offer
will be set forth in the applicable prospectus supplement. The rights agent will act solely as our agent in connection with the certificates
relating to the rights of the series of certificates and will not assume any obligation or relationship of agency or trust for or with
any holders of rights certificates or beneficial owners of rights. The following description sets forth certain general terms and provisions
of the rights to which any prospectus supplement may relate. The particular terms of the rights to which any prospectus supplement may
relate and the extent, if any, to which the general provisions may apply to the rights so offered will be described in the applicable
prospectus supplement. To the extent that any particular terms of the rights, rights agreement or rights certificates described in a
prospectus supplement differ from any of the terms described below, then the terms described below will be deemed to have been superseded
by that prospectus supplement. We encourage you to read the applicable rights agreement and rights certificate for additional information
before you decide whether to purchase any of our rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
prospectus supplement relating to any rights that we offer will include specific terms relating to the offering, including, among other
matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            date of determining the stockholders entitled to the rights distribution;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            aggregate number of shares of common stock, preferred stock or other securities purchasable
                                            upon exercise of the rights;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            exercise price;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            aggregate number of rights issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            the rights are transferrable and the date, if any, on and after which the rights may be separately
                                            transferred;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            date on which the right to exercise the rights will commence, and the date on which the right
                                            to exercise the rights will expire;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            method by which holders of rights will be entitled to exercise;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            conditions to the completion of the offering;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            withdrawal, termination and cancellation rights;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            there are any backstop or standby purchaser or purchasers and the terms of their commitment;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether
                                            stockholders are entitled to oversubscription right;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            U.S.&nbsp;federal income tax considerations; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            other terms of the rights, including terms, procedures and limitations relating to the distribution,
                                            exchange and exercise of the rights.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
less than all of the rights issued in any rights offering are exercised, we may offer any unsubscribed securities directly to persons
other than stockholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to
standby arrangements, as described in the applicable prospectus supplement. In connection with any rights offering, we may enter into
a standby underwriting or other arrangement with one or more underwriters or other persons pursuant to which such underwriters or other
persons would purchase any offered securities remaining unsubscribed for after such rights offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_010"></A><B>DESCRIPTION
OF UNITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We
may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements
with a unit agent. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular
series of units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following description, together with the additional information included in any applicable prospectus supplement, summarizes the general
features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus
that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that
contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an
exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we
file with the SEC, the form of each unit agreement relating to units offered under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without
limitation, the following, as applicable:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            title of the series of units;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">identification
                                            and description of the separate constituent securities comprising the units;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            price or prices at which the units will be issued;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            date, if any, on and after which the constituent securities comprising the units will be
                                            separately transferable;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">a
                                            discussion of certain United&nbsp;States federal income tax considerations applicable to
                                            the units; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            other terms of the units and their constituent securities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_011"></A><B>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may sell our securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. Our securities may be
distributed from time to time in one or more transactions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">at a fixed price or prices, which may be
    changed;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">at market prices prevailing at the time
    of sale;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">at prices related to such prevailing market
    prices; or</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">at negotiated prices.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Each
time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the
method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the
securities and the proceeds to us, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Offers
to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers
to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus
supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal.
The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed
with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter
will use to make resales of the securities to the public. In connection with the sale of the securities, we or the purchasers of securities
for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter
may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions
from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus
supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell
the securities at varying prices to be determined by the dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions
or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters,
dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities
Act of 1933, as amended, and any discounts and commissions received by them and any profit realized by them on resale of the securities
may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents
against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make
in respect thereof and to reimburse those persons for certain expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any
common stock will be listed on the Nasdaq Capital Market, but any other securities may or may not be listed on a national securities
exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize,
maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve
the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would
cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option, if
any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the
open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed
if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to
stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These
transactions may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties
in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions.
If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related
open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings
of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in
the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial
institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement.
Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection
with a concurrent offering of other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not make any representation or prediction as to the direction or magnitude of any effect that the transactions described above might
have on the price of the securities. In addition, we do not make any representation that underwriters will engage in such transactions
or that such transactions, once commenced, will not be discontinued without notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
comply with applicable state securities laws, the securities offered by this prospectus will be sold, if necessary, in such jurisdictions
only through registered or licensed brokers or dealers. In addition, securities may not be sold in some states unless they have been
registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available
and is complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for
which they receive compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_012"></A><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lucosky
Brookman LLP will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on behalf of HeartBeam,
Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable
prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_013"></A><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
financial statements of HeartBeam, Inc as of and for the year ended December 31, 2025, has been audited by CBIZ CPAs P.C., an independent
registered public accounting firm, as stated in their report which includes an explanatory paragraph as to the Company&rsquo;s ability
to continue as a going concern, which is incorporated herein by reference. Such financial statements have been incorporated by reference
in reliance upon the report pertaining to such financial statements of such firm given upon their authority as experts in accounting
and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
financial statements of HeartBeam, Inc. as of and for the year ended December 31, 2024, has been audited by Marcum LLP, an independent
registered public accounting firm, as stated in their report which includes an explanatory paragraph as to the Company&rsquo;s ability
to continue as a going concern, which is incorporated herein by reference. Such financial statements have been incorporated by reference
in reliance upon the report pertaining to such financial statements of such firm given upon their authority as experts in accounting
and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_014"></A><B>WHERE
YOU CAN FIND MORE INFORMATION </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
SEC maintains a web site that contains reports, proxy and information statements and other information about issuers, such as us, who
file electronically with the SEC. The address of that website is <I>http://www.sec.gov</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
website address is <I>https://www.heartbeam.com</I>. The information on our website, however, is not, and should not be deemed to be,
a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the
information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms
of the documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement. Statements
in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by
reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant
matters. You may inspect a copy of the registration statement through the SEC&rsquo;s website, as provided above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="k_015"></A><B>INCORPORATION
BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
SEC&rsquo;s rules allow us to &ldquo;incorporate by reference&rdquo; information into this prospectus, which means that we can disclose
important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference
is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede
that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
incorporate by reference our documents listed below and any future filings made by us with the SEC under Sections 13(a), 13(c), 14 or
15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &ldquo;Exchange Act&rdquo; in this prospectus, between
the date of this prospectus and the termination of the offering of the securities described in this prospectus. We are not, however,
incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that are not
deemed &ldquo;filed&rdquo; with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits
furnished pursuant to Item 9.01 of Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been
filed with the SEC:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
                                    Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1779372/000119312526104080/beat-20251231.htm">Form
                                    10-K</A> &nbsp;for the year ended December 31, 2025, filed with the SEC on March 12, 2026.</FONT></P>


</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The description of our securities contained
    in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1779372/000121390021058171/ea150371-8a12b_heartbeaminc.htm">Form
    8-A</A> filed with the SEC on November 10, 2021, including any amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination
of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior
to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will
also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports
and documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
may request a free copy of any of the documents incorporated by reference in this prospectus (other than exhibits, unless they are specifically
incorporated by reference in the documents) by writing or telephoning us at the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Robert
Eno<BR>
Chief Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2118
Walsh Avenue, Suite 210<BR>
Santa Clara, CA 95050<BR>
Telephone: 408-899-4443</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibits
to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus and
any accompanying prospectus supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Shares
of Common Stock<BR>
<BR>
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>HeartBeam,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Prospectus
Supplement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Sole
Bookrunner</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Titan
Partners<BR>
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>a division of American Capital Partners</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>April
[&#9679;], 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 61; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea028535401_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028535401_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $U /<# 2(  A$! Q$!_\0
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MI]QYQ\0?@!\*OVC;71? OQ=TF_U'PY%K;:GIT>DZO=Z#/I=\;6\MD%I=V?\
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M=691]13_ !$\*R)B'5-TH#&-8[6YG8R;&"DQPQN2%R6/F%(R0%+AF7/X-_\
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MJ552[,K(P9%B#(92RDKLWK@$ODE I;2?,&1E8H5<,67A\88'RV_Y9N<XWX;
MR-ISD692BXNST=D_DST;X3ZS9:1XM;0;+P[//J/BK3KC7-?\0VD;C3]/LM!A
M%KIT%]<L9 +KS+R*TBL54,WVI[A7"V[1R?3RR,S$;-JC.&9@"_RQ,K1H 28_
MG9&9S&ZO'CRV5PP^*],EU9+RSL-#U]O##ZAJ5F;G42!,D-A93KJVH 0L8DDN
M[FVT^2W$\TR01Q33%H9&*+7V-IUQ!>1Q7EM-'-!=VL-Q%(C1$W,;C,5W^Z+(
MRRH< H5"A0"IRJQ93^+Y(TA\/S9IT445!84444 %%%% !1110 4444 %%%%
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M74,5U P:&YB2:)A_$KJ"#CV!&3SUZU9K/8M-/5!1110,**** "BBB@ HHHH
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M>JW_ (RUN\AU'5-.U*1[ZSBGLM);PW'8-?W$#R7JZG!Y;F>Q&';[(\5^'O\
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M\+@C=+;FX<KNRNS&Y\Y'TP&!. ?[W_CC;6_(\5C/XF:P^'YL=1114EA1110
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MFYX*I.[GJJ,H8K^?%S\=_BC<EE3Q&++/46-A:)'@C[JQW,=T$Y((96$@Q@.
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MME4,RYP,E&ZG R6Q@8YN5-K#33U04444#"BBB@ HHHH **** "BBB@ HHHH
M**** "F/D;2 #M))R<<!&]CU.![ YYQ@OJ.;'EMGH"I/7D!E)7C^\!M/U[]*
M /S9^-WAQO#7Q#UR*!0L.JBSU>R<)L4F99#<Q*N3N\IR(VD!7>7W%%QAMCX0
M7ZN^L^'I#Y9U&!M0MXV8-Y4\#10^6JD#?Y@G=PP*;=I7:V<K[#^U#X=%QHVB
M^*8E(;2;B:UO;A8]W^A7JM+&S$,"!!-;QQX(.\7 .8_+Q)\H^%M4;1?$5AJ.
M\^9;W%O',H;9NMKH95RV&P.%."ISC&1UK:'P_-G)6^/Y(]Y*^6QC)#&*22.:
M,KQQN4KG)&3G<&Q\I4<$C->9^._A9X4\>FPFU:.^M[O3PT$-[878@N7LY-S2
M6T\AA<RYD$3I)P4$84*0Q(]AU^!+:_9H\%+J..ZC<# G6==[2 <[0APF,MNW
M;LKC!PV;<,8QSGK_ /6H=.,G=M7]/^ S.#J*:<5[O>ZWZZ'CVE? CX6Z4R2'
MPX=5G3K-K=Y-?LX)!(956!<$A3Z8!&.<CTG2]!\/Z(-NCZ#I.E*#PNFVBVPV
M\'8YW2.ZD@,07 ) .,@5JT5<:=-*S:W?3_[4Z92<G=[V2^XDEFFD.1(4P,!<
MN\7XPRN\1XXRJJW8, 6!C4LJ&-&$:%MWEQ6]DL9)SG<KVDC$'/(#J>!S110U
M%.T=5_7DB1X<[=K#OG"LZ1=",^2&,0?T=54@$@8#',>#G.>,=*6BD 4444"<
MDM&_S"E&W#^8 T91A(",\,-J_E(4-)0%WD+G"DC=QU ^8#J,88*V>>F.^0"Y
MX]_P9],?![6)=0\+FPN9/,N]%N6LYB?O!)"TD (_APF1C)SUS7K%?+'PJU<:
M5XP.GNX%OKMM/"Y+[%;4(PEQ;2A=K;F,5O-;*FX$F?S-_P A5OJ1&9L;DV'8
MC$;LX=L[DZ#.S YXSNZ#OC/XG\C>FTXW7=CZ***DL**** "BBB@ HHHH ***
M* "BBB@ HHHH *0@$8(!!X(/<4M% '&?$#0$\2>#/$6B-&DGVS3+@01,N[-Q
M"IGA5>0=SR1A 1RNXGD#!_+1HV&\2GRYO+CAE;.6$]N9,PE>"/L_D^7N)^8O
MG:N #^O,P)"[2 1(A)/9=WSX'0EDW*,]-VX<@"OS,^,?AT>&O'_B"PCA^SVV
MH7,FJ::5!"+%>/%)*J(2=RQ-E =XSYG(7&&UAM;U.:K"3ES):66MUT/5],O?
M[?\ !FAZD 'N+2$VET=V]HC&&"1,< G>%WY(& F #UJC@;58'.X9QCH?3W^M
M<U\(=1$Z^(?#A;_6H+VU0L#\\(2%MJD#.3/G((QR,'K73&-XOD<8=6=64@_*
M5./U^@JR8?#\V-HHHH+"BBB@ HHHH$Y):-_F%%%%!E)INZ[(*/I110)1;U2_
M(=%=-I]Q9ZDC$3:=>VMXC [2?+F4.N<'&^-W4G#8SG:>A^WM+O$U&QM+^)E,
M5W +A0IW?ZTAPN[ SY63'G'S=2%P!7PZRHP'FC,0W>8,XRK1NB\^TKQGZC''
M4?2OP;U9K[PN--FD\RYT*9[.9BV6*3,TT(VX^4*@('S-GKD=*SFG=OI9'32:
MC"ST=W^/H>NT445F:IIZH****!A1110 4444 %%%% !1110 4444 %%%% #)
M & 4]"<'W!!'_P!>OD;]IWPX);3PYXK2(EK-I-+NW"Y(6:.2=&=P1]QX" "I
MW< $=_KIAD#!P0<@D9_3(K@OB;X</B?P/XBTE%1IY=.GGLU9-Q%Y;JTR,OS+
M\TB+)",=/,+#)&TW%VM?S_K\ON)FFXV6_P#PY^<W@K5!H7B;1[T,61+E;>\D
M+>6)8+GY\D8;:%>./@EL^H&:^@==A\C4KCO'<,MS;L. \,H+$@ D#!*@XR#U
MXZ5\I,KEIEYA8+:@G.]H;BW60W$>!M+&)XEC)RI/F X7;AOJ6UO_ .W_  ?H
M>M+&#-#$MC, ^]E$2,/F?8OWS&& V_+C&3UK1-/5'-'W$XRT=V[;Z.UMC.HI
MH;) QC*[NO3IQ[]>M.ICYX]_P84444!SQ[_@PHHHH,93BYV3ULM+,**<J[CM
M! )Z9S@GTPH9S]$1W/9#SAI9 RH6/F&01B(QRPS.Q#$"""Z2VGE/&0WEI%CK
M("55DWRJ[C)KO&,I?DF#LI1BY14I_#'F7-\U>Z\KVOT"D8[1G&><4LF4+#Y2
M4;9(GFPF6%R"52:))7>-F4$\@J ,%LD Q,VX8QCG/7_ZU*,E)75[7:]Z,HO3
MRDD_P-:;NFK-6E*+NFM4]=]UV:T?07?NPA'RN0K<YX!W#MV95/OC'>O1_A-J
MPTCQ>;&20?9]>MYX9&9A&IOXQ'/:R[<,"WE6\MLJ;ER9]X?Y"C>9D9[XYSG\
MZD2Y>R>"^B8K/875I>1N#@_N+B'>G3@21&1">=H;<%;&#35TUW+/O".1G.&3
M81'&S#=NVNX8M'G:,[,#YN-VX?**EK.TR\CU"RM;^(@QW\$=VB@[MH>.,%-_
M&[RS\N[:N[KM7&#HU@]'_7];_D:P^'YL****184444 %%%% !1110 4444 %
M%%% !1110 5'*#L^4 G<O!&05+ .O.?O(67.#C.<5)36.,#NQ(!]#M9LX[].
MG'UH _+_ .*GAZ+PKX^\26,41%LU[-?V4>W8LL.I21R-&HRP MR<;QN$FXC;
M&.#VWPDOEN-.\0>'I'^:W47MK&3G<N41@BD<!?/QN!_ 5Z/^U#X=Q_8/BQ(@
M%4G2;UE3_EI,6EBD=\\[%@9 A3D '>#P?G'P3K']B^*=&NRORSWDME=J9-@E
M@^4 LVU@H9_+?!5L;0N>21M#X?FSDK?'\D>R,BH[*&W;2RGC'(/(QDXVGBDK
M5URW6UU.>)%Q&<RQN.!(DY#@@=!L^[U.[.<+T.55&04C':,XSSBEIC]!]?Z&
M@:BWJE^0*X) 9E0'NQ;D^BA58LQ[#C.#SQSJ:;HNM:O)LTW2KNZ!; 98V0$
M@NY\U4&U$W-\I9F("A>2RT;&Z:RO+6\"HZVT\<LJ.JLKQ[PC+\P8+RX.=K<
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)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028535401_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028535401_img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $P ,0# 2(  A$! Q$!_\0
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M8Y9B.@) (Z,JG:KC_9D #K[,.M-I\L?DRRQ98B.654#+M94$C"-"O.WRTVH
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MV]:0L5.T8P/7KZU*8Y(@?,B>*..8++*Z7&U(VD,.P*+7+2),K$R ^6\0615
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MWO)II7;VO]Q#1D]F8>PQ_A4@@NIL?9K268LT0B6$_:$N'>X:)[:WN8T2&:9
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MCZ17H/H/Y45'O(P!CH/Y#WHH-3YK_:P_Y)5+_P!AO2?_ $H%?/EF@-K >?\
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M>0=,#NYJ78RME2Y';,C?_%#_ #[5,&V]7?0/9P_E7]?,_<O_ (?Q?'ORB_\
MPH#X4AL@ +K&K(N,\X2/4E4?@!DY)R<YN+_P7>^.^!_Q8+X6] ?^0YJXZC/?
M4<]Z_#(;FBV\Y)SC>_&">GS]^,_C5B,LY <LIP 0KR <8 QESU'/N>1Q6@>S
MA_*OZ^9^X;_\%W_CUQL^ 7PL/][.MZN<#\-2'ZU(O_!=GXZN=S? ?X6KGL-9
MU@]!CJ-2(.3^0]Z_$';Y>,,YWD YD<XZCC##!X]ZG61XT$:NVT9()9BV6)8\
MY]6./;\ZF;:6CMJ'LX?RK^OF?MXW_!=3XZ ;A\#/A8%/0'6-9+#'7.-3 Z]/
MJ*0?\%TOCFZK(/@-\*'WYY;5+]CPQ7EI+QG/3^)C@8 P,"OQ'A#EMQ9F&>C,
M2/R&.OIW/-7BBM@LN".RLX'U^^1GZ=\GO67-+N_Z^0>SA_*OZ^9^V'_#\SXZ
M[HE3X%?"D;P25_M;5EVD$\ 1:@B#/4X7DG)Y)-2+_P %R_CJ&*O\#/A8""<X
MUC61QVZZD>V/3GVZ?B>JLKI(I8; 0J[SM]\@G=U_VA[<8JVK2LV]@!GW;Z?W
MC^G?\:.:7=_U\@]G#^5?U\S]K#_P7(^.RJ"OP/\ A2!S@-J^LEOQQJ8ZGI[>
MO)I%_P""X7QXN&BC/P/^%(>7++,NL:R(8E4E66<'4R2S$$KM=>",@]:_%IEE
MD(P%PW Y?/7!_CZ\?ES5I$>!7A&2KX+ L>N,\?,",9Q_//-7!MO5WT)G""6D
M5O\ UU/ZIOV%O^"E&G?M:>+=7^%'C;P9:_#WXJ)ITFN^%H],NWN?#?BW2;$L
MNHP:=+</+.FHPA&C7?,(UE1]T,@ 8_J(F-H*LS*PWKO&'0/\XBDZ RPAA#*R
MA5:1&9552%'\CG_!*9'?]O+X2!W!1-,\6-AF<M\FD[D&=YPJ'D(@13]Y@S$E
MOZY%+,J,S;V9$);CDE >P'3IZ\<Y.36AA-)+16U J"0>>*]_^#AS>ANYM)OI
M\L\H'\N>:\ ;C;CN1G\R/Z5[]\&^;T+V^R3?7YIY2:!0W?I^J/I (" 3GH/Y
M?2BF[R, 8Z#^0]Z*#4^:OVL./A5+_P!AS2/UN0*^?[+_ (]+?_KF/ZU] _M8
M<_"J7_L-Z3^ER#7SU9N1:P#C_5K_ )ZT$3V7K^C+_F;>../8_6OQ=_X+K*LO
M[)'@!B3_ ,ENT'IQ_P N$OJ#Z5^S?EJ_S$D$]<8QQQW!]/6OQD_X+J?N_P!D
M;X?!>1_PNW0NO_7E-Z8H,XI.2NK[_DS^4&)0=JG.,#Z]A5Q0T8*J,CGD]>>O
M0C^55XP %8==H^G8U;CD8D+@8_'/7Z^]!Z5DJ>BMJOU)8P=@RR*>>">1EC[U
M.J @'.?=>G7MU_GUIBA<MO4'^Z1U/'.>OX=/ZE8RY^7:H /8'N?J>O;U/I2:
M3W5R"15"G(S^-6T<[1P._KZGWJ((,<YS^%3H@VCD]_3U/M0DELK 2PL69L@?
M+C''TZU,IS*3@#GMTX(%11H4R5&=WJ1VX]O2K,<8X<YW'.1QCK]/;UI@3'G&
M>W3\R?ZU(%# $Y_#VX_I344,P!S^'U%3A,':N3CU]_\ ]?84FD]U<"6(A0 .
M2,\'W/MC]/6K+$X4D %B 1V')''/H!WIEK;@NYD<+P"HZ=@1DGU/L.#ZU:,3
M. 6Y(/52 #@G'7)Z=?TJ)I):*VH$D1; 4 ;>/7//)[^I( Q5U!E2I & >1U]
M>3SZ_P J@A## P,#CGD_H>IZ#%:*1 @L<@L""!C [#'![ =S68$$:@@89LJ3
M@ C'WCV(YSQ5MBX"G YXYR>AQQ@]>F!42P[&++DY]2/K[=ZM*7<@,JC![#D\
M]^3UZ8[_ (4TVMG8+)IW5[*_XH_0S_@E1&H_;H^%$C("ZZ9XN&3GG.CGKSGZ
M=/?FOZT$ 6., 8'E1G'U13_,U_)M_P $K% _;G^$P;(WZ7XOZ>HT@J,<'K@Y
M]^XK^LB,DQQDC!\N/IGH$ '7V S[U<&V]7?0X9M\UKZ6O;[O\QS]$^H_FU>_
M?!K_ (_A_P!>DO\ Z.DKP3:&ZY^6)I!C^\KL #[>O?WKWOX-?\?R^]FY_.60
MUH.&[]/U1](! 0"<]!_+Z44Y>@^@_E10:GS/^UA_R2J7_L-Z3_Z4"OG:U+?9
MX< $>6O\OK7T3^UA_P DJE_[#>D_^E KY^LO^/2W_P"N8_K01/9>OZ,D5V
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M6(R#&=IBP<XVLV2>N<\\'./:O?\ X.#;>*1_SY2=?:5\5\_2#$# ?WA_,5]
M_!SF^ [?8Y/UEDK4J&[]/U1](KT'T'\J*%Z#Z#^5%!J?,W[6''PJE_[#FD?K
M<@5\_63 6L )_P"68[&OH']K'_DE4O\ V'-(_P#2E:^>[2)6MH&);)C7H1CC
MCTH(GLO7]&7@0>17XQ_\%T_^32/A]_V6[0?_ $BFK]FU4* HS@9Z]>3FOQE_
MX+G_ #?LF?#Y#T_X7;H'3K_QY2_7U]* HI.;NK^ZW^*/Y2XUWD@HI 5,'O\
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M$FY7_E_5'W5_P2_C _;5^%S<Y_LWQ=QQ@?\ $G/ [\?6OZE4_P!7%_UQA_\
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MF-W\+F=F/F+#XKE*QC<>I^Q\@KACT SCW-02;U5] ]M?2#L^MNW_  ]CSO\
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M4R8;OT_5'T>O0?0?RHH7H/H/Y44&I\S?M8_\DJE_[#FD?^E*U\_V7_'I;_\
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MZ8' '3GG)I:*:26RL-::K3^OF( 5QL8H <X&T]3D\LK-R22?F[\8& '$Y.0
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MH7B_0+EWCM]9\-:A;ZGIER?($L3VM_;2S6T\>XM'(8V;#H\>5=3@ V:*9^\
M7(4DI&QQT#,BLPY;(VDE<'GBG#..>M "T444 %%%% #UYWD_\LXRZ^Y#=_;G
MM@^]?0/P?<_;PO&/L+'OG+NS'OZGCVZYKY_^Y$[CJP\L@]-I/4=#G\2/:O??
M@[\VHG/\-BP'_ 6(&?ZT%PW?I^J/HX<@'U HH7H/H/Y44&I\T_M5?\DUMO\
M9\5:$X^JM<D9]O7O[U\]:4$_LS3\DY-E:D_4PH?3WKZ&_:J_Y)K:_P"UXKT%
M#]&:Y!Q[^G;VKYTTQ0VG6!.?^/.V''HL**/T'/O01/9>OZ,TCC/'2HG<J0!C
MDCKGOGWIX&!BHW4L1QP,8Y';_P#709#MH;DYR0.GTIP&!BA<X&>M+0 4444
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M)S^ +''MC))YKWW]K!G_ .%9)L"G9XCTF3D$\QEV7."."9#NY!QC!&#GP2Q
M%C8J.BV5H@]<);QJ,^^!SVSTXH(GLO7]&6J<'(&./\_C4+.02./\CZT]3D _
MYZT&0XG)S2444 -);/ &/\^]*,XYZT\.0,<?Y_&C[QYZMTQTST]_\_6@J"3>
MJOH8GB<N/"GBQD!%S'X2\526T@)41B+0;Z1)@RE6$UO/ODA?>%1L$HU?F+\(
MGED^%7@&6:66>>X\/)<W%Q.YDFGG:XN#)-+(?OO,V9'/<L<8& /MW]J#XR>
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MI&?P)S7TQ_PIFU_Z#LG_ (")2?\ "F+,]=<<GU^R#^A H#ECV7]?,^:@'89
M&#TSP?QYIP7CY@V>^T<>V/P_6OI+_A2]G_T')/\ P$'^-3)\&+,*/^)U(>O/
MV5?4_P"T/Y4!RQ[+^OF?-L<,DQ$4*D,S %G!*\D=,8QV]>AZ5]2?"[0Y]/@-
MY<=! 8XV485@SLS$@@DD,2HPP' R,YJSH_PKTG3YP]Q?27FU@PC\J./)'.#N
M5R 1@<$^Q'2O5(;>&"%8(8EAB4;51  % /;&1SU_'GF@:26RL2J05!'3MGVX
-_I13@,# Z#@44#/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ea028535401_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028535401_img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $H 3\# 2(  A$! Q$!_\0
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MOZ:?%T F^)_PGF$P$]M_PG>!ZC^PQQCMP,?3BOR;U[P+X4\!?\%'?C]^SO\
M$&S)^ __  4\^!<FLVEDIVZ5)\9? 6BR^&_'N@N6!(\0>*?AZ#XJ)'\48(SP
M"?AY@]N_D?=OCS]B[]C_ /:)UFW^+/CWX->"?B%K'BC2=*O!XIU==5,M_I?]
MEC^Q6RLL<?EB&1-@V!XUP[^9(PC/$Q?\$POV!KN(S0_LW> +B*Z&?M &M,N.
MF=P\09ZCLI/;@5\$^%/VH_BS_P $R_ ;_L[?MPZ-XEU[X.>"?#]]X7_9^_;'
M\&Z7K6O>!-7\,!Y(?!7A'XX*L+3> /$GA>W;1O#,7B:4M:W)@@> Q"22[;]>
MOV8(]$C_ &>O@U;>'/%.C>,]'M/AUX7L[/Q%H6LKXBTW6UCT6(B2'6E#B926
MSN8Y5LHP!^6NYYOF^'26$S>M&,5:*A6KP22V2Y*D;::65NVIYO\ 9N";;>51
MNWK)Q@];O5W3OW^6QF_!;]E']GO]G6^U[4_@Q\*_#GPZO_$L"6VM3^'5U$F_
M6,AT$H>1^CJL@9 C;D!4H17TIT![GD_CU_+V].*> B\8R/Q&/\?Q/I4A;Y<@
M'GCZ=J\_$8G$XI_6<5.4IVNW.4IS?2[E)R;WOJ[]6=>'P\<-I!*VNB5DNZ5K
M+3;;\-#R#XA_&SX/_"=M/@^*'Q/\ _#F;52?[('C7Q?HOAMK_']R37)8 ,'(
MR">ZD\&O.O\ AL[]DE0<?M,? K_PZ?@H_P#NPCT _4]*_GR_X.-X(9O$_P"R
MP;CG.D?%''8X_P"*?'J1QC'7\>U?C5^SW^Q1KGQX^'VL?%.^^(WPN^#GP_TO
MQAI?P^L_$/Q-O#IVEZ]X\'71<^O(X_GBOU[AWPPRO..&\MXCQF<RI<[<>6T&
MX24I15KKWN9*Z33WTUT/A\RXMQF#S?ZCA,KY_P":[^*WY7Z^9_='_P -F?LE
MX'_&2_P,X_ZJKX+_ )?\)"?7MQ^M>E?#SXS?";XK0ZC-\,OB9X*^(RZ65&J'
MP9XGT;Q-]@). )&T*24\]%RN22 /F*@_P8_'C]A;_A1'P<\,?&'5?C1\'O&M
MMXGU?4_#.C^'_"@UG4M2U'5-#S_;H4CJ1@9';(]J_:;_ (-R(&BTO]J?!( U
MGX7Y]?\ D"Z^,?J>>WYU'$7AQE>4\.YEG>#SFI6]G/DMR1AS2YXTYMOE37+=
MZPM%VO&4EJWEO%F,Q>;_ %#%Y9R:Z-/X;_-K[^Y_4'1117Y,MEUT6O?1'WP4
M444 %%%% !1110 4444 %%%% !129'J/SHR.N1CUS0*Z[K[U_F+11D'H0:^!
M_P#@HS^T/XD_9L_9:\6^*?A[;+>?%[QSJ_AGX,?!.V;:6;XI?%?61X>\/R@
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M>$]+^$.H^)[+3+W1=&TW;JK:WH,.[,8W@K'(X!!7 9E+H&9A^B?[:(7XD?\
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M\01>$/$07&>1.S'H4&<U\]_M&?LC_P#!2#XX_#W6/AA^U#^U)\'=0_94\/\
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M[\HO^"U5[_P2P^.GCG2_V@;_ ,#_ +5'[.?[8?B"[TO1/%;:OX"\9?"BQO\
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M\1^-O'>B>(_B98_+XA5U91SX?^'RE0S'8 P<'<S^;M_O*XR\8YW %3ZX[@\
M@8YQWXZ5.'JX+-<+'%>SA)-)MN$7I9/X7!WTDTU9VU#,,'G'"F;YGDU>K6H9
MKDU25*]*I5I/W6XWA*E5BVGR*2<9-/W7VY?S3^-_[$O[*'C7XG?#G0O%/P=\
M'6FEZ]X?^)U[JUSI6F+H+!-%TKP\&/F:&+;(C1F9@S9"* FYL!O@GP%_P1I^
M%?BS4?$'QY^%WQ7^+/P7\0>*;G4+3X5GP[XFCU#3/"W@,R;=',4<C$L/$B@3
M3 L2B,@0R.0#^G_[7GBZ\\)7W@G3[;&?&7A[Q_X,M<9X/B%_ >CD'\923QT/
M;(K[%T+0=/\ "^B:3X=TJ".VTO0M)T_2-+MLY\NPT>%((OJ?*5%/<X##!(%>
M77X6X?Q;;Q.6+F;;O!\C;=]5[-QUNKJR5I/OM]3D_BUQ_DD%#"<4<15%&*@J
M=?EQ5)1C=\CABEB>>+7NR4F^:"Y&^5GXB3?LF?\ !47X+IO^$/[7$'Q7TBW'
M^B:3\3;)6U8 8X,NLM)C;V^<9P>N:9)^V7_P4T^"$7G?&K]D'3_B/I*_\Q3X
M9W[L1SGYHM$/C!L=!G [\U^X=C?V5\;C[)=6=U]ENFM+K[.3^[O4V[HR>@*Y
M&>2IZY.!6F8PPQL4 \'A&&.AZKD^_O7GOA54(N.5YOQ'DZU]U5%5IK1/6%93
M=DM%K>RT/I5XQ1S2<9<8< <'Y\K6J3AP]'AK$S6CE-8CAWV%JKO*3G*#O-N<
MKZI_C)X8_P""TGP(%R=,^+_PV^*_P8U3!Y\2^'C>:<?0"6*,D<\8VYYZC&*]
MB_9__P""H_[//QV^)'Q)\"PZQIWA32_"%FFNZ)XU\07ZZ9X?\4^&0A_MC50^
MLB"/2(8)&,;"5MK(QE+X4JWWAXR^$_PW\>Z4^F^*? ?A+Q#:,6XUSP_I6I;6
M)P67S$^4GCH,=QZC\K-)_P"")/[)^I>&?B3HOQ9TW4?'\OQ0L?$UGJ8M;M_#
M.G^%M.UX,'3P9HF@*$M@IV!2Q=F.1M# (W*L)QE@L?EW+F5/.<JYOWLIPC2K
M-6LG5<7KOS)ZV:NW:Z/869?1^S3A[BK%5.%>*^',_E3IKABE1XACQ#A:=9S<
MYRBJE"C.,%RN$W5ERNE-1]FJL5,_3OX/_M%? ?X^6NL3?!#XR_#GXM6VA70L
M]9;X?>,=#\2KHKX(\MFT%W<'. "Q*_=42$G:WO%?SZ_\$)/^"8?[-G[#/P\^
M+WQ$^#__  E.I>,/B-\1?B=\/_$6K>*M634&_P"$7^'_ ,3==\/:%I C557<
MG]AQL\IW-([%I SN6;^@JON/7?J?@;M=VO:[M?1VN[7\[6OYW"O)_C'X?L_%
M'PE^*?A6]A%Q;>(/AUXYT>ZM3@[H];T'6$8'IRV&V^^#R.OK%?'WQ*\1^-OB
M/J'CWX:?#K5)/#F@^&-)U&R^(OQ(CMVOM3T_4M;TAQ_PA_@A/,C4^($2;=/X
MH?/_  AH5%$;2K$A!'XJZE\0O"WB/_@W2M[?Q5XHT;3=?TS]F(FTMKO6(_[0
MOS\*/&>.>1(2!H.!A6'S#)X.W]D/V;?VJ/A;\7_"GPUT+PDWC6_U?5OAMX7U
MP7MU\-O&^G^&@W_"(Z++)_Q6>L^'8?#A.'^\DY9V/*#:1+^+O[+_ ,&O %G_
M ,$!?B9K<'A?1KGQA=_L]_M&V.L^*KK1XCXEU'^P_&/Q (WZXP\SC8=OED D
MG?N4,%_>+]CK5!KW[)G[-&JGG^T?@-\+GSVP?!>A#^0/^136Z]5^:$]GZ/\
M)G\@7_!;HY_X*!^/SZ^!/ 7_ *9#7GGQ4_X)J^,/AM^Q_P"%_P!KK_A/]$UK
M2-5T;PQKFK^$_P"R-7TW4['2O'!4:(5UO)/&]-Q( &Y1DDBO6/\ @M9X5\1Z
MS^W[X^GL/#GB34K8^ ? 9%WI.D:N<9T7ID<'!]"1Z9'->(^,/VWOVKO&'[.F
MG_LS7W@>VTWP1:^&],\%WNK6G@/6?^$EO_"^A8_L+1<?@/RQWK^L\B6)?#7!
MO]E2PRFE2>)YU0;E#D7M(^]JI.5VF]4ELTVC\4S-4/[6S?ZTJMO>Y+*IH]>6
MW*K=MC]-/^#<[_DH/[3O_8I> O\ T\>(:_JW7^+_ '3_ $K^5K_@W?T+6]&\
M>_M*_P!JZ)J6F;O"7@)5_M6R_LXL?[8\0DC&".@).!P 2<8)']4J_P 7^Z?Z
M5^#^)?+_ *[9MR\G+[GP<O+?EA>W)[N]]C]#X/O_ &#3YN:]YVYKWV=OBU[$
MU%%%?!GU(4444 %%%% !129'J/SHW*>01CUR*+";2W:7JTOS:%K\KO\ @L-X
M3U;Q#^P%\8+WP[I,^HZ]X%\0_"[XB:):6F-YF\%?%+P/+<@'J%/APZRV!G'/
MI7ZHU\<_MZZIK>@_L6?M4ZYX=.-8TWX#_$ZZL/=E\&SE@/\ @*,?H#0%UW7W
MK_,^H/#>H+JOAWP]JP_YB>E:=>X/7,VEJ[?J3_DUM7$L5I;33D\6UN3V^Z%)
M7\R!7S_^RCXC7Q?^R_\ L\>*1-]H&O\ P4^&.M&YN,#YI/!N@LS' &"6)9FX
MR26).:]4\>ZC8:1X)\7ZI?LHT[3?"/B.[N1U_P! ATF264 8SRL>,^@.:!_Y
M7^7?T\]O,_-+_@C6XUG]C[5?';$>=\3OVDOVGOB%@^NO?&;Q)'^&?[('Y&OU
MEK\P/^"/FFVVF_\ !.3]FAH=,_L6VUOPYXD\265C<W?]HLEAX@\9^(=;SOW#
MADF7Y3]P ./O<_I_0 4444 %%><^*OB?X"\"?+XO\7^'="&WBWO=647Y/0@Q
MEA*.>Q5?7/2O)YOVFO!UTL*^$?"'Q9\>QW )M+[PI\.?%^I::0!EC)K1A6-0
M!G)STX(H ^GJ*^:M&^)'Q_UQYXKK]G8>%(5'^CW>N?%#P?J*.>@Q%X?:9U'<
M .2.<L<8JUJ5W^TS>#;H>C?!W16 S]KU;6O&6H,!G_8\-IVSU&/4CB@3V?H_
MR9\1?#+_ )3*_M4?]F:_ ;_U-=>J/_@LMX<T/7?V$/BLNJZ)IFI?Z5X6P-5T
M@:C_ ,SGH'1<;AQG'.,8]*^9/A_HG[5C?\%@/VB(I?B)\(+'5KG]C3X-7EW<
M6?@_6KZQ;34\<:\N,S/$<AQG+LN[&0S C=Z=_P %3/"?[0-O^Q;\4+GQ1\4O
M NLZ#;QZ5=ZMI&E_#J33+Z^1=8C.(]6/B?RXR 5!(BC.5.3Z^!Q0G_J]F75V
M7+WO=6:OTOU7W;GZ-X1.WBOP'?9\29 G=M)Q<9J25NDK\MOA;=FS\X/VO_V$
M_P!D+Q/^SM_P2UUH_ OP!X=UKQU^T_\ LP>#/$OBGP1H\?@GQ-K7A37=)FBU
MK_B=^'55\/Y3-ERV3D \$#]._%7_  3CTGX&>']6\6_!+]NO]K+]G'0M"M-0
MUB\L=>^*A^)?PXL)&0R,7\/^/PZ0JH!(9IV7;U?=M#?,_P"TQ>VY_9)_X)&W
MTTXMH+3]L3]DJ[-W=7>#D)KC<YY)RW?KGMDFJ_[5WQI\:_\ !0/XQ7O[,'P)
M7Q%+^S_\-=52]_:"\8^%M*.HZAKLB:FJ_P!@>'D^9=:0)&#(D";5^9B';+'@
MK9Q'+<GRJ$(\V<2A&*A"SUE!6YDD_=47=ODV6K6K/I\%P-C>,?$3BRICI/)^
M$LBXIXEJ<4<4U8RE#(N':>+F_9J5224ZE:4?8T*:J2;J58J$6DHK\5-!\&?\
M%M/VW_V\OA9\<?AY^T3HGQ2^#WP(\1C6O!S>*](/PC^&/CC3O \RLVDZ_P"!
MO#JMN\0>+5+JY.U4W><SA4;/]"_Q,_:%_P""L_Q"T"S^"?@[]B/3_@)\1O'6
MLGPW<?M-K\8?!?Q'^&'PF\*NK+K/C'^P;=4\2S:[$LA6".02+N*R8>9(Y%]?
M^%/QU_9J^&GQ'^$GP1\$6GC_ .'.C^!_!OCO1KS2O%/PU\9>'-)5E3P^H35]
M9E\/J#KP?<X5I%)+OEU+9K].] \4Z%XKTD:OX2UO1O$&GW(_T6]TN]34=/(]
M2T#$#)/12 3VXKWLH^MT,(OKO+/-&FW>]M7S*RVDO>>LNB6B5HK\XXRQ/#^+
MX@S+%<-97+)LG3Y*=Y<TIQB^2-25G*,9581C4E&-^651PYI-.3_ARTW]O[XX
M?LZ_\$WI_P!ES]FSQ9XE^*/[1]I\<_BCXD_:/^-EUJX&I^!?A@?VA!X$.N:]
MKI)W?$7XK ;8@-H3S)B2_F*$_;/PO_P5K\->.?\ @HEXK_9\T[7;71?V9OV8
M?V6/$_Q!^,/Q,O4C?2?%_P 3=!;0/^$@AT;6)$=&A^%T3/;W P'D\6RR*KJQ
M5EYCXF?\$<KGX??\$V?VN/V:O@'<6NH_M&_MA?%W_A8'Q#^)=HHTMO[6\;_&
MG0M?<EMY+>'?A;X:.8HQ$"%MYI"Y#!4\*^)__!&N?5_VQ?V#/V??AT^LZ'^Q
M[\!?V9)!^TSXBV,VI_'?5(_B8==?P7KVLC!=OBMXF23Q3XW"8W* %.?F/HW;
MW;N]]7OU/FK^;?S>I]H_LY_\%FOA7XS_ &"?BQ^WW\9X?^$(^&^A?M"^//AG
MX%T"Z5-,\3:EX:_X3/0- \#:/( %SXDD&N#>1C@#&P\U^W6AZWI_B31]*UO3
MY!<V&MZ3IFL69./FL-:B2:(\8)&PY)Z@C;Z5_);^SO\ \$RO&7[6WQ^_X*+>
M _C/HEOX8_8P^#O[3O[1-I^ROX'>)[#3M>^,7CK1AHC_ !+UV-2KZ]H'PHC&
MBKX&R?D<@E'QY;?!7_!7K]J3_@JE^R?\/_V)/V.?CMXXL?V1?V>;N\TWX>_$
M3]MCX$:OK?C8^+?"_@M1H#?VOHD*+XG\/X\/A+AO"TLA,DNS/FQ 1H@/Z]?^
M"=?_ ";[J_\ V7C]HS_U=7CROO2O\V']E+]HCQ#^Q=_P49_9)^"G_!+'_@H3
M\4?^"DWPX^,?B0CXV?![Q!X=US2O#=E_;Q*Z]K']N:^P*%1GQ2'0ILVD$EF4
MC_0&U:\_:2\0VD<6@Z1\//A\P56N=1UZ[U7QGJ=H2.$@TC16@@:1^N'N !R<
MJ,Y /3_'?Q \-_#C0[GQ%XDN_L]M!O6UM+1@VK:YJ+9QI&AZ/YN==UR3RP$B
MC4G>P8!0LA3R;X5^$]<\%_!?Q1+XJ /B_P 3MX\\?>)1E'%EJ>N(TB:7QDH4
MT.+28-K8.]78C"H:ZOPI\$]-TS7_ /A./&.NZQ\1O&?VM;ZRU;Q44;3O"I()
M=/!>AE&C\.IG@A&9VQNWJ,AN\^(\WD> ?',__/MX.\3_ (9T:5OZ^E 'X7_L
MF6OG?\$!/%ZC_F)_L]?M/7P]MVL_$,8Z_P"P/Z5^GO\ P3[F\[]B+]DN;CGX
M"_#$_3'A" _U/N17YU_LF6GD?\$" L__ "]?LE_'B]/T8?$ @>O5?PY]:_0O
M_@G7_P F)_LD_P#9!OAC_P"F*VH ^NKS1=*O)1/>:=87,ZC'VFZM(VZ= 2ZE
MNO\ M?\ UH/^$5\-_P#0M:+_ ."C2_\ XW7244+$XU)1C4J*,=(I5:D4EY)5
M4DO1*Q+A!N[A!M[MQBV_5N+;^\RK+3-+TT$6.FVUCGK]FM%7T[Q)6K@#H **
M*;E*3;E)R;W<FY-^KDVW\V-)+1))=DDE]R27X!1112&%%%% !2'H><<'GT]Z
M6D.""#T(.?IWI/1-]DW]R;_0-].^GWZ?J?D#^U-_P5A^%O[+GQIU7X.:_P"
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M::1X!\0ZSX=T73(=,M=*O=7:YM=7TW3KX-\-=>UYC\VOLOCXKK_(+*YY/WB
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MT.*6D/0_0T-733V:L_1Z/\&&VJWZ>O0_FP_;]_X)A_M,?M'?M*^*_BQ\/6\
MOX:US1_#5C;#7?$.LZ?J?F:)I;*P*P^'IU7]XQ0*9&(.5SN!%?'"_P#!%?\
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M]&FY>1AAXP<'G!KPB'_@B]8Z;X2U_0_ W[;_ .V1\)?[?/'A[X9_$8Z9\--
MTOD_V-HO@;Q!_P )<0N1C)\7]<'&.: /T8\4:C%\:?B+;_#/0=;FE^'G@RU?
M5?BC>Z)=KLUW4VF6/0/!BZS"[YB<+K+^,+<2K(Z>3!*\,NXI[KI^G>"?A9X<
M^SV-MX;\!^%=,7.U!I'AOP[9Y'=B8TCSR!O;YB" 0:_*+PI_P3<_:\\">'=/
M\#>#O^"I'QDT/PAI=C]CL[2U^"?PR&J =B=;SN'IT/8'I72V7_!)/X1^+[FS
MU?\ :E^-7[37[8%[9G[4NC?&#XJ:NOP[E9L "/P-X+-I;H5Y96,TJ/C Z$4
M=EXN_P""HOP&;XBV_P '?V>]*\9_M8_%;^TTL-5T'X!:,_B#PWX64!CK6L>(
MOB>ZCX;QK 6!15NRSL\F[R\[:_3V'_4CZ'^5>:_#CX3?#CX.^&;#P7\*_!/A
M3X<^#]+!6S\.^$/#NF:!I:\D@"&)-IY_C*F3!P6Q@#TF@#\@/VX]5TGX%_MT
M?\$\_P!I36[VPT;PQJFL_%#]F3QYK^JWBZ9IFGZ=\5-!37/ @U7696*1J?$G
MA_6F0$A-Y+DD,6/!>-?VA_CK_P %'?%_B;X%_L.^)M4^$?[-?A_67\-_&O\
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MVC/#WQ'_ ."H7P#\.?&7PE\0/AUX)_8\^"OB?XT:Q;7GAS5O&FFQ?%_XLD>
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MT2?P;K?BG6#\0;;XK1W_ (Z\7'7BRPZ)XSUP^'L2Z!X<8*MN@VY(;S'1PJ$
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M4O%?_!./]JB70+47'BKP-X"'Q*\(X;!'B/X?ZYH_CN%MI!X)T5L#/\9Y^7%
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M=S@]"6[FJWARZL_^"<?Q?_L?Q_\ %;QOXG_9L_:R^+L>D?"+2/%<#Z[I_P
M?B=KL32ZQHFK^-KB2-K?X>^+I#_Q1,-RV;=_,AE)!\]K.O\ VCQC_P %I_AO
M88!M_@Y^PAX\\3$=CJ/COXH:!H!^G[LY[\T ?KG1110 4444 %%%% !1110
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MHM-+TK3;,6.G64:@[41(P%13_LH"268AG8FN@H **** "BBB@ HHHH ****
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<@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ea028535401_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028535401_img4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %" EH# 2(  A$! Q$!_\0
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M\&_V6_"FD:)IWQ;O_'OPG)/Q7T;7!KWB1/#OA_P_X38 2>)F<QL@CVMN:0*
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M!WAS5/VH_':$:[K7C7X6[O$A\,Z!\&/"?A^3_A&3XL\6NK Z$#R26'T9KO\
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M ?T?T5_*;^S;_P %*/BI^T+?_P#!#OQ3\</'7[4'P,\??M4WWQDL-5\!>'/
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M1XD#>&1XKQ_PASN!M=D5E7YW_8U_X+I>/-:\'_\ !5#XV?MH_ ?XM?#7X/\
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M;^&-[I.L?&W]H3XQ_"5?V=_B=H/@O0_ GCL^._!'P_7'Q^^'7BHK)XH/AEF
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MKT^(O#?A7XH?L;#Q!H/@71?&^MZ$Q'A_Q#XK \#H?"[.I+.,D@_+]3_MW_\
M!('X^^)?V^?VEOVK_@A^S=\%/VQ?"/[67PO\#>&+[PK\8?VD?B3\ K_X%?$[
MP-HQ\.IXP)\ IGX@?#[Q3X>!+^%5D!$NU<(I(E_IC^'OP,^$/PQ\1^./&?P[
M^%G@'P#XH^)&K+KOCSQ!X3\'Z%X<\2>.-7"C_B<>,M<T)4D\0.S98-.6"D#
M7.T>WT ?RNZ1_P $P_VT/V+OVD/V0?VKOV+_ (4_LO>/O$_@W]C3_ACSX[_!
M(^,?&7PE^&/A,:YXT/CQ_B;\+=;\0KXM\3CP[_PD@_Y%<G_A,2F""P<@??W_
M  1E_8K_ &B?V(O@G^T/X._:AU#X?:Q\2?C%^U]\9/V@/[5^&E]K.I>&=0TO
MXJ+X;=B(]>"+H)/B%==<>&<,T>0Q,FYV;]I** /Y#?VEO^",G[9WQ4\(_P#!
M8S2?"O\ PJ47'[;O[9?[+WQS^";7GC$(C^!_A3XT_M_QQ_PF8/AH?\(_X@*%
M=JAI,[7PX)"C]#OVK_\ @GG\;OCS_P %#/@_^T7X=E\%:?\ "GPO_P $[?VG
M/V2_$>K:IJW_ !4FG_$[XLZ1XAT#0&.A,,>(?#R_VV'8AP4"$[,M'C]Y** /
MXGI?^"+W[=?C']C/_@G5X3^)GP/^"FN?&#_@F5\2/'GA?1O@Y_PT+XO\,^!?
MVH_@3XZ$<FN:S_PM/P I\3_"+XB'Q Q*[,#C+$ >6WKVN?\ !'']I_QW_P $
M_P#XW_"73/@!^S!^SS\;OCQ^UY^SM\9A\+_A]\4OB7XTTO1/AG\#_&W]M)I'
MQ5^-OQ \0^+YO'_Q%@\/G6R3X4"1E9 22#NB_L#HH _$K_@LI^P;\;OVS?@K
M\)_$7[)?BC1O 7[8W[-7Q''C7X#^-_$%Z=,TX:=X@T.3P+\5=$DUK8_E+XI\
M,ZTK%I H<Z"%&V1@3\(_M<_\$-/%$_[&_P#P3#^&7[/7A[P!\4?%_P#P3RUG
M^V/$GPJ^(7CSQA\(_"_[0NG>/-&1?CDO_"U? *_\)/X!\2>+?$I/B9?%*@_-
M\K<C:W]4=% '\>.L?\$9_P!I[QK^R;XN\*:)^SE^R_\ LR_&#XD_MX?LP?'.
MY^'_ ,/?BE\3?&IL?@3\"]8D<K\4_C=X_P#$7BZ3Q]\1%7578MX65$;*JAD=
MOE^^OVT/^";?[0G[1/[?7[0GQT\*S>"=-^&7Q9_X)+_&7]B;PWJEUJ[#Q+8_
M&'QUK>O:YH;:WH;X \.KN5CXF))0$*N[ !_H4HH _E"_9T_X)K?M\G4_^"'6
MM_&[P)\'/AR/^"95_P#&3P7\4[7P]\4_^$X7Q9X#UOX9Z%X \#^,M"*^&L'Q
M'XI=6+^%"S/&Q(D*C;7G=[_P3$_X*E_"/]F7]J7_ ()9_ WPM^R]XM_9(_:>
M^,?Q/UKPW^U;XT\>:[IOC?X1_!WXZ:NNN>.]&\0? \>'BWQ!^(GA8EV\&>)?
M"_BX1Q2!6"J0HB_L!HH _ ']E'_@F5\4OV9/V^OCM\6]$G\/7_[/&H_\$X_V
M>/V//A#JU[K&WQQJ'B?X2Z)H6@%M=T,C&@PD:*I# E0SIG#J17TA_P $9/V1
M_BW^PM_P3^^$G[-OQN7PR?B1X.\3?%+7-:_X176&\1>'A%XY^)>O^(=#,>L[
M27;^P-:A#+T&3D[E"G];J* /Y$]"_P"",O[9&G?LA_LY?!&8_"[_ (3#X4?\
M%EM0_;G\88\7M_9@^!!\:Z]KR_V)K(\-\>(R)$W^& H/S#>Q ^7]>?AY^QI\
M6_#G_!87]H[]M_5#X</P9^)_[(/P@^!GA(V6L'_A)F\<>!O&?]O:XFL:&N&7
M0@,_.7;>2H55P6/ZYT4 ?S-_M[_\$EOC;^UQ^UQ^W[\3+2;P5:?#K]H+_@FK
MX:_9]^$&J7?B1]/\3:)^T;X&^)/_  G_ (&U?5]#VAM$\/CQ#H6C,OBB/<6"
MMM0>6P'@/[(W_!%G]J;X!:__ ,$HO$?B*^\ :AK_ .S5I?[>'BC]K'Q!_P )
MD-4U/7OC%^U7HVNKH>LZ%CPX6\0",MH<;%@"I!+8&#7]<5% 'XU?\$-_V,/C
M1_P3_P#^"?O@C]FWXZGPDOQ!T/XD_&/Q3>+X+U=O$/AS^R?'/C36O$&B$:RR
MAC\D@#X VL5C;YL@>'_\$[_^"3L7P5^,O_!1#XF?M:?!W]GGXD:A^T%^VIX]
M^,_P(\0ZMX=\&_$;Q)H7PPUY<:"ADU_PV7\.DDY'AF,$H4R<< _T"T4 ?SV?
M\%4/V'/VM?VD/VE_V9_%_P ./ /A3]I?]DKP9X%\=^&OB/\ LC>-/VA/&7[.
M7@7_ (67K+9\#_&/7AX!5S\0/#_A<; WA;B3_6%,OAD_-;0_^",_[?7PK_X)
MN_ KX+>"/"WP,\2_'W]F+_@I\W[;GAKX?Z/\2=7T#X:>.O UMK*ZWH>@Z'XW
M\0>'EDT$LW")XHA<Q+$Z.Q<1(_\ 9Y10!_*G\7_^"./[27[4_B__ (+&ZW\3
M+[P#\.;'_@HO\$OV2['X6#P[XPUCQ(WA3XQ? S1DU[7])\:EO#:+)X:C^(ND
M)X9=T+8\& H 9/EKAOV4?^"1O[3>F>(_%'B/XE?L7?LJ_ 36?!O[(7QA^#7A
M#QOI7[1WQD^/WQ+^)'QT\=?#/7? )\::!KFN^(U\,?"#X=^+!K3OXU\+-X19
MF8G&4VI7]<M% '\N</\ P28_:U'["O\ P15_9T+?#<?$#]@G]JGX-_&GX[J?
M%[?V:OAGP/KGB'7-</@C7&\._P#$^\0-_;0"@(JE@QW,7XV?A/\ L#?\% /A
MDG_!87X,V/PU_96\5_"_]L3XZ_%/]H_]G_QK\;]5U?XC^!/'&J?%;6?#Q'P:
M^*WP3.#H'A]?#>BO_P 5064?\)>^[,@*^7_3G10!_*I_P2S_ ."5_P"U!^S+
M^VI:_'RV^"_@_P#8'_9XM/A%XE\-_$?]EWX8?M4>,OC[X)^-7Q@\0E57QKHF
MB:XK^&_ 'AGPJL>8D8_\)=E652OF.3_57110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %?/6M?\AG5O^PG?_\ I5+7T+7SUK7_
M "&=6_["=_\ ^E4M 'T+1110 45SOB37]+\+:7<ZYJLXMM/M1FZ;KP1QQZCO
MCC!_/R[_ (7Y\.?^@MJ/_@H;_"@#W.BO#/\ A?GPY_Z"VH_^"AO\*/\ A?GP
MY_Z"VH_^"AO\* /<Z*\,_P"%^?#G_H+:C_X*&_PH_P"%^?#G_H+:C_X*&_PH
M ]SHKPS_ (7Y\.?^@MJ/_@H;_"C_ (7Y\.?^@MJ/_@H;_"@#W.BO#/\ A?GP
MY_Z"VH_^"AO\*/\ A?GPY_Z"VH_^"AO\* /<Z*\,_P"%^?#G_H+:C_X*&_PH
M_P"%^?#G_H+:C_X*&_PH ]SHKPS_ (7Y\.?^@MJ/_@H;_"C_ (7Y\.?^@MJ/
M_@H;_"@#W.BO#/\ A?GPY_Z"VH_^"AO\*/\ A?GPY_Z"VH_^"AO\* /<Z*\,
M_P"%^?#G_H+:C_X*&_PH_P"%^?#G_H+:C_X*&_PH ]SHKPS_ (7Y\.?^@MJ/
M_@H;_"G?\+^^'/\ T%-1_P# *@+:VZO9=7Z+=_)'N-%>*_\ "]OAQ_T%-2_\
M$^K_ /Q-5O\ A?GPY_Z"VH_^"AO\* ::=FFGV>C^YV?X'N=%>&?\+\^'/_06
MU'_P4-_A5G_A>WPX_P"@IJ7_ ()]7_\ B: MK;J]EU?HMW]Q[517BO\ PO;X
M<?\ 04U+_P $^K__ !-5O^%^?#G_ *"VH_\ @H;_  H#9V>C>R>C?HM_P/<Z
M*\5_X7M\./\ H*:E_P""?5__ (FJW_"_/AS_ -!;4?\ P4-_A3L^S^Y_Y!9K
M=->J9[G17AG_  OSX<_]!;4?_!0W^%'_  OSX<_]!;4?_!0W^%%GV?W/_(/U
MV\_3N>YT5XK_ ,+V^''_ $%-2_\ !/J__P 31_PO;X<?]!34O_!/J_\ \32
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M4?\ P4-_A0![G17AG_"_/AS_ -!;4?\ P4-_A1_POSX<_P#06U'_ ,%#?X4
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M^V>/Z4NL?#?P!KVH:AJNN>!_"6MZQJG_  B_VS5M6T?1M2U2_P#^$%UK^W_
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MQ)%Y'B/X2?#?Q)!_PDFJ>)_LFK>#]&U+_BJ-=_Y#NM?]C%XL_'V[4OJF;?\
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M%8KAW"XK+)83A7_A5LF[JT8[MW;]UWNOBY;6TO=V_*_X8_\ !1OXT?"7X!^
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M\,?$C2_BUK'P]\)_V-IGAGQYXGT/6O[=T/\ X3CC_H8_^*I[9[^WJ'C#X>^
M/B%+;S^./ WA+QM]EL]4LK/_ (2'1]&U+[!_;O\ R'??ZCT!XH^JXS_H:_\
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MNWWUNWJWWV]=.HHHHKT;?/S[_P##GP_X^84444 %%%% !1110 4444 %%%%
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M_'$_@[5?AO\ "[_A*/VA/VC/B#9^(?"5G_9OB?0?A?\ %?X+_P#"!Z%X+_\
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M'@#6KG5/"'CRS^/'BSQ#>ZUJ7V[QYXZT77]>UW6M"[:__P )7XBUS_BM^?\
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MPN:+:]G:]DKO\$T?IQ1117?9=E]R_P CY%W3:;U3:;\TVG^*84444Q!1110
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M\?R^GM_G)]L%EV7W+_(Y_P"T\PO?^U)W^?\ \D?C_P""/V#_ !%X/^-WQ/\
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M^$J;2(4U,Z;-A]=71/OOH.B^(M;0MM!VO&<GS/E9/6J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYZUK_ )#.K?\ 83O_ /TJ
MEKZ%KYZUK_D,ZM_V$[__ -*I: /H6BBB@ HHHH **** "BBB@ HHHH ****
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MGQ)-_P *V\"Z7K:QG/C?6%.[XM_$)3L'_"0'9X-\),)4\"PD%WD /MFBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYZUK_D,ZM_V
M$[__ -*I:^A:^>M:_P"0SJW_ &$[_P#]*I: /H6BBB@ HHHH **** "BBB@
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M9=?&GPG_ .3R/VOO^Q0_9B_],?Q!K[+H **** "BBB@ HHHH **** "BBB@
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MM6O);SPU8Z7K$OP^'PL;P_K*>)))/B&,Z'KA3PEXK\(>$H_@]N\2QF1XI0[
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M'N_AOX"NQX2\;WG]I>-M 4:'HC+H_C76]\G]M^(O"RL8996V>8\8VQJ"AKZ
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MOT;P3\)OBOJ":K9^&;;2-8U3XL^&-!R=NB:KK);P]X/.ND; 7!5$)VG>65E
M!]'5Q'BKQ1X;\#Z!K/BKQAK>B^'-!T&Q^VZOX@UZ]72]-T_35PN[5]8E)C0
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M1\:3077C;XX_#GX*Z2+()>>'O@EX&?QMXD..H_X6A\7MR*X/+,O@H'&1PO0
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M<\>_\%!OV//A!\1_&'P(^'_[.K?\%0OBQH5[XHUOXE#]CC]ECP=XEU3X3?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/6M?\AG5O^PG?_\
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MWC?P+HVB>(/&W@K1M8*L?^$A\+>']<T?Q*594&TR $&/! ,3X3_\GD?M??\
M8H?LQ?\ IC^(-?9=?&7PF_Y/#_;%_P"Q<_9?_P#3'\0*^S: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **\5/Q3^'_P#PE7B[P/:^)+<^+_ NC:;XD\1^%4L=
M6;4] \-:P)1HNMKHWWM<T-I-'<,WAAI(@8S&?+DF._K? ?CWP=\3?"/A_P >
M^ =>T[Q)X/\ $]DNKZ/X@TI@VG7^FGC<&)SDDD'<H)VL<!>2 =[1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7SUK7_(9U;_L)W_\ Z52U
M]"U\]:U_R&=6_P"PG?\ _I5+0!]"T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7Q?X;_9;T/PK\;]6^,FD>*?$6IV%YXQ\3_$#_ (5\!HP\-Z'\
M3O'&AZ#X(\;^,DUTY\22 ^&M%*CPR95B5V(#;SLK[0HH _(+P)\/_P!M<?M>
M?M8:_9?&'X4:)HVIZ1\"QHUU>?L]ZV?[1TS^R/'_ /86C+K/_"RLN?"K ?\
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M%:?LQZ)J>I^+/,T7.O?VWHK?$K'A[_A%_$NU5 /)95P!G;/I/PT_X*#76O\
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M1H:-X( D:2@"G\#?A)^TA\1O!!\1^./VN_CGH>OVWC'XH:*=*L_ 7P:\-_\
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M1D>H_,477=?>O\P%HI,CU'YBC(]1^8HNNZ^]?Y@+11D>O^?\D?G1D>H_S_\
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M%^;_ (1XJ<^,L*!L#F8[R@HNNZ^]?Y@>^?\ "@OVF_\ H^?XC_\ AGO@#_\
M,W4O_#/O[3/_ $?;\2O_  SWP%_^9>OS/^-G@KP?-^T'_P %&_@[<7^M^!_A
M_=_L4_LF^&-'7P[K&KZ9_P (G_;WQ,^+^A:YJW@K6RS_ -@^(E&MZ)DH<LR^
M&&!$>X57LO%_QK\1>(_V"_#OQP;Q;X>\4_LY_MFG]G/Q;<W7]L:9IWQW\3Z'
M\+_'H_X7+N<D>(O#WBSX>_\ "%^*5)VHOC+7_$RXPF6+KNOO7^8'Z9_\*!_:
M4\S/_#=OQ'SU_P"20? /UQ_T+/XXV]>?:I?^&??VF?\ H^WXE?\ AGO@+_\
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M_?#_ .+/PLT)]<D#EO$$GB#6-;3P6?"Q+>-%P<AE##0'[2OC_P"(?@'X0_M
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M:$^LZ]_PC6?$'AO_ (6'/K@\<^'$SXPC7_A'!X&D3:^,/JS\_P 3O_M!Z?\
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MA_:'_4NI_<__ )(^9_[0_:L_Z GP3_\ "B\:_P#S->P_*D^V_M3?] /X&?\
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MBBMSR3SO[=>_\_EU_P"!$O\ \71]NO?^?RZ_\")?_BZ**!679?<O\@^W7O\
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MY_+K_P ")?\ XNBB@++LON7^0?;KW_G\NO\ P(E_^+H^W7O_ #^77_@1+_\
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M")?_ (NC[=>_\_EU_P"!$O\ \7110 ?;KW_G\NO_  (E_P#BZQFZGZG^=%%
(K+LON7^1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ea028535401_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028535401_img5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #3 'L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBOE;XS_%Z6R>Y\+^&YF610([[48)2I=V53);P,@S]GC21EEE1
MU\ZYC-O&^V.4, >I^*_C%X/\+-) UT=3O8RZ&WLBODK(A(9)+QLP@JZF-E@%
MPZ2$*Z+AB/+5_:9LFN=AT***W+2!)'O;LR80L$+(NF @3!1DJKFW9E5ED4B0
M_(LC3SRM<3/YDT@+;L9&,D*BX?:$1=B(B.L850BQ@J @(2!SG.P$#<XW,?E!
M.X#)"X56(8L<J^#F@#[NTKX_^#;XLMXESII548O)-9SP,6(!$;B>*=BA8%Q)
M;1,B[G90JMCT33O'_@S566.S\1Z497V!(9KI+:9V< JL:7!B,Q((QY/F DX!
MK\@_&WE:OX=>-)&LG:^G@MI'DE,4Z6<A\UG@@9#Y,YQ&@E1O)DVCDL">B\'1
M2Z5HEOIT6J7-W+8_Z/.'<$6DKKYDD$:QR3!;5@RM$#(" &(50K!0#]AHY8YE
MWPR1RJ>C1NKIG_>4D=QWJ2OS#T#QYXF\-2PSZ9JEQ;%&C(2-D9/+1ON&!U^S
M2F15V,LR3^:A#*5D4$?<OPP^)MIX\L#'.(K76;9"TUNI(6ZB1MC7$*$81US&
MUS;J\OD>=&5DDB='(!ZO1110 4444 %%%% !1110!PWQ$\3+X4\+7^IB0QW#
M[;2U8?>6:;<6D &&_<PI-("H)!4'IDU^;\TTE_<-<2Y+LV[#,S&- H"*"YE9
MECC5%9B5W-F7.YW)^P/VCK\IINBZ:IE'G-<W3>65\M?WMK;;KC=G:&265(61
M&;<TN2J@AOE33+%[N1%C5B\CJBA<@?[/=@#P%&2I1L?PD$ $=GIDMRRHJDEL
M?,<-_"#UW9));<>26(#H20-W<:;X'U&ZB1TM)R'Y"+'*>,]20J)AAG)^=7!W
M* 0I7J9)_#W@:U5M0CCO]:,9E^Q[E:&T1$,A:8K@F1"7)5I!%%C./F*5RL_Q
MUO/,TU(;FW@BU599=(@L=0M(SJ$<$2W$PTZ*$%+LQ6[K,3'(1&AW,22"4Y);
ML:BWLF9&K_"VTBF\ZZT4Q.+F*YE< @R/'+]HV&.99+=8KA\&XQ"#*F ^5.*Y
M>?1H-->2.WMH84/SXAA$0=VR [^5DADY522ACQM("%37OGAWXOKJ4!.J0?V_
MI.YHK^SO8TAUC3N#YC+(5:5Y$3,J1R.R31X\IVSSE^/=!TW<NJZ)/'>:->V\
M-W8W,/[P%9E<M&QC!VRH,)(I*!I!+$<$ %W[:B:MHSP"52A'S8XP0N0OEIDM
MD\';C[T?F,RE=Z< A>Q^'OB.;PMXITW5(RPC2X0S)OCC6=,$.C?-&C/) T\"
M8=BPG!4&0".3G;M%1C\W0A,Y< ="6+;LJ , $R J25<'@U7L2$OK-@5#+<PL
MV\_(564* P3RB4P#YBB1F"LQC(&* /U=1UD1)$.Y)$5T.",JP#*<$!AD$'!
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M++N>.VMW9V9&$4D\\8($ENRBR#["L+5;&QL[)3E;2U@M@0,!A#$D>X#MG;D
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M\WW00'QG .!M!4<\D\#J5KDM-\>>#=9FNK2P\1Z3/-:W,5F5:X-JDUQ/)-#
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M(!<KG!#5Z3X7TI]4US3;"-0[3WMK!M\LR!V>10(MFZ1BMPQ$/( VRMO;"^8
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MBAMM[DB1Y(?W1^DHXHX8XX88TBAB1(XHHU"1QQQJ%2.-% 5$10%5% 55 4
M8H ?1110 4444 %%%% !1110 4444 %%%% !1_6BB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ea028535401_img6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028535401_img6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $[ E(# 2(  A$! Q$!_\0
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M"=E)X5L+'X1:)X.TCX@68TWQ4S7G@OQ!J4$+Z3=+'_:DD\$)A0RQ*0 ?L?\
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MY+X>$GA+XM?M'^']5T_PO8>*ID\4&>\MKJQTO1;!! \_FVUV+9<INC'[(_\
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M44 %%%% !1110!X#J]U=1:KJ<45S/'%'J%[''''-(B1HES*J(B*P5450%55
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MSGJ[?,V6YI##$S,S11EG"!F**2PB=I(@Q(RPCD=Y(P<A'9V7#,29** (Q%$
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M'WHV *'JI&5((S0(HDP1'&"I=@0BC#2%FD88'#2,[LY'+EF+9)-244 %%%%
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MW:/_ -_I:_-W8G]U?^^1_A1L3^ZO_?(_PH]@_P"9?<PYUV?X?YGZ1?\ "S_
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M$AO9/@OX(^(__"L7^(FEE;8/XMOO$\__ !/M(\&^%39>(9+3$L=T>M;VF?\
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M,PT\115.]/FYJ<IQ4ERW[M=C^IW_ (6?X _Z&[1_^_TM'_"S_ '_ $.6@_\
M@PA_^-5_/O\ '?\ ;7M/@5\5_$/PL?X*^._B"_@ZV^#&I>*/%OA[6_"VCV>B
MO\>O'6M>$?AG:C3=9BE348QXPT*>PUJ,HZ3:.6M)PUL3'7@_B?\ X*6V^@>+
M_#=S>_#3QM:P6Q^('@'QG\'(I? 4NMK\7_#/Q\\(?"$PV/CY=>_LY-(BNO$,
M<:P(@A3<450":(X["OXJKAVYH2U_ 5#@S/*])U84()*3BU[2+:MUT>E^A_4!
M_P +/\ ?]#=H_P#W^EH_X6?X _Z&[1_^_P!+7\\/A[]OSPOK.I>(?#E_\)/&
M?AWQ7X.\&_M.>*?%&C:AK?A36+;1=9_9+UO1(?&'@ :CHT5F-1U#Q)%KL$=A
MJI9Y)8PJ!RH&/$]"_P""E^H#5/B7?^+O@T]KX8/CGX%?#KX%Z58^+-(TW5O$
M7B/XO_!C_A<-Q;^-=?OX9].TRUL=(_XG4>H16^([;_B2JXB/EU?US"/X:U_^
MW6OS"'!F?S]K;")>RBY/]Y'WDDWIKU2/ZBO^%G^ /^ANT?\ [_2T?\+/\ ?]
M#EH/_@PA_P#C=?A7/^UUX0E_9Z^'O[0>@^ /&7B(?%'Q;X1^'/@SX8(EEI/B
MF]^(OC3Q,/ ]GX,U&\O#%9Z=;IX@/VR/Q*[KML?N3!!S\:^"?^"G,OA:R\1Z
M;\9/A[XDUSQU8?%3]H9;GPOX>NO#=GJ7@?X0?"[XFZ!X%TRV8Z9;#3_B7\1Y
MYYYE2Q\-M;V $TJ@@2-F7C<*MZC_ / 6+ \'9WC859PH0@Z<G&495(7=KJZ=
M[6T/ZGO^%G^ /^ART'_P80__ !JF?\+1^'W_ $.FA?\ @P@_^,U_+]!_P4BD
M^'?@CQ_XQ^*'A.?QUINC?'CXY:#IMUX8U/PWX0U71/A/\._$NB^'O">H+X.N
MK=M:\;^*EFUV#^W]/TJ6STF<A/M&X@5]1_#K]L;PS\2/C+IGP-TSP/XBM/'0
M\7?%/0O%%I-JNC;/ WACP#I?AG7K?XCZI']G_P!/T3QQ;>+?#J>$+64/ R:I
M?K:#;H[>6UC,,_\ EXUZP9%?A'/:$7-X6,DI1C_$BMW:^KV['[O?\+1^'W_0
MZ:%_X,(/_C-/_P"%G^ /^ANT?_O])7\P$/\ P4AD\(R_&'3M7^%WCGXFW'PG
MU?XZ^-_%FN:1=^!/"=GX,^%GPZ^)W_"""WEM+_Q!(FN:EH$YVZ*665O% XU7
MS >/LKXN_M&1?#S7_AEX'\#_  R\2_&GXD?%GPUXP\=>%? GAK7_  IX1NX?
M"7@[2M%U7QQ?7NL^+8CIS7<<>NV__"/6+S%[4!1:J@ K2&(PTU)JLER]'&6O
MI]QG6X6SFC.E3="#=:-XVJP5M%9.[WU/VU_X6?X _P"ANT?_ +_2T?\ "S_
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M/XJ^ 'CW1]-^$FD_"P^+]6O?%'@.UGA\;?&&S^S?#GX<6MG=>)=0TJ[\1?\
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MS=V)_=7_ +Y'^%&Q/[J_]\C_  H]@_YE]S#G79_A_F?I%_PL_P  ?]#=H_\
MW^EH_P"%G^ /^ANT?_O]+7YN[$_NK_WR/\*-B?W5_P"^1_A1[!_S+[F'.NS_
M  _S/TB_X6?X _Z&[1_^_P!+1_PL_P  ?]#=H_\ W^EK\W=B?W5_[Y'^%&Q/
M[J_]\C_"CV#_ )E]S#G79_A_F?I%_P +/\ ?]#=H_P#W^EK6TCQEX9UVX-EI
M&N6&I7HA^T>3:2,3Y8_BVL>ASSDXQ@X!K\Q]B?W5_P"^1_A7OG[/<:?\)W<-
ML3*Z%?%6VC<"ESM0@XR-B_*N.5' P.*4J+BF^9:+LQQES7TM8^YJ***POK;^
MNO\ D4?/6M?\AG5O^PG?_P#I5+11K7_(9U;_ +"=_P#^E4M%,#Z%KR#XW 'X
M<>(,@'_D$]1G_F*VG_Q3?]]-ZFO7Z\?^-W_)-_$7_<._34X\?EM7'IM'H*:W
M7JOS)E'FMK:Q^?\ 1117>O@C_71&<H\MM;W"BBB@D**** "BBB@ HHHH ***
M* "BBB@ HHHH ****I.R:[H<.15%4G%RY8RBE>VK6C^1R_CWP%X4^)7@OQC\
M.?&^G+K'@_X@>&;SPCXJT:>Z?3;KQ%X5U%/*U#3;6YML&QEOHOW=Y "J74?R
M3K(N!7A.A?L:? +P_P"#OB%\.;7P[XNUGP?\2O!G_"L_'GA;QG\2OB-X]T[4
M/!YBAA_LBPA\2ZS?VGAF]\FW@B^WZ3%"_EP11[MD487Z>/.[/S;I?/;/.Z?_
M )['/67_ *:'Y_>D8!E", R!=@0@%0G]P*?E"_[(&/:L72A)MSA"=]5SQO;T
MT>^S?D>AA<UQ^$I.E1Q%2C#F<K4I.*=WI=72=O0^>/$O[)?P#\51?#./6/ "
MPP_"3P[I/A#X>OH6J>)?!]U8>$H+G[9#X7N9-%N[5];\.PWG^E1:)J32:9'<
MXG2U67YJ\X^-O[%G@_XL?!CQ/\!?#-Q9> OAW\5/B[<?%7XKV \.WOBW5/%[
MW'B6'QIKNG^&KW5I)G\.Z_XMU&VM]*T'7(&BO=#A@A@@N(DBC4?9NU<R-M7=
M-M\YL#,NS[GF'&9-G\._.WMBE*JP8,H(?:&! 8.$D\Y P/WMDW[U=V[$G[P8
M?DYRPM"=KTXPLV_<25[]]$=,.),XIWC+&5:E.5X<LI.]YJR:UZ7_ *L>/_%G
MX!?"7XV^'?#7A/XB>$VUG1_"1ED\+1:?JWBKPWKFC6UQI<NAW&DV6K>$;W3[
MJPL9]$FFT>6RM9H;>32Y9=/DC:TD:$\\?V3?V>%\>>!?B+!\*=(LO%?P_P!!
M\-:?X2ETZ;6[73;*Q\&0ZA!X/N?^$/MYDT'6M<\*6^K:I!X;NM0MWN="BU+4
M(M+DM8[RX$GT"0#G(!W'<V0#EO[Q]3[GFA555,:J%1G\QD4 *TG]\J, O_M$
M;O>A8;#QG&*IPJ<UTW))J-K+;>]F*>9YGAHQOCJ]-3NW"G*<>9U=KZV]V^M]
M^AXKXR_9N^#OCOQ-K_C3Q=X(36/%'B ?"]=4UF6ZU_3(KA?@CXPNOB'\. +>
MUN@9!X9U^^O;?5U;(UB6[NF<.]S,7XO4_P!BG]FO6=5?Q'J'PT:XU23QIKOC
M"34XM8\201OXJ\8_$.Q^*&M:D]J+H;XH?B'X)TJ_DN"-Q%R+EG,I#CZ>  96
M  9=NU@ &79)YR[2.1MF_>K@C$G[P8?FE8!V+N S;'CW, S".4?O(]QR=D@)
MWKG:X^\#5SP>';<98>F^79J*LT^NS_,BCGF=81_5Z688E\SYY.4Y-6E=I+7I
M=)GR[XN_8M_9G\9?VA-XG^&WGMJGB'X@>)=4NK'Q/XPT#4-1O/B9+:R_%BUO
M[G3+V*>\\,>)9+&RD_X1JX>33M0>RM7N+6=K:$I5U7]BG]F"]M-3GOOAQ_9*
MW]KX(M[G48?%7B;P\FGWGPQT3_A&/!.MZ7JL%_;/X;UVT\-X\/ZQXHM);;43
MHF-)DO/L)\BOJL*H.X !M\<FX  ^9#_JI,CG?%_RS;[R?PD5B^(O#?ASQ?HV
MI^$/&>FVVL^'M?L[O3M?T'56,4.HV%^/].L9W17BN;.\_P"7NVE#PW _UT;\
M5A5PM."7LL-!WO=<J_RTZG?@>(LSGBO98C,<1&$E*+:J.*?-I?5ZV;VW/"="
M^'G[-GQY^ 'A_P $^&;;P_X_^ [7UA;>&I-#UGQ5>16=Y\.?$$-E'K7A_P <
MVMW;:J==L]8TF]U&V\427,>H6^H3S7<5VMQ+)(V%:?L+?LQ6UKH^GZ=\+KJQ
MA\,:MXDUVTO-+\7>*=.UAK_Q3J\>O^,[;Q-KDFLPW?B7PEXCUZ"+6[/3[^>Y
MT^ZUB&+4GBDO$68>(?L[?L]?&KX=?L[_  Y^%^L^,O!GP;^&'A_5/VA+;XS_
M  TE\%)K]WJW@+QM\0_%=]X;C\+_ !&T#Q3;CX57&EZ#K-IJ>E_:(Y18O##/
M:B)HT8?FYX,^"/[8'Q^^&?AWXHZ7KWBGXC>%_#/CG7_@'HWA30O$VJ:#J7Q-
M^#OPW\&^(O#'PA^,<,/BSQIX&M;W4/$7C'6;?6_$USJGB&2XU-='L+J\EEEL
M[:2+S:]7V4HQE@8RYO)*UK>7F?79;EV*K0KSH\21PR34YQK5G%R4VVDKSMHG
MKH?L)XH_8*_95\6-J5SXE^$<$\GBEOB5<Z]=VOB;Q7X9_MRT\?WMKJ/C^SU=
M=,U6'5M3\-W^H6-E?Z9I]Z)[%[VSM;I8C/;PR)TOPH_9EM/AI\?_ (P_'S6-
M;MO$/Q#^)^B> /!NDPVOA#_A&I_!GPS^'-K-9^#O#[(]]+<ZWXMO[+5[.S\3
MZKJ%_)=7UK#!;7<DD4:1I^;VH_LY_MLCXR_"+Q&FE>+]03P5)\.O#WB+XGV7
MQ.TF^/Q&\)M\&_$NGZ_%K\5YXO:/4/%5O\0]1TS2)-*\+_#ZRTC^U[.T\2,/
MMEO#<)[M#^S!\5=$_P"":&D? 7PSI/BJ#X]ZMHGP[3XA6<'Q)\0:AXE@\7R^
M,O"FH?$>_D\;W>H-JMC#?:3I%W8:;+87P+V,LUJK&!WC-PFY)M8)))-_"NOI
M^'8,QPU3#X>$*G$\,1*M5BE[&JYNFDU=RM/1.^FST/JM_P!C']G<#Q]GX;\_
M$[1O&GAOQO(-;UZ63Q-H7Q.\8?\ "P_%%N;*RU5O[&_M+Q!^X?4;%%&CR_,S
MH_-=K\5_V;_A5\:=+\,:)\1/!\FKVW@M;VT\,ZEI7B#7O!NM:.9[>UL]?TRR
MUG0=9M_$MCI&L6EC96NJ^'+;5(K/4+>SM(;NVFB@B1/RMUG]C3]J71M>\8ZA
M\$+SQKX*U2]^./[4-IX*\2ZE\5O$VO:;H_[.GBGX-A?!EL-+OM7>.TT-?B$?
MM5E>1(FI6^K?Z; B7>)JD\-?LG?'S7==\'6-WX ^(OPG^!2?&?\ 9XU'QY\)
M==^/=_XC\6FT\(>$?$\'QJ^)<_B;1?'JSVGA[Q-?W?@>[U7PQ93_ &36+Y-2
MN[ZVFE=\3[>2ER1P*U^U9)=MK:W[L53*Z,L1AYRXHYN2G&4>64[1;2;3O-Z]
M-K:-:'UUX _8E_9VU[XP^/?C-IMMX>\:>&Y]2^$?AGP)X%\/W&H0^!/AYJ'[
M-NA_V-INBZOI.B:E9Z+\0[\>)_\ B=01ZQ:W;Q:N/[1B"WG[ZJ=C\-O^"?>A
MZMXU\(I+X:TN?0/%=MXI\4^'[GQ1XS_L7X<^)?ACXRTSXBO;6>CW]\OAWPM#
MX8\1>)-$ACT?0H;2/5)YT=8F<JP_.G7_ -BC]J?PU\&M8^$/P=^"&J^'9[#X
MG?M,>+=&\6^&?BQ</JBZ]XD\0?VW\'=?T[1)?&\5A8:/!I ^SZCK_C%=0\8C
M4OG/@82\U)\8OV&_VJ/B?=?'B.Y\!W&N:/\ $6+XK^)[/3;KQUX>T>V\8>)A
M)^SK-H.I7=K:^)EAAU6YE\"_$*5;^9#=F66SD$VX*:PE.49RC+ Q:;T;2[Z]
M/Z\MSW*6'PE5>SJ<3R4HKW'&I)*+7\WO];+M^9^NFM?L7?LX^(I=7O=;^&$5
MU/XGU#Q=>ZA+_;GB,Q:@GQ8\>:1\1_%]T_V/56%MJ?B_QWX,\)3ZI96'[VV@
M34WNPS.[-X%\6OV.?A+^TM#XHU?X+>,]"\&ZWIWQE^*6J?%WQ V@:IXABU?X
MLZSX5M/ OC?2[R_O[WP+K.B:I!H]C97]UX1M77P?+]CM'FB8V\13R?\ 9O\
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MP[XCTN\AU'0V.CG^Q?$%W974$USI?_$NN9'M/W-?0BJJ A%5 Q=F"@+EI?\
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MY'W7X_Y')45UO_"OO'O_ $)WB/\ \$=__P#)-'_"OO'O_0G>(_\ P1W_ /\
M)-%UW7WH.1]U^/\ D<E176_\*^\>_P#0G>(__!'?_P#R31_PK[Q[_P!"=XC_
M /!'?_\ R31==U]Z#D?=?C_D<E176_\ "OO'O_0G>(__  1W_P#\DT?\*^\>
M_P#0G>(__!'?_P#R31==U]Z#D?=?C_D<E176_P#"OO'O_0G>(_\ P1W_ /\
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MZ]\4-.^.WA3Q!H7ACPU\9OVB?!/A'XKZ!9Z')X%FTOX"Z"_B@^%M2CM_$_\
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MK[T'(^Z_'_(Y*BNM_P"%?>/?^A.\1_\ @CO_ /Y)H_X5]X]_Z$[Q'_X([_\
M^2:+KNOO0<C[K\?\CDJ*ZW_A7WCW_H3O$?\ X([_ /\ DFC_ (5]X]_Z$[Q'
M_P""._\ _DFBZ[K[T'(^Z_'_ ".2HKK?^%?>/?\ H3O$?_@CO_\ Y)H_X5]X
M]_Z$[Q'_ ."._P#_ ))HNNZ^]!R/NOQ_R.2HKK?^%?>/?^A.\1_^".__ /DF
MC_A7WCW_ *$[Q'_X([__ .2:+KNOO0<C[K\?\CDJ*ZW_ (5]X]_Z$[Q'_P""
M._\ _DFC_A7WCW_H3O$?_@CO_P#Y)HNNZ^]!R/NOQ_R.2HKK?^%?>/?^A.\1
M_P#@CO\ _P"2:/\ A7WCW_H3O$?_ (([_P#^2:+KNOO0<C[K\?\ (Y*BNM_X
M5]X]_P"A.\1_^".__P#DFC_A7WCW_H3O$?\ X([_ /\ DFBZ[K[T'(^Z_'_(
MY*O??V>_^1YN?^P%J'_I57E__"OO'O\ T)WB/_P1W_\ \DU[1\"_#/B/2/&=
MU=ZII&HV=E_8;6OG3P*@\UV#,Q<X(=VY9NK'DY-9U)I1:WYDUH]BXQY;ZWN?
M9=%%%<=M;_UU_P RCYZUK_D,ZM_V$[__ -*I:*-:_P"0SJW_ &$[_P#]*I:*
M8'T+3=JC.% R #@ 9 X [?='3T'2G44 ,\N/_GFG_?*_X4>7'_SS3_OE?\*?
M11Z;] &>7'_SS3_OE?\ "CRX_P#GFG_?*_X4^BIO/NOOE_F SRX_^>:?]\K_
M (4>7'_SS3_OE?\ "GT47GW7WR_S 9Y<?_/-/^^5_P */+C_ .>:?]\K_A3Z
M*+S[K[Y?Y@,\N/\ YYI_WRO^%'EQ_P#/-/\ OE?\*?11>?=??+_,!GEQ_P#/
M-/\ OE?\*/+C_P">:?\ ?*_X4^BB\^Z^^7^8#/+C_P">:?\ ?*_X5\[_ !L^
M/GAOX#Z9X)U#Q3HWB?6H_''Q#\!?#:P/ACP_<WT>D:SXZ\2:?X=TW5_%ET\C
M1^%_"D5S?V_VN^OS-< S%"I):OHNO)OB?\,_#_Q9\-V7A/Q%+?6VFV7C+P-X
MKA.ESR6CR:KX \4Z5XPL(Y?*9=]E=WFBI9RQ.3&\:JFUMJI5)RZO[FP/,O 7
M[0-MXY^*_B[X.ZAX$\;>"/%7A[1&\5Z1/XH@TF+3_$WA :]>^#X_&&GV&E:W
M)JEGI^IZQ!,=,TK5YXKZ2P-KK,<$:[)!ZMX0^)OP[^(4VK6G@/Q[X+\9R>'I
M(;3Q%'X-\3Z#XIO= O+L0?V?;:K;Z+?ZM)ILUSY=X?\ B8*Q;[+<'H'V^'?
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MQMVGY>5V_+CICCI2&)"<E(R2-N<+G&& &<= '< '@!F QD58VKZ#_/\ ^O\
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MLQL2  2S>'_'R,V0,Y* (2<DJ I.,"@#[.HHHH **** "BBB@ HHHH ****
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M'!(XQ@$CI69/=Q1*TUQ.]O"JW$LLKO'%;V<=CG[7<W%Q(Z*MJF 6,A$8 .0
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MXKTG3M3NM(NLG=JFEV%[:W%M87V<D7MJL-P,D>8HP!ZUY<>T)Y:; ,!=J[0
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M1!MPBC8,)A0-@QC"\?*,<8&..*=5<LJ*':0I'%]]I&//'\1)YQQUYS0!,$0
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M %%%% !1110 4444 ?/6M?\ (9U;_L)W_P#Z52T4:U_R&=6_["=__P"E4M%
M'T+1110 4444 %%%% !1110 4444 %%%% !1110!_-%XL\$?\%7_ -H[XYZS
M\1/C'J'Q2_8^^"/P[^(^KW?PP^%G[#GASX2:E\9_B]X(\-:Y=V'AS_A<?Q[^
M)OCR>UT?1?'^DZ=87EQX>L_ DMC9K(&DME49K^B#P1K%_K_@[PMJNJZ1JWA?
M4=2\/Z1J.IZ!K$4$.N:1<7>GAKVPUA+7-O9WEL^5<6LBLLBG 4DJ/YO/B[_P
M5T_;6\.>/?%W@OP)X3_X)[ZHGQ9\9?$+P7^SCXC\0?M?>%O"UQ^S7I?@2]6S
MU[QS^V[8ZGXA8HUQX96/Q=IO@GP(L6OKJ"#P_P#:6F4(O]$7P?U#5=2^%?PY
MU#Q#XNTGXA>(+OP+X8O-;\?>&[5+#P_XYUO^Q]*C\1^,-#T^WC2*QTK5=0>Y
MN])M(D"KIL\<<(>%A0!Z]7QG\)_^3ROVPO\ L4_V8O\ TP^/Z]H/QA\ +\78
M_@(/%-K<?%8?#^]^)3^#K:749=2M_ <>O:/X:&M7MZEF;*!EUW4K735BDN/[
M6%G*VJA51VED\ ^">M:+K/[8/[9$VCZUI>K_ &7P_P#LWVEV=,O8[TV,FF:%
MX\$]G=B.1]MV2QW;R&QSR!0!]QT444 <!J7CSPKHVA^(?$^H^+-#MM"\)+=_
M\)'J+:I";/29=,P=436 L%S<Z7>6OS!M-;?*@ #1;F&WS?PO^T5\.OB)\/?$
MWQ*^$U_KGQ2T/PM]OM7LO!>B:G=:QK>K1*2-(\/V.LII\E]JBDHH$RM9*6!!
M5=S+ZMX;\">#/!T&K6OA3PCH'AZVU_5;W7==@T;2--TJ'6M;U/G4=8U6*QMX
M(]2U6_P/MNH7BS7=U_R\3/BNM\J+;L\J/9M9-FQ=NQ_OIMQC:_\ $N,-W!H
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M9K<W! ,TXA\V7 WNW6NP6.-=H6-%" *F%4!5'15P/E [ 8 [4X@$8(R/>@!
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MMV_+C&,<=*-J_-\J_,,-P/F&,8;CD8XP>W% 'CO@_0/@_P#!;3="^&W@O2O
M7PXM#9WUYHGA30+;2_#JWMIHEHCW^K0Z;8P6<>HW%CI2K=:O=^3-*P57N)MB
MJU>C:;J-EK5A:ZCI%[;:CINI06=Y8W=I,;FWN[!R/WL;2%E*,#@LN200'&X$
M#X^_:]^!GB/XKVGPE\3?#BRT>'XH_#3XK>#M1MM>>\L-$OU^%6N:FN@_'3PK
M#JM]!)=1Z7X@\!RZRDVC1RBSU2]@TK[5#.UK%CVWQ1\*=6U"3PW;>#/&U_\
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M*** "BBB@#YZUK_D,ZM_V$[_ /\ 2J6BC6O^0SJW_83O_P#TJEHH ^A:***
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MXQU]Z=10!&(HU.Y8XPPWX(101YKB63D#(\R0"23^\X#MEAFD$$"@!88E *$
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M(CM;=(T]&H C$,0.1%&#B09"*#B9E>89 SB5U5Y/[[*K-D@$."J JA5"KC:
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M:I_A4\,/NCHYRP^C=6_O'DTZBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>M:_Y#.K?]A.__ /2J6BC6
MO^0SJW_83O\ _P!*I:* /H6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0H!KV?PX_:UB^.LO@:[_ &K/B?=_#B7X8'Q4/%*?!_X40-%XU_X2XZ6N@)K
M\!_V3M.A8OOLB6^<?O\ 8$PU 'Z,45^9NM> /VNI_P!HOPW\--/_ &HOB];?
M";4?@OXH\::IXWL_AA\'9IK7X@Z7XO\ #>DZ/X:_M^3X>#2P+W0M3U:_%J8
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M;:=<?$S0=1UOPI+!>VWV2_CO]-T:5-7G@N[1([:ZB:;9/ BQ3!X0J+\LZ?\
M"K]L[38M/CTFZ_85L;;2K^?5M*2R^"OQ'M5TW5+BWGM+C4]/2W\;QK9W\]K=
M7-K/>6PCN)+>XGA>1HY9%8 _0 Q1DJ6C0E2&4E5)5@, J2,@@< C! X&!Q1Y
M<?'R)PH4#:O"@$!1Q]T!B .@!. ,FOBC^R/^"AO_ $4+]D/_ ,-G\7O_ )X=
M+_9/_!0;_HH7[)7_ (;'XP?_ #PJ /M8QH26*(6(&25!)(! R<9. 2!Z D=Z
M/+CR3L3+%&8[5RS)C86.,DI@;">5P,8Q7Q9_9/\ P4)_Z'[]D?\ \-E\8/\
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M1^$RUO:^(M!\9&_MA: B1M+NV7.UZZ3Q7^WOX@TCXK:KI$>@^$&^'GPPU/\
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M3[/[D+EEW_\ )I_YGJY5.>7^;K[]>O//;KZ>](8TQP6'ITXZ]L_3\O>O*?\
MA(-8_P"?U_\ OW!_\:H_X2#6/^?U_P#OW!_\:I+E_E7W+_(&I=&U_P!OR_S/
M5RJGJ7..G.<=>G/T_*C:F207!/4YY/7KSSCCKZ<=37E'_"0:Q_S^O_W[@_\
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MWYZ?B>KE5/4N1VR<^OJ>V?T]Z0JC8R7..F3G'7ID]LC\O>O*?^$@UC_G]?\
M[]P?_&J/^$@UC_G]?_OW!_\ &J247KRK7T7Z,;YNFG_;\O\ @'JGE0DDA>69
M9"<+DNN=CDYY9>-K'D;1@CFG[5_O/_G/O]/R]Z\H_P"$@UC_ )_7_P"_<'_Q
MJC_A(-8_Y_7_ ._<'_QJJ]WI%?<O\A<LF[MNWE*7^9ZML3U;\OK[_P"<?7)L
M3U;\OK[_ .<?7/E/_"0:Q_S^O_W[@_\ C5'_  D&L?\ /Z__ '[@_P#C539=
ME]R'R^<O_ Y?YGJVQ/5OR^OO_G'URGE1^A_[Y'O[_P"<?6O*O^$@UC_G]?\
M[]P?_&J/^$@UC_G]?_OW!_\ &J++LON0<OG+_P #E_F>J^5'Z'_OD>_O_G'U
MI=B>K?E]??\ SCZY\I_X2#6/^?U_^_<'_P :H_X2#6/^?U_^_<'_ ,:HLNR^
MY!R^<O\ P.7^9ZML3U;\OK[_ .<?7)L3U;\OK[_YQ]<^4_\ "0:Q_P _K_\
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;9B222222:*JU/L_N1%H_\^X_^#*O_P D?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
